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COURTNEY ELIZABETH KING. Role of the Oxytocin System in Alcohol 
Consumption and Stress-Induced Alcohol Relapse-like Behavior (Under the direction 
of HOWARD C. BECKER). 
 
Alcoholism is a widespread public health concern with limited therapeutic 
interventions available to help individuals battle relapse, moderate their use, and 
sustain abstinence. While many variables contribute to relapse vulnerability, stress is 
considered to play a prominent role in triggering relapse. The neuropeptide oxytocin 
(OXT) has recently been implicated in a number of neuropsychiatric disorders, 
including drug and alcohol use disorders. Given that OXT is known to interact with 
brain reward systems and exert anxiolytic and anti-stress effects in humans and 
rodents, the main overall hypothesis of this dissertation is that OXT (and OXT 
receptor signaling) will be effective in reducing alcohol consumption and stress-
induced alcohol relapse-like behavior. We demonstrate that systemic administration 
of OXT reduced binge-like alcohol drinking, operant oral self-administration of 
alcohol, and stress-induced relapse-like behavior in a dose-related manner in male 
and female mice. Targeted chemogenetic activation of OXT neurons in the 
paraventricular nucleus of the hypothalamus (PVN) reduced binge-like alcohol 
drinking and operant oral self-administration in a similar manner as systemic 
administration of the neuropeptide and this effect was reversed by pretreatment with 
the centrally-active OXTR antagonist in males. Finally, administration of an OXTR 
antagonist systemically and directly into the central amygdala blocked the effects of 
OXT on stress-induced alcohol relapse-like behavior in male, but not female mice. 
These data highlight potential sex differences in oxytocin receptor signaling and 
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Alcohol Use Disorder  
 
Alcohol consumption represents a major social, economic and health 
challenge that affects millions of people in the United States and around the 
world. Alcohol intake, particularly heavy drinking, is identified as one of the most 
relevant risk factors for disease, and premature disability and mortality 
(Collaborators et al. 2015; Medina-Mora et al. 2016; Shield and Rehm 2019). 
According to the most recent comparative risk assessment conducted by the 
World Health Organization (WHO), alcohol consumption was the fifth highest 
contributor to the global burden of disease and injury in most middle and high-
income countries, exceeding many classical risk factors such as hyper-tension, 
high cholesterol or tobacco use (WHO 2009). In the United States (U.S.) alone, 
alcohol misuse is responsible for an approximately 88,000 deaths and 2.5 million 
years of potential life lost (YPLL) annually from 2006-2010, making excessive 
alcohol use the leading cause of premature mortality and the fourth highest 
preventable cause of death (Stahre et al. 2014). However, one of the most 
important consequences of alcohol use are alcohol use disorders (AUDs). As 
currently defined by the Diagnostic and Statistic Manual, 5th Edition (DSM-V), 
AUD (which encompasses both alcohol dependence (AD) and alcohol abuse) is 
a heterogeneous disorder stemming from complex interactions of 
neurobiological, environmental and genetic factors. This chronic, relapsing 
disorder is characterized by compulsive and preoccupied alcohol use despite 
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negative consequences, loss of control over alcohol intake and the emergence of 
a negative affective state (e.g. dysphoria, irritability, anxiety) when access of the 
drug is prevented (Koob and Volkow 2016; Zorrilla et al. 2014). In the United 
States, approximately 51% (120 million) of the population over the age of 12 
reported as current alcohol users (Koob and Volkow 2010). Of these users, 
approximately 13% (30 million) met the criteria for AUD (Grant et al. 2017). 
Alcohol use disorder represents a staggering and substantial public health 
concern, resulting in a myriad of medical, psychological, social and economic 
problems.  
Chronic alcohol use is extremely damaging to the human body. Indeed, 
alcohol is a casual factor in more than 60 diseases, including liver cirrhosis and 
cardiovascular disease and is involved in the etiology of more than 200 medical 
conditions (WHO 2014a). Excessive alcohol use can have an effect on numerous 
organs such as the gut, liver, pancreas and heart, contributing to endotoxemia, 
advanced liver disease, pancreatitis, irregular heartbeat, stroke, high blood 
pressure and cardiomyopathy (Souza-Smith et al. 2016). Further, increasing 
research has documented a dose-relationship between alcohol consumption and 
the development of cancer in different body locations, such as oral cavity, 
pharynx, larynx, esophagus, colon/rectum and female breast (Medina-Mora et al. 
2016; Rehm et al. 2018). Chronic alcoholism has also been associated with mild 
to severe impairments in cognitive, behavioral and emotional functioning (Bates 
et al. 2002) and has been shown to induce mood, anxiety, psychotic, sleep and 
dementia disorders (Hayes et al. 2016).When left untreated, the co-occurrence of 
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AUD and other psychiatric conditions (mood disorders, post-traumatic stress 
disorder, schizophrenia and the use of other drugs; Petrakis et al. 2006) can 
interact to further aggravate alcoholism’s effects on brain and behavior (Hasin et 
al. 2007) and complicate treatment. Although dependent on the extent of 
impairment at the time of drinking cessation, abstinent alcoholics have shown 
improvements in neuropsychological functioning with continued sobriety (Oscar-
Berman et al. 2014). However, up to 2 million people with an AUD development 
permanent and debilitating conditions that require lifetime care (Oscar-Berman et 
al. 2004; Oscar-Berman and Marinkovic 2003; Oscar-Berman et al. 1997) 
Alcohol consumption may have a marked impact on others beyond the 
health of the user. Alcohol-related harm affects families, neighbors, friends and 
communities through risky behavior and negligence of drinkers while intoxicated. 
Among a long list of consequences, harm to others includes (but is not limited 
to): driving while impaired, family income loss, unemployment, work injuries, 
increase in health expenses, property damage, absenteeism, domestic violence, 
abuse, neglect and impact on family member’s mental health (depression, 
anxiety), especially as a result of dysfunctional family environments affecting 
normal child development (WHO 2014a). Harmful use of alcohol is also a major 
contributor to violence; estimates suggest approximately 30% of total violent 
deaths are attributable to alcohol (WHO 2011a).  Additionally, increasingly 
significant consequences of maternal drinking during pregnancy are pre-labor 
complications and/or neurodevelopmental abnormalities, including fetal alcohol 
syndrome (FAS) (Foltran et al. 2011)  
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On average, alcohol dependence life-time prevalence rates are high 
(roughly 15%; (Hasin and Grant 2004). Though treatment-seeking has been 
found to increase rates of recovery from alcohol dependence, only a minority with 
AUD seek and undergo formal treatment (Cohen et al. 2007). While some users 
achieve long-term sobriety without active treatment, many individuals continue to 
relapse despite multiple levels of intervention (Ferri et al. 2006). In fact, after a 
single treatment episode, roughly only one in four patients will abstain from 
alcohol in the first year (Miller et al. 2001). This may be due, in part, to many 
different barriers to treatment such as stigma, not recognizing problems related 
to alcohol, not acknowledging or perceiving a need for treatment, or wanting to 
handle alcohol-related problems on one’s own (Cunningham et al. 1993; Glass et 
al. 2017) In this regard, psychosocial interventions are perhaps the most utilized 
and efficacious forms of intervention(Dawson et al. 2006) to achieve and 
maintain recovery. Mutual help and self-help organizations, such as Alcoholics 
Anonymous (AA), play a significant role in recovery for those interested in 
reducing or ceasing drinking. However, while participation in AA or similar 12-
step group programs are often suggested as an adjunct for professional 
treatment (and may have affiliations with treatment institutions) these groups are 
not considered a formal treatment option (Medina-Mora et al. 2016; Sussman 
2010). Clinical interventions, such as professional counseling, out-patient or in-
patient programs can be costly (an additional barrier) and require high functional 
social support to achieve program adherence (Dobkin et al. 2002). Thus, there 
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remains a pressing need to develop lasting, successful and easily accessible 
therapeutic strategies to prevent return to heavy alcohol drinking. 
 Pharmacological intervention is a potential treatment strategy to reduce 
withdrawal symptoms and prevent relapse to alcohol drinking. Currently, there 
are three drugs approved by the U.S. Food and Drug Administration (FDA) for 
the treatment of AUD: Disulfiram (Antabuse), Naltrexone and Acamprosate 
(Akbar et al. 2018). Although these pharmacotherapies have proven to be 
beneficial for some people, success rates are variable and patient compliance is 
poor due to deleterious medication side effects (Heilig and Egli 2006). 
Additionally, there are a number of off-label medications (e.g., anticonvulsants, 
antipsychotics, antidepressants, for review see (Akbar et al. 2018) for the 
treatment of AUD targeting the physiological and negative affective symptoms of 
withdrawal. However, there is currently no single medication or intervention that 
boasts one hundred percent efficacy rate in supporting abstinence.  Thus, 
understanding the neurobiological underpinnings of alcohol addiction is critical to 
the development of effective pharmacotherapeutics.   
 
Addiction Neurocircuitry and Stages of Addiction 
 
Addiction has been classically conceptualized as a cyclic brain disorder 
composed of three general stages: ‘binge/intoxication’, ‘withdrawal/negative 
affect’ and ‘preoccupation/anticipation’ (Koob and Volkow 2010). This composite 
framework encompasses aspects of both impulse control disorders (positive 
reinforcement mechanisms) and compulsive disorders (negative reinforcement 
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mechanisms), in which impulsivity dictates the early stages of addiction and the 
combination of impulsivity and compulsivity dominates the later stages (Koob and 
Volkow 2010). While many individuals partake in occasional, controlled 
substance use at some point in their lives, some substance users transition to 
loss of control and chronic use. Research suggests that this transition by some 
users in response to drug and/or alcohol use is mediated by neuroplastic 
changes in brain reward-, stress- and executive function systems (Kalivas and 
Volkow 2005; Koob 2008; Koob and Volkow 2010; Koob and Volkow 2016). 
Alcohol and other drugs of abuse have both positive and negative 
reinforcing properties. During the early stage of addiction (“binge/intoxication 
stage”), drug use is motivated primarily by the acute reinforcing effects 
(“positive”) of a substance mediated by mesocorticolimbic dopamine systems 
(Koob 2013a). All addictive drugs have been shown to (directly or indirectly) 
activate dopaminergic neurons originating in the ventral tegmental area (VTA). 
These projections converge on targets in the limbic forebrain, including the 
nucleus accumbens (NAc), which appears to be the primary region assigning 
importance to the drug experience (Koob and Volkow 2010; Wise 1998). In 
addition, alcohol has also been hypothesized to recruit non-dopaminergic 
systems, particularly GABA and opioid peptides, to induce activity in the 
mesolimbic system to signal reward (Nestler 2005; Tabakoff and Hoffman 2013). 
Activation of dopamine systems by drugs of abuse sensitizes the reward system 
and attaches incentive salience to both the substance and drug-related stimuli to 
drive goal-directed (impulsive) behavior (Uhart and Wand 2009). The transition 
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from controlled to compulsive drug taking has been associated with a shift in the 
involvement of NAc to the dorsal striatum that is associated with habit formation 
(Everitt and Robbins 2013; Volkow and Morales 2015). 
As an individual continues further into the addiction cycle, neurochemical 
systems other than those involved in the positive rewarding effects of drugs of 
abuse are recruited by chronic activation of the reward system (Koob 2013a; 
Koob 2013b; Koob and Le Moal 2005). The “withdrawal/negative affect” stage is 
marked by the emergence of a negative emotional state (e.g., dysphoria, anxiety 
and irritability) when access to the drug is prevented (Koob et al. 2004) and 
primarily mediated by brain stress-systems (corticotrophin-releasing factor; CRF) 
in the HPA-axis and extended amygdala (Koob 2008; Koob et al. 2004). Both 
stress- and drug-induced activation of the HPA-axis allows glucocorticoids to 
sensitize reward pathways, characterized by increases in reward thresholds 
during withdrawal (Koob and Kreek 2007). As dependence and withdrawal 
develop, brain “anti-reward” systems, such a CRF and dynorphin (DYN), are 
recruited in the extended amygdala (Koob 2013a) contributing to dysphoria and 
distress. Thus, the motivation to take drugs is not only driven by conditioned 
response cues, but by negative emotional states.  
The final stage of the addiction cycle (preoccupation/anticipation or 
craving) is a key element of relapse and defines addiction as a chronic relapsing 
disorder (Koob and Volkow 2010; Koob and Volkow 2016). In an addicted 
individual, intense preoccupation with obtaining the abused substance develops 
and often precedes the somatic signs of withdrawal. This behavior, commonly 
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described as craving, represents a shift from goal-directed behavior to habit-
driven (compulsive) behavior that results from drug-conditioned reinforcement, 
altered incentive motivation and maladaptive stimulus-response learning (Koob 
and Volkow 2010). In other words, continued heavy use becomes a conditioned 
response to relieve and avoid withdrawal symptoms (ex. withdrawal-induced 
seizures in alcoholics) (Tabakoff and Hoffman 2013). 
This stage of addiction primarily involves loss of prefrontal cortical 
executive control over intake (Everitt and Robbins 2005). Hypofunction of cortical 
circuits is thought to play a permissive role in which subcortical structures that 
drive addiction are no longer inhibited (Koob 2013a). In drug addicted individuals, 
the ventromedial prefrontal cortex (including orbital frontal cortex (OFC) and 
anterior cingulate cortex (ACC)) is hypofunctional in the absence of drug or drug 
cues, but becomes hyperactive when exposed to drug or cues thereby enhancing 
the reward salience (Volkow and Morales 2015). More specifically, exposure to 
drug-associated cues results in activation of glutamatergic systems (projections 
from the ventral prefrontal cortex, ventral hippocampus and amygdala) to striatal 
regions that increase dopamine in the NAc and dorsal striatum (Volkow and 
Morales 2015). Reduced dopamine signaling in the striatum contributes to 
reduced activity of prefrontal cortical regions, particularly the OFC and ACC, 
which represent brain regions essential for shifting behavior when a reward is no 
longer reinforcing (Volkow and Morales 2015). As a result, circuits of the 
extended amygdala that mediate enhanced reactivity to stressful stimuli, 
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dysphoria, anhedonia and increased craving drive behavior, ultimately leading to 
drug consumption (relapse). 
 In summary, during addiction the enhanced salience value of the abuse 
substance in reward, motivation and learning/memory circuits overrides control 
circuits. These circuits also interact with those involved in mood regulation, 
including stress reactivity, which contribute to heightened awareness of craving 
and drive vulnerability to relapse.  
 
Disruption of Neurotransmitter Systems by Alcohol 
 
Alcohol does not a have a specific receptor or site of action, which makes 
it challenging to identify which specific factors are affected during the transition 
from controlled to compulsive alcohol consumption. Alcohol is thought to impact 
brain function through interaction with multiple neurotransmitter systems, 
disrupting the delicate balance between inhibitory and excitatory 
neurotransmission present under normal conditions. Acute alcohol exposure 
enhances the function of inhibitory neurotransmitters and neuromodulators, such 
as Gamma-aminobutyric acid (GABA), glycine and adenosine, and decreasing 
the function of those involved in neuroexcitation, such as glutamate (Oscar-
Berman 1994). More specifically, alcohol potentiates the effects of GABA through 
the GABAA receptor subtype, increasing inhibition and sedation similar to 
benzodiazepines (Nutt 1999). Chronic and repeated alcohol exposure reduces 
the sensitivity of GABAA receptors to alcohol and GABA, such that more alcohol 
is needed in order to achieve the same depressant and intoxicating effects. 
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Additionally, alcohol increases the function of glycine receptors (inhibitory 
neurotransmitter found in the brainstem and spinal cord) which may account for 
some of alcohol’s behavioral effects (Valenzuela 1997).  
Glutamatergic signaling is critically involved in the neuroplasticity that 
occurs as dependence develops. Short-term alcohol exposure has also been 
shown to interfere with some aspects of excitatory transmission by inhibiting N-
methyl-D-aspartate (NMDA) receptors that mediate post-synaptic excitatory 
effects of glutamate (Nutt 1999; Tsai and Coyle 1998). Repeated cycles of 
alcohol exposure and abstinence lead to elevated levels of extracellular 
glutamate and/or dysregulation of glutamate transporters, particularly in the 
amygdala and PFC (Bell et al. 2016) that contribute to craving that occurs in 
abstinence (Pulvirenti and Diana 2001). 
In response to prolonged exposure the brain undergoes compensatory 
neuroadaptations to restore equilibrium. This includes the upregulation (hyper-
responsiveness) of NMDA receptors and downregulation of GABAA receptors, 
leading to tolerance. When alcohol consumption is abruptly discontinued or 
reduced, the compensatory neuroadaptations are no longer in opposition to the 
presence of alcohol, leading to hyperexcitability and development of alcohol 
withdrawal syndrome, such as withdrawal-induced seizures, stroke, and 
excitotoxicity (Tsai and Coyle 1998). 
The mescorticolimbic dopaminergic system is altered in patients with 
AUD. Alcohol directly stimulates the release of dopamine by disinhibiting 
dopamine neurons in the VTA. These dopamine neurons project to medium spiny 
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neurons (MSN) of the ventral striatum (VS) including those that express 
dopamine D2 receptors in the NAc (Volkow and Morales 2015). Additionally, 
alcohol intake enhances beta-endorphin release to stimulate mu-opioid receptors 
in the VTA, resulting in the inhibition of GABAergic interneurons that normally 
exert tonic inhibition of dopaminergic neurons in the VTA, resulting in a net effect 
of enhanced dopamine release into the NAc (Di Chiara 1997; Di Chiara et al. 
2004). 
Alcohol exposure has also been shown to alter various aspects of 
serotonin’s (5-HT) synaptic function (Lovinger 1997; Lovinger 1999). Acute 
exposure has been shown elevate serotonin levels in regions that control 
consumption (McBride et al. 1993) and appears to interfere with the function of 
serotonin receptors. With prolonged exposure, serotonin receptors (ex. 5-HT2 
subtype) undergo adaptive changes in response to increased serotonin activity, 
and likely contribute increased anxiety during withdrawal (Lovinger 1997) and 
development of co-occurring of mood disorders. Serotonin also plays a role in the 
regulation of GABA-mediated transmission and dopaminergic activity, which may 
also contribute to alcohol’s effect on the brain.  
 
THE ROLE OF STRESS IN ALCOHOL USE AND RELAPSE  
 
Stress and Alcohol 
 
Stress, defined as any stimulus that disrupts the body’s internal balance 
(i.e., physiological homeostasis), is recognized as a significant factor that 
promotes alcohol drinking and, in particular, triggering relapse (Sinha 2001; 
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Sinha 2008). Abnormal variations in the production of the stress hormone cortisol 
are a risk factor for developing alcohol dependence (Blaine et al. 2016). Alcohol 
serves as an effective anxiolytic (anxiety-reducing) agent and its ability to 
alleviate stress may be a driving factor in the motivation to drink (i.e., self-
medication; Becker 2017). At the same time, alcohol-induced elevations in stress 
hormones stimulate the HPA-axis at multiple levels, such that alcohol, itself, is a 
stressor (Becker 2012; Becker 2017).This includes stimulating the release of 
corticotrophin-releasing factor (CRF) from the hypothalamus (Sinha 2001; Smith 
and Vale 2006), norepinephrine from the locus coeruleus (Koob 2008) as well as 
other stress-related neuropeptides in extrahypothalamic stress circuits in the 
brain (Koob 2009; Koob and Mason 2016). Repeated chronic alcohol exposure 
and withdrawal can produce profound alterations in neuroendocrine function and 
engage brain stress systems, which collectively contribute to increased alcohol 
seeking and consumption (Koob and Kreek 2007; Lu and Richardson 2014; 
Schank et al. 2012). Therefore, stress, alcohol and addiction are interconnected 
in several ways. Stressful life events may predispose an individual to engage in 
problematic drinking behavior (Sinha 2008), and excessive drinking may cause 
activation of the HPA response, followed by sensitization of extrahypothalamic 
CRF systems (Koob and Kreek 2007). Stress is reinforcing in certain contexts but 
can also work to suppress the reward value of other (natural) reinforcers, which 
contribute to negative affective states related to withdrawal (e.g., anxiety, 
dysphoria, irritability) along with increased craving and drive to drink (Becker 
2012; Heilig et al. 2010). The compulsive nature of alcohol seeking and use, 
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along with high rates of relapse present a major challenge in the treatment of 
alcohol addiction. Therefore, understanding brain mechanisms underlying 
relapse and the influence of stress on drinking has emerged as a central issue in 
addiction research. The following section presents what is known about stress as 
it relates to alcohol abuse and the trajectory of dependence. Further, sex 
differences in the role of stress reactivity and negative affect in initiating and 
maintaining alcohol use will be discussed.  
 
Alcohol, Stress and the Hypothalamic-Pituitary-Axis (HPA)  
 
Many of the acute and chronic effects of alcohol are related to allostatic 
adaptations in hypothalamic and extrahypothalamic stress regulation pathways. 
Stress responses in relation to AUD includes the neuroendocrine responses of 
the hypothalamic-pituitary axis (HPA), and two branches of the peripheral 
autonomic nervous system (ANS), specifically the physiologic responses of the 
sympathetic (SNS) and parasympathetic (PNS) arms (Boschloo et al. 2011). In 
response to stress, neurons in the paraventricular nucleus (PVN) of the 
hypothalamus releases two neurohormones, corticotrophin-release factor (CRF) 
and arginine vasopressin (AVP) into the blood via a system of blood vessels at 
the base of the brain (hypophysial portal system) connecting the hypothalamus 
and the pituitary gland. Both hormones stimulate the anterior pituitary gland to 
produce and secret adrenocorticotropic hormone (ACTH) into peripheral 
circulation. The ACTH travels to the adrenal glands (atop the kidneys) and 
induces glucocorticoid synthesis and release. The main glucocorticoid in humans 
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is cortisol (termed corticosterone (CORT) in rodents). To protect the body against 
prolonged activity, the HPA system is carefully controlled through negative-
feedback loops designed to maintain precise hormone levels and homeostasis 
(Stephens and Wand 2012). At the level of the anterior pituitary gland, PVN and 
hippocampus, secretion of CRF, AVP and ACTH are in part controlled by 
negative feedback exerted by cortisol (Herman and Tasker 2016; Stephens et al. 
2012). There are two types of receptors for cortisol that participate in the 
negative-feedback mechanism- mineralocorticoid (MR) and glucocorticoid (GR) 
receptors (Herman et al. 2016). Cortisol has a higher affinity (i.e., binds more 
readily) for MRs than GRs. This mechanism allows MRs to main low cortisol 
levels circulating in the blood under normal conditions that rise and fall with a 
daily circadian rhythm (Herman et al. 2016). In response to a stressful situation, 
cortisol saturates MRs and binds to GRs with lower affinity, which terminates the 
stress response. Basal and stress-induced cortisol are maintained carefully, as 
correct regulation of cortisol levels is necessary for survival, and too little or too 
much cortisol exposure can result in serious harm (Stephens and Wand 2012). 
 In addition to the HPA-axis, the also ANS plays a crucial role in the 
maintenance of homeostasis. The ANS has two divisions: the SNS, which 
mediates excitatory processes (“fight or flight”) and PNS which is responsible for 
inhibitory processes (“Rest and Digest”). From the PVN, CRF-containing neurons 
send projections to noradrenergic centers in the brain and spinal cord (Wehrwein 
et al. 2016). More specifically, the locus coeruleus (LC) sends direct projections 
to sympathetic preganglionic neurons in the spinal cord and to the 
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parasympathetic preganglionic neurons in the brainstem and spinal cord. In 
general, the LC modulates sympathetic and parasympathetic activity through a1-
adrenoreceptors and a2-adrenoreceptors, respectively (Karemaker 2017; 
Wehrwein et al. 2016). The activation of the SNS in turn stimulates the release of 
CRF by the hypothalamus, creating a direct feedback loop (McCorry 2007). The 
principle neurotransmitters of the ANS are norepinephrine (NE), epinephrine (E) 
and acetylcholine (ACh) (McCorry 2007). The sympathetic system controls 
catecholamine synthesis and secretion (NE and E) from the adrenal medulla in 
response to stressors (McCorry 2007). The SNS and PNS are meticulously 
coordinated to maintain homeostasis. Under normal conditions, the PNS is 
activated when a stressful situation is alleviated, however, in prolonged stress 
experiences the SNS remains engaged, resulting in chronically high levels of 
peripheral catecholamines (Karemaker 2017). 
The relationship between stress and alcohol is complex and likely 
changes throughout the trajectory of alcohol dependence. In the beginning 
stages, direct activation of the HPA-axis likely contributes to the acute 
physiological effects of alcohol (Becker 2012). Chronic CORT exposure in 
rodents has been shown to reduce sensitivity to the subjective effects of alcohol 
(Becker and Baros 2006; Besheer et al. 2012). In this regard, blunted subjective 
feedback regarding intoxication may act as a permissive factor that promotes 
increased levels of drinking (Becker 2012). Continued heavy drinking constitutes 
a potent stressor, holding the HPA-axis in a constant state of activation that leads 
to disturbances in HPA-axis functioning. Indeed, chronically high levels of alcohol 
 
 16 
consumption have been shown to produce overall elevation in blood 
glucocorticoid levels, flattening of normal circadian fluctuations and dampening 
HPA response to stress challenges (Becker 2012; Le et al. 2000; Wand and 
Dobs 1991). Changes in basal HPA-axis activity (hyperactivity) is associated with 
blunted responses to alcohol and stress related cues and increased craving 
levels, which in turn, may result in high levels of alcohol intake to physiologically 
normalize the HPA-axis (Sinha et al. 2011). Thus, allostatic adaptations in stress 
systems in response to heavy consumption contribute to a state of incentive 
sensitization and increase risk for relapse during periods of abstinence (i.e., 
withdrawal).  
In conjunction with HPA-axis dysfunction, impaired autonomic regulation 
may contribute to and perpetuate sympathetic dominance over central and 
peripheral processes in alcohol dependent individuals (Blaine et al. 2016). 
Chronically high levels of NE, acting on a1 receptors, are thought to induce 
sympathomimetic states associated with withdrawal (Hawley et al. 1994). Altered 
ANS activity, in the form of enhanced sympathetic tone, has also been 
associated with dysfunctional emotional regulation (Boschloo et al., 2011) that 
may contribute to the emergence of a negative affect state when access to 
alcohol is prevented. Increased NE in circulation may further prime the brain to 
depend on habit-based responding by holding bodily systems in the fight-or-flight 
state (Blaine et al. 2016). 
It is in this vein that the dynamic interplay between stress and alcohol 
facilitates the transition to dependence. Alcohol may relieve stress, while at the 
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same time provoke a stress response. Continued use perturbs the HPA-axis 
beyond allostatic limits, leading to symptoms of chronic stress. Finally, alcohol 
serves as a negative reinforcer, in that consumption leads to the removal of an 
aversive state (physiological withdrawal, dysphoria, anxiety).  Thus, continued 
heavy alcohol consumption produces changes in neuroendocrine functioning that 
may alter an alcohol-dependent individual’s response to stress, particularly with 
respect to emotional regulation and motivation to consume alcohol, thereby 
increasing the risk for relapse (Sinha 2012).  
 
Alcohol, Stress and Extrahypothalamic Targets 
 
As previously note, prolonged excessive alcohol consumption represents 
a potent stressor. Persistent dysregulation of the HPA-axis resulting from chronic 
alcohol exposure and withdrawal produces profound alterations in 
neuroendocrine function and may activate brain stress systems outside of the 
HPA-axis (Koob and Kreek 2007; Lu and Richardson 2014; Schank et al. 2012). 
Indeed, it is well established that chronic alcohol alters CRF neurotransmission 
independent of the physiological response to stress (Koob, 2013) and an 
extensive body of research has emerged indicating the CRF plays a critical role 
in alcohol addiction (Heilig and Koob 2007; Zorrilla et al. 2014). CRF-containing 
neurons are found in numerous extrahypothalamic regions associated with brain 
reward and stress systems, such as the central amygdala (CeA), bed nucleus of 
the stria terminalis (BNST), VS and PFC. The actions of CRF are mediated 
through interaction with two G-protein coupled receptor subtypes, CRF1 and 
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CRF2 (Bale and Vale 2004). Chronic alcohol exposure results in increased 
extracellular CRF and up-regulation of CRF1 receptors (associated with 
increased stress-responsiveness; Koob and Heinrichs 1999) within the extended 
amygdala and is thought to be a key element in the emergence of negative 
emotional state during alcohol withdrawal (Koob, 2013). In support of this idea, 
CRF receptor antagonists directly administered into the CeA have been shown to 
reduce both alcohol withdrawal-induced anxiety-like behavior and alcohol self-
administration in alcohol-dependent rats (Agoglia and Herman 2018; Gilpin et al. 
2015). Additionally, the recruitment of CRF in the CeA during early drinking 
behaviors (before dependence) may initiate neuroplastic changes in the stress 
system that intensify with repeated alcohol exposure (Haass-Koffler and Bartlett 
2012; Lowery-Gionta et al. 2012). Evidence suggests that binge-drinking blunts 
CRF-mediated GABAergic transmission (Lowery-Gionta et al. 2012), whereas 
dependent animals show enhanced GABAergic transmission in the CeA (Roberto 
et al. 2004). 
Additionally, glucocorticoids secreted via alcohol-induced hypothalamic 
activation modify reward-related behaviors by stimulating dopaminergic 
transmission and increasing NE levels in the PFC (Piazza and Le Moal 1997). 
Chronic a1 adrenoreceptor stimulation via NE in this region is known to impair 
attentional processes by increasing “noise” and attenuating salient “signal” 
(changing “signal” to “noise” ratio) (Birnbaum et al. 1999). This hinders the ability 
of the PFC to distinguish between relevant and irrelevant stimuli, which may 
contribute to mesolimbic control of behavior (Blaine et al. 2016). Therefore, 
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persistent increases in NE in extrahypothalamic regions and in the PFC decrease 
the ability of cortical pathways to inhibit habit-based responding to alcohol-related 
cues (Volkow et al. 2010). Additionally, negative affective stimuli increase 
amygdala activity, in part, through the release of NE, which leads to heightened 
arousal, attention, and fear memory formation and anxiety. Chronically elevated 
NE induced by long-term alcohol use can desensitize beta-adrenergic receptors 
on GABAergic amygdala neurons, which may lead to the loss of inhibitory 
signaling (Belmer et al. 2016). Interestingly, in animal models increased NE 
signaling has been associated with enhanced stress-induced reinstatement to 
alcohol following periods of abstinence (extinction) (Haass-Koffler et al. 2018).  
 
Gender Differences in the Etiology of Stress-Related Alcohol Use  
 
 Stress- and reward- systems in the brain are influenced by sex hormones, 
therefore, it is reasonable to suspect that the sex differences exist in the 
development and expression of alcohol dependency. Historically, rates of AUD 
have been higher in men (16.7%) compared to women (9%), though this gap has 
been closing over the last decade (Grant et al. 2017; Peltier et al. 2019b). 
Similarly, national data sources tracking trends in alcohol use in the U.S. have 
shown changes in drinking patterns and substantial increases in the prevalence 
of alcohol misuse and binge drinking in women (Grucza et al. 2018; Peltier et al. 
2019a). Potential factors that may contribute to the increased rates of AUD in 
women include drinking to regulate negative affect, increased experience of 
negative emotions, stress and a greater sensitivity to alcohol-related health 
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consequences (Agabio et al. 2016; Cole et al. 2006; Nolen-Hoeksema and Hilt 
2006) While stress and negative affect are strongly associated with the 
development of AUD for both men and women, these factors appear to be 
especially crucial role for women (Peltier et al. 2019). 
Increased rates of alcohol consumption in women are especially alarming 
as women experience exacerbated alcohol-health related consequences 
compared to men. While drinking is associated with significant health risks in 
both sexes, women are more vulnerable to developing alcohol-related liver injury, 
including liver cirrhosis and hepatitis, cancers and cardiovascular conditions than 
men (Agabio et al. 2016; Agabio et al. 2017). Further, psychiatric comorbidities 
such as depression, anxiety disorders and posttraumatic stress disorder (PTSD) 
occur more often in women and are associated with problematic drinking (King et 
al. 2003).   
Compared to men, women begin problematic drinking later, consume less, 
and drink less frequently (Greenfield 2002). However, female drinkers exhibit a 
phenomenon known as “telescoping” in which they progress more rapidly, 
compared to men, from drinking onset to serious-alcohol related problems and 
dependence (Piazza et al. 1989). Although a number of factors associated with 
biological differences (such as alcohol metabolism) may contribute to differential 
alcohol use, sex differences in stress reactivity and negative affect may play a 
key role in initiating and maintaining heavy drinking in women. 
Women are more likely than men to drink heavily while experiencing 
unpleasant emotions, psychological distress, or while in conflict with others in an 
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effort to relieve internal tension (Peltier et al. 2019b). Consistent with these 
observations, preclinical work has demonstrated that female rodents consume 
more alcohol in models of depression and are more responsive to stress-induce 
relapse (Bertholomey et al. 2016). In humans, several studies have found 
increased prevalence of anxiety disorders, mood disorders (i.e., depression) and 
PTSD in women (Brady and Back 2012; Brady and Randall 1999; Greenfield et 
al. 2010), particularly in those with AUD. Compared to men, there is a stronger 
correlation between negative affect associated with these co-morbid disorders 
and alcohol-related measures, including overall consumption, binge-drinking, 
craving and instances of dependence (Peltier et al. 2019b). Additionally, women 
generally show a greater propensity to relapse in response to stress, and 
demonstrate a sensitized response to stress during periods of alcohol withdrawal 
(Becker and Koob 2016). Thus, chronic alcohol use may enhance vulnerability 
for these disorders, and sex differences in the neuroendocrine adaptations that 
occur in stress- and reward- systems in response to alcohol consumption may 
mediated female susceptibility to alcohol abuse and relapse. 
 
Animal Models for Stress, AUD and Relapse 
 
The understanding of the neurobiology of addiction has largely progressed 
through the study of animal models. Although no animal model of addiction can 
fully emulate the human condition, they provide an avenue to investigate specific 
aspects or symptoms associated with the psychopathological condition. Animal 
models have been developed for various stages of the alcohol addiction cycle 
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with a focus on the motivational effects of withdrawal, craving and relapse. Such 
models provide a heuristic means with which to pursue the underlying 
neurobiological basis of the disorder, particularly the acute and long-term 
neuroadaptive changes in the brain that result in relapse.  
Binge alcohol drinking is the most common form of alcohol consumption 
and contributes to a host of long-term negative consequences, including anxiety 
disorders and the formation of alcohol dependence (Koob, 2008). Repeated 
episodes of binge-induced alcohol intoxication followed by periods of withdrawal 
are hypothesized to cause aberrant plasticity in brain reward and stress systems 
that drive increased alcohol consumption (Koob, 2008). One commonly used 
model of voluntary alcohol consumption that mimics binge patterns in rodents is 
the Drinking-in-the-Dark (DID) model. The DID procedure promotes high levels of 
alcohol drinking in alcohol-preferring strains of mice by taking advantage of the 
time in the animal’s dark cycle in which activity and nocturnal ingestive behaviors 
are high (Thiele and Navarro 2014). A “binge” session, as defined by the National 
Institutes on Alcohol Abuse and Alcoholism (NIAAA), is a pattern of drinking that 
produces BECs exceeding 0.08% (80 mg/dL). Using this limited access 
procedure, mice typically consume enough alcohol to reach BECs greater than 
100 mg/dL and resulting in behavioral evidence of intoxication in a short period of 
time (Sprow and Thiele 2012). 
In the most common variation of the DID procedure, first implemented by 
Rhodes et al. (2005), C57BL/6J mice are presented with a single bottle 
containing 20% (v/v) alcohol in place of the home cage water bottle for 2hr, 3-hr 
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after the beginning of the dark cycle, for 3 consecutive days. On the fourth day, 
the drinking session is extended to 4 hr during which mice exhibit binge-like 
behavior, consuming significant and physiologically relevant amounts of alcohol 
(Rhodes et al. 2005). Several studies have characterized DID and have shown 
that BECs of < 100mg/DL produce significant motor incoordination (Moore et al. 
2007; Rhodes et al. 2007), tolerance to this effect after repeated binge-like 
episodes (Linsenbardt et al. 2011) and increases in subsequent voluntary alcohol 
drinking (Cox et al. 2013b). The DID model does not require training, prior 
exposure to alcohol or inclusion of sweet compounds to motivate high levels of 
alcohol intake. Further, in contrast to other models of binge-like drinking, DID 
does not require alcohol to be administered by the experimenter as by gavage, 
injection or ethanol vapor exposure (Becker and Lopez 2004), or by fluid 
deprivation or inclusion of alcohol into an animals source of nutrients. Such 
procedures may cause stress to the animal or other confounding variables, 
calling into the question the motivation to drink alcohol (Thiele and Navarro 
2014). Thus, DID provides a simple and effective high throughput tool for 
characterization of potential pharmacotherapies and may provide a useful model 
for studying binge patterns of consumption and the transition to alcohol 
dependence.  
The most direct procedure to evaluate the reinforcing properties of alcohol 
is to test whether animals are willing to work to obtain it. One way to do this is 
through oral operant alcohol self-administration procedures. Under this 
procedure, operant responses reinforced by the acute reinforcing effects of 
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alcohol provide information about voluntary intake and the motivation to obtain 
reward. The first phase of this model is the acquisition of the operant behavior. 
Animals are trained in a continuous reinforcement in which each response (lever 
pressing) is reinforced with access to alcohol (via presentation of bottle or drop of 
alcohol solution in a well). Typically, the alcohol reinforcement is paired with a 
presentation of a stimulus (cue light or tone), which may become secondary 
reinforcers through repeated pairing in the training process. In addition to an 
“active” lever that results in alcohol delivery, a second “inactive” lever is 
available. Response on this lever are measured but do not result in any 
consequences, which allows for the measurement of differential responding and 
(nonspecific) motor activation.  
Once stable responding is achieved, an animal’s propensity to relapse can 
be assessed using the extinction-based model of reinstatement. During this 
phase, lever responding is extinguished (dramatically reduced) over repeated 
trials in the absence of alcohol reward and alcohol-related cues. During the 
reinstatement test, the resumption of alcohol- seeking behavior after extinction 
training is assessed following exposure to the alcohol itself, cues or contexts 
previously paired with alcohol reinforcement, or stressors (Shaham et al. 2003). 
The reinitiating of responding on the previously extinguished lever is 
hypothesized to reflect the motivation for drug-seeking behavior, which may 
mimic the “craving” aspect of the preoccupation/anticipation stage of addiction. 
This model is considered to have high face and construct validity (Leong et al. 
2018; Markou et al. 2009) as factors that provoke relapse and craving in humans 
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(re-exposure to drug, cues or stress) also reinstate alcohol-seeking in animals. 
However, this “relapse-like” behavior does not involve return to drinking which 




Neuropeptide Systems as Targets for the Treatment of Stress and AUD 
 
Neuropeptides are short sequences of amino acids that are co-expressed 
with neurotransmitters and widely expressed throughout the central nervous 
system (Thiele 2017). A number of neuropeptides arise from the hypothalamus 
and are of particular relevance to AUD due to their role in maintaining 
physiological homeostasis, energy balance and ingestive behaviors (Thiele 2017) 
such as galanin (GAL), melanin-concentrating hormone (MCH), neuropeptide Y 
(NPY), orexin/hypocretin (OX), DYN and CRF (Barson and Leibowitz 2016). 
These hypothalamic peptides can act locally (within the hypothalamus) or 
project to extrahypothalamic regions to interact with other systems. The 
mesolimbic dopamine reward system, for example, is heavily regulated by 
neuropeptides most likely due to its involvement in acquiring natural reinforcers, 
such as food, water and sex (Barson and Leibowitz 2016). Other neuropeptides 
are produced within the extended amygdala (i.e., CRF, DYN) and are critical for 
the integration of emotional behaviors (Koob and Le Moal 2001) These too can 
signal locally or project elsewhere to modulate neurotransmission. 
A growing body of literature has emerged implicating a crucial role for 
neuropeptide systems in the modulation of the neurobiological response to 
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alcohol. Neuropeptides are essential when the nervous system is trying to adapt 
to various challenges and likely interact in multiple and complex ways. Repeated 
alcohol exposure and withdrawal are thought to produce neuroplastic alternations 
in these systems, contributing to allostatic shifts in activity and function (Koob & 
Le Moal, 2001). During the progression of AUD, alterations of neuropeptide 
activity in systems that modulate energy balance, reward, stress and emotional 
function are thought to contribute to escalating consumption and anxiety aspects 
the of addiction pathophysiology. Alcohol-induced adaptations of stress-related 
neuropeptide systems within the extended amygdala, such as CRF, DYN and 
NPY, promote the dysregulation of emotions that contribute to the emergence of 
a negative affective state, especially during periods of withdrawal. Negative 
affect, in turn, is thought to motivate alcohol intake as a way to alleviate adverse 
symptoms (Koob & Le Moal, 2001). Thus, both hypothalamic and 
extrahypothalamic systems are likely involved in the repeated periods of 
abstinence following by return to heavy drinking that are reflective of 
dependence.  
The neuropeptide oxytocin (OXT) has recently emerged as a promising 
therapeutic target for the treatment of alcohol use disorder. Oxytocin modulates 
the adaptive processes associated with reward, tolerance, memory and stress 
responses (Lee et al. 2016). Aside from its known hormonal role in parturition 
and maternal behaviors, the nonapeptide has well-documented roles in 
mammalian (pro) social behavior (e.g., pair-bonding, social reward processing, 
aggression), which has been largely contributed to overlapping organization and 
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projection sites in the midbrain dopaminergic system and direct modulation of 
dopamine neurotransmission by OXT (Charlet and Grinevich 2017; Love 2014). 
Convergent pathways within the mesocortiolimbic dopamine systems involved in 
the processing of motivationally relevant stimuli not only has important 
ramifications in social and maternal behavior, but may extend to influencing the 
rewarding aspects of alcohol and other substances of abuse (Baskerville and 
Douglas 2010; Burkett and Young 2012). Oxytocin is also known to exert potent 
anti-stress and anxiolytic effects (Jurek et al. 2015; Peters et al. 2014; Slattery 
and Neumann 2010) through interaction with the HPA-axis and extra-
hypothalamic stress-related brain regions, thereby enabling OXT to contribute to 
the regulation of negative affect and stress-related behaviors relevant to 
addiction. The following section will review the structure and function of the OXT 
system, as well as discuss its role in the treatment of psychiatric and stress-
related disorders, including alcohol addiction. 
 
Neuroendocrine and Neuropharmacological Function of the Oxytocin 
System  
 
Oxytocin is nine amino acid polypeptide that exerts a wide spectrum of 
central and peripheral effects, ranging from the modulation of neuroendocrine 
reflexes to the establishment of complex social behaviors (Gimpl and Fahrenholz 
2001). Oxytocin synthesis within the central nervous takes place in magnocellular 
neurons of the mammalian hypothalamus, specifically within the bilateral 
paraventricular nucleus (PVN) and supraoptic nucleus (SON) (Jurek and 
Neumann 2018). These neurons possess major axonal projections to the 
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neurohypophysis by which OXT is released into the bloodstream for peripheral 
distribution (Leng and Ludwig 2016; Quirin et al. 2011). In addition to the 
magnocellular neurons of the SON and PVN, a small portion of magnocellular 
OXT neurons can also be found in the accessory nuclei of the hypothalamus 
(Jurek and Neumann 2018). Oxytocin is released from the posterior pituitary in 
response to a variety of stimuli including suckling, parturition and stress (Gimpl 
and Fahrenholz 2001). Moreover, OXT may also be synthesized in peripheral 
tissue such as sexual organs, placenta, corpus luteum and the heart (Gimpl and 
Fahrenholz 2001) for local release or release into the bloodstream.  
Central OXT derives from at least three separate systems; magnocellular 
neurons of the SON and PVN, and parvocellular neurons of the PVN. The 
magnocellular neurons targeting the posterior pituitary develop axon collaterals 
that extend long range projections to various forebrain regions, including the 
PFC, anterior olfactory nucleus, NAc, lateral septum (LS), hippocampus, BNST 
and amygdala (Stoop 2012). Oxytocin synthesis also occurs in smaller 
parvocellular neurons of the PVN and to a small degree in selective extra-
hypothalamic neurons (Jurek and Neumann 2018). These neurons are distinct 
from magnocellular populations in that they do not release OXT into blood 
circulation (Knobloch and Grinevich 2014). Parvocellular OXT neurons project 
mainly to the brainstem and spinal cord where they synapse to effect autonomic 
functions, pain regulation and analgesia (Eliava et al. 2016). Since various 
subgroups of OXT neurons may innervate distinct brain regions it has been 
hypothesized that certain stimuli may activate select neuronal populations within 
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specific intracerebral projections, in addition to OXT neurons projecting to the 
posterior pituitary (Jurek and Neumann 2018). This enables OXT release to be 
both stimulus- and region-dependent. Further, OXT neurons have been shown to 
exhibit both axonal and dendritic release in which OXT binds to local OXT 
receptors (OXTR) or may diffuse over long distances to bind to adjacent OXTRs 
(Grinevich et al. 2016).   
Many OXT processes contact the ventricle system and may interact with 
cerebrospinal fluid (CSF) directly (Jurek and Neumann 2018) and a number of 
OXT-receptive brain regions border the ventricular system and arachnoid spaces 
(e.g. Amygdala, Hipp, BNST; (Gimpl and Fahrenholz 2001). Therefore, diffusion 
of OXT within the fluid of extracellular space could be underlying the behavioral 
effects of the neuropeptide (Knobloch and Grinevich 2014). To this idea, central 
release of the peptide triggers OXT release from neighboring dendrites, inducing 
a coordinated response from all OXT neurons in the activated brain region 
(Veening and Olivier 2013). As a result, extracellular levels of oxytocin released 
into the SON or PVN rapidly increase and reach the CSF by targeted release or 
“spilling over” of EC-concentrations alongside the CSF compartments (Veening 
et al. 2010). The half-life of oxytocin in CSF is considerably longer than in plasma 
(28 minutes versus 2 minutes) and transport by ventricular CSF is relatively fast 
(1-2 minutes). Thus, it has been hypothesized that CSF may be a ‘message-
carrier’ for endogenous OXT communication between hypothalamic regions and 
receptive target areas in the CNS (Veening and Olivier 2013).  
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Currently, there has been only one oxytocin receptor (OXTR) identified 
(Gimpl and Fahrenholz 2001). Receptors are abundant throughout both central 
and peripheral systems and are expressed in a sex- dependent and species-
specific manner (Dumais and Veenema 2016). In the periphery, receptor 
expression is observed in numerous tissues including mammary gland, 
endometrium, ovary, testis, gastrointestinal tract, heart, kidney (Kimura et al. 
2003). Centrally, OXTRs are expressed in brain regions that regulate learning 
and memory, stress, mood, social and reward related behaviors, such as 
prefrontal cortex (PFC), VTA, NAc, hippocampus, hypothalamus, ventral pallidum 
(VP), amygdala and brainstem (Gimpl and Fahrenholz 2001). 
The oxytocin receptor is a member of the family of the rhodopsin-type 1 G 
protein-coupled receptor (GPCR) family and together with three vasopressin 
receptor subtypes (V1a, V1b and V2) forms of subfamily of structurally related 
receptors (Devost et al. 2008). The OXTR is diverse in its signaling pathways 
(many of which remain unexplored) and the precise mechanisms by which OXT 
exerts multiple biological actions have not been fully established (Devost et al. 
2008). Nonetheless, OXT appears to be functionally coupled to the Gq/11- 
mediated pathway, stimulating phospholipase C (PLC) to induce increased 
intracellular calcium and inositol trisphosphate production (InsP3) (Vrachnis et al. 
2011). However, depending on brain area and concentration, OXT also promotes 
activation of Gi and Go coupled signaling cascades (Busnelli et al. 2012). While 
the precise role for these OXTR signaling pathways within the brain is relatively 
unknown, the promiscuity of OXTR (coupling to Gq or Gi/Go) most likely results in 
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opposite effects on cell excitability (Gravati et al. 2010). One possible hypothesis 
is that the local concentration reached by OXT may engage different signaling 
pathways to allow for more finely tuned signaling mechanisms and behavioral 
responses (Grinevich et al. 2016). Further, due to high structural homology OXT 
can also bind to and activate the related vasopressin receptor subtypes (V1a, 
V1b and V2) (Knobloch & Grinevich, 2014). Under some conditions, this may 
constitute alternative targets for OXT, especially at high local concentrations and 
in brain regions that have little or no OXTR expression (Grinevich et al. 2016). 
 
Role of Oxytocin in Neuropsychiatric Disorders  
 
 Oxytocin has been shown to play a key role in the regulation of several 
behaviors associated with neuropsychiatric disorders, including social 
interactions, social attachment and social cognition, feeding behaviors, emotional 
reactivity and threat perception, stress responsiveness and reward behaviors 
(Shamay-Tsoory and Young 2016). Indeed, an increasing body of evidence 
suggests that dysregulations of the oxytocinergic system may be involved in the 
pathophysiology of numerous psychiatric disorders, particularly those 
characterized by social deficits. These disorders include, but are not limited to: 
autism, schizophrenia, mood and anxiety disorders, PTSD and substance use 
disorders (Martinetz and Neumann 2016; Romano et al. 2015). The following 
section will briefly discuss preclinical and clinical findings that evaluate the role of 
the oxytocinergic system in some of these disorders. 
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 Oxytocin appears to be involved in number of complex social behaviors 
across a range of species (Bosch and Neumann 2012). One of the most well-
understood aspects of this behavior is the regulation of maternal bonding (Ross 
and Young 2009). Oxytocin promotes maternal care behaviors and plays a 
crucial role in the bond formation between mother and offspring (Ross and 
Young 2009). Oxytocin is also involved in the development of adult-bonding, 
including the formation of pair bonds (partner preference), social memory and 
social recognition (Engelmann et al. 1998; Insel et al. 1998). The effects of OXT 
on social behaviors are complex and may be dependent on the context in which 
they occur. More specifically, OXT appears to promote sociality when social and 
environmental cues are perceived as “safe”, whereas OXT may induce defensive 
and/or aggressive behavior when cues are interpreted as “unsafe” (Olff et al. 
2013). Genetic studies have reported associations between genetic 
predisposition and social behavioral phenotypes. For example, one OXTR gene 
variant has been associated with positive social traits, such as increased 
empathy, optimism and trust, whereas carriers with the opposite allele appear to 
display lower optimism and self-esteem, negative social perceptions, and higher 
levels of psychological stress (Martinetz and Neumann 2016).  
 In this regard, it is not surprising that dysregulation in OXT signaling 
mechanisms have been proposed to contribute to the socio-emotional 
dysfunction seen in autism spectrum disorders (ASD) (Insel et al. 1998). 
Decreases in plasma OXT levels have been reported in autistic children, 
correlating to low social and communication skills (Modahl et al. 1992; Modahl et 
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al. 1998). Further, several large-scale studies have demonstrated an association 
between a specific OXTR gene single nucleotide polymorphism (SNP) and ASD 
(Campbell et al. 2011; Jacob et al. 2007; Lerer et al. 2008). Interestingly, OXT 
administration (intravenous (IV) or intranasal (IN)) has been shown to reduce 
repetitive behaviors and improve social cognition in adult and adolescent patients 
with ASD (Guastella et al. 2010; Hollander et al. 2007; Hollander et al. 2003). 
Additionally, preclinical and clinical literature suggests OXT 
neurotransmission may be involved in the regulation of cognitive deficits, as well 
as the expression of both positive (hallucinations, delusions) and negative 
(anhedonia, asociality) symptoms seen in schizophrenia (SCZ) (Feifel 2012). 
Low plasma OXT has been associated with more severe symptoms across all 
three domains of SCZ (Shilling and Feifel 2016) and genetic studies have 
revealed multiple OXTR gene variants associated with both positive and negative 
symptoms (Haram et al. 2015; Souza et al. 2010). In clinical trials, chronic co-
administration of IN OXT and atypical antipsychotic medication in schizophrenic 
patient populations has been reported to improve negative symptoms (Feifel et 
al. 2010; Gibson et al. 2014; Modabbernia et al. 2013). Additionally, a single 
dose of IN OXT was able to modulate the neural response (measured by fMRI) to 
different facial emotions in patients with SCZ (Shin et al. 2015). 
Perturbations of the OXT system may also be involved in the 
pathophysiology of stress-related psychiatric disorders such as post-traumatic 
stress disorder (PTSD) and Major Depressive Disorder (MDD).  In terms of 
PTSD, lower levels of salivary OXT were observed in men with PTSD (Frijling et 
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al. 2015) and PTSD symptom severity has been associated with lower plasma 
OXT levels during exposure to abandonment-related film scenes (Munro et al. 
2013). PTSD is characterized by an exaggerated fear response which fails to 
extinguish overtime and cannot be inhibited in “safe” contexts (Koch et al. 2016). 
There is some evidence to suggest that deficits in OXT signaling contribute to 
these processes and that increasing levels of OXT may be helpful for symptom 
relief. For example, single doses of IN OXT have also been associated with a 
variety of promising results in PTSD patients, including increased reward 
responsivity (Nawijn et al. 2016; Nawijn et al. 2017) improved working memory 
(Flanagan et al. 2018), reduced provoked PTSD symptoms (Sack et al. 2017), 
and reduced amygdala reactivity (Koch et al. 2016). With respect to MDD, lower 
levels of OXT have been observed in depressed pregnant women (Massey et al. 
2016a; Massey et al. 2016b) and a negative correlation was observed between 
serum OXT concentrations and depressive symptom severity in a clinical 
population (Scantamburlo et al. 2007). Oxytocin administration has been shown 
to be effective in enhancing the processing of affective cues and increased 
motivation to affiliate (Sippel et al. 2017) and in an open trial, IN OXT was 
reported to increase measures of life enjoyment and satisfaction in chronically 
depressed patients who previously did not respond to treatment (Scantamburlo 
et al. 2015).  
Although OXT application appears to hold some promise in the treatment 
of multiple psychiatric disorders, little is known about the mechanisms that 
underlie these effects. One potential mechanism may be through interaction with 
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serotonergic systems. Serotonergic neurons display OXTRs and OXT modulates 
the release of serotonin (5-HT) within the dorsal raphe nucleus (Mottolese et al. 
2014). Both OXT and 5-HT regulate various aspects of social behavior and may 
interact in both MDD and ASD (Martinez and Neumann 2016). Additionally, it is 
speculated that OXT may produce its anxiolytic effect, at least in part, by 
modulation of 5-HT activity within the amygdala.  Oxytocin interactions with 
glutamatergic systems, specifically with mGluR5 in the lateral septum (LS), also 
appears to be important in affiliative behavior and sociability. Furthermore, there 
is strong evidence for interactions of OXT with dopaminergic systems, especially 
within the NAc, where OXT modulates reward. This interaction will be discussed 
more in depth in the next section. Finally, OXT is known to exert potent anti-
stress and anxiolytic effects (Peters et al. 2014; Slattery and Neumann 2010) via 
interaction with the HPA-axis. Oxytocin administration has been shown to 
dampen increases in CORT levels and stress-induced HPA-axis activation, as 
well as reduce behavioral responses in animal models of anxiety and depression 
(Neumann et al. 2000; Windle et al. 2004; Windle et al. 1997). Conversely, mice 
genetically engineered to lack the gene for OXT (OXTKO) display more anxiety-
related behavior and greater CORT response following exposure to stress 
(Amico et al. 2004; Mantella et al. 2005; Mantella et al. 2004). Further, high 
levels of OXT and OXTR mRNA expression are localized to forebrain regions, 
such as the extended amygdala, that are critically involved in anxiety and stress-
responsiveness (Dabrowska et al. 2011; Veinante and Freund-Mercier 1997), 
 
 36 
thereby enabling OXT to contribute to the regulation of anxiety, stress and 
reward-related behaviors.  
 
Oxytocin in Addiction 
 
A large number of preclinical studies have investigated the effect of OXT 
on various drug-induced behaviors throughout the phases of addiction pathology 
(Lee et al. 2016; Lee and Weerts 2016; Leong et al. 2018). Oxytocin has been 
shown to modulate the development of acute and chronic tolerance to multiple 
drugs of abuse, including the analgesic effect of morphine and heroin (Kovacs et 
al. 1984; Kovacs et al. 1987), physiological effects of alcohol (i.e., sedative, 
ataxia and hypothermic; Szabo et al. 1987; Szabo et al. 1985; Szabo et al. 1989) 
and sensitization to hyperactivity and stereotyped behavior associated with 
psychostimulants (Sarnyai et al. 1992). With respect to self-administration 
behavior, OXT has been shown to effectively decrease both acquisition and 
maintenance of heroin (Ibragimov et al. 1987; Kovacs et al. 1985), alcohol 
(Bowen et al. 2011; MacFadyen et al. 2016; Peters et al. 2013; Peters et al. 
2017; Stevenson et al. 2017a), cocaine (Leong et al. 2017; Leong et al. 2016; 
Sarnyai and Kovacs 1994; Zhou et al. 2014), methampethamine (Carson et al. 
2010a; Carson et al. 2010b; Qi et al. 2009) and nicotine (Lee et al. 2017a; 
Manbeck et al. 2014). Additionally, a number of studies have also been 
conducted investigating the ability of OXT to attenuate relapse-like behavior. 
These studies will be discussed in the following sections.  
The mechanism by which OXT interacts with the development and 
maintenance of addiction is not fully understood. However, OXT appears to 
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modulate reward signaling in the mesolimbic dopamine system through direct 
interaction with various neurotransmitter systems. Oxytocin projections from the 
PVN synapse on dopaminergic cells within the NAc (Knobloch and Grinevich 
2014) and OXTRs are present on VTA dopaminergic projection neurons that 
target the NAc and mPFC (Knobloch and Grinevich 2014; Peris et al. 2017). 
Indeed, central OXT administration has been shown to inhibit drug- and alcohol-
induced increases in dopamine in mesolimbic regions, particularly the NAc 
(Kovacs et al. 1998; Peters et al. 2017). Additionally, recent studies have 
characterized the presence of OXT/dopamine heteroreceptor complexes 
(OXTR/D2R) within the NAc and CeA (de la Mora et al. 2016; Fuxe et al. 2012; 
Romero-Fernandez et al. 2013) in which OXT-induced OXTR activation cause 
increases in D2 receptor signaling. Interestingly, the D2 receptor subtype is 
downregulated following chronic drug- exposure and activation of DR2 has been 
shown to reduced drug-seeking behavior (Volkow and Morales 2015). Thus, 
OXT, serving as an allosteric agonist to increase D2R affinity in the NAc, may 
reduce drug-seeking behavior.  
There is also some evidence to suggest that OXTRs may also interact 
with a2 adrenergic receptors (a(2A)ARs) in a similar fashion (Fuxe et al., 2012). 
More specifically, OXT via signaling at OXTR-a(2A)AR heteroreceptor complex 
may act as an allosteric antagonist to reduce adrenergic signal transduction 
(Diaz-Cabiale et al. 2000a; Diaz-Cabiale et al. 2000b). It is also likely that 
a(2A)ARs can also modulate OXTRs through reciprocal receptor-receptor 
interaction (Fuxe et al., 2012). Interestingly, OXTR-(2A)AR heterodimers have 
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been located within hypothalamic and amygdala regions as well as the nucleus 
of the solitary tract (NTS), which is well situated to mediate both central and 
autonomic stress effects (Fuxe et al. 2012; Diaz-Cabiale et al. 2000) that may be 
involved in withdrawal-related symptoms.  
Oxytocin receptors have also been localized on GABAergic interneurons 
in the NAc (Dolen et al. 2013), CeA (Huber et al. 2005), hippocampus (Zaninetti 
and Raggenbass 2000) and PFC (Li et al. 2016; Nakajima et al. 2014). There is 
also some evidence that OXTR-expressing cells contain GABA (Yoshida et al. 
2009), implicating a role for OXT in the modulation of inhibitory tone. Indeed, 
OXT administration has been shown to effect GABAergic transmission in multiple 
brain regions critical to the addiction process and may regulate both drug-
seeking and anxiety-related behaviors through interactions with its own receptor. 
Additionally, there is some evidence to suggest that OXT may also modulate 
GABA via direct interaction with GABAA receptors (Bowen et al. 2015; Dong et al. 
2017), particularly in regard to the acute physiological effects of alcohol (Bowen 
et al. 2015). 
 
Oxytocin and Alcohol Use 
 
Oxytocin signaling in brain has been shown to be altered by both acute 
and chronic exposure to alcohol. Results from human postmortem studies shed 
some light on the effects of alcohol consumption on the OXT system. In male 
patients with AUD, OXT peptide immunoreactivity was decreased in both the 
SON and PVN compared to controls (Sivukhina et al. 2006). More recently, Lee 
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et al. (2017b) reported a significant increase in OXT peptide mRNA in the PFC of 
human post-mortem AUD subjects compared to controls (Lee et al. 2017b). In 
addition, the authors report hypertrophy of OXT producing neurons in the 
hypothalamus in AUD patients, in concordance with previous evidence to 
suggest that this is an effect of chronic alcohol exposure (Madeira et al. 1993). In 
congruence, a loss of hypothalamic OXT neurons after prolonged alcohol intake 
has been reported in animal studies (Silva et al. 2002; Stevenson et al. 2017b). 
Finally, following repeated cycles of chronic intermittent alcohol vapor exposure 
to induce dependence in rats, Hansson et al. (2018) demonstrated that OXT 
mRNA was reduced in the NAc by acute alcohol and during early withdrawal, but 
increased after prolonged (3 weeks) abstinence, suggesting dynamic 
dependence-related neuroadaptation of the OXT system. Additionally, after 3 
weeks of abstinence, dependent rats showed increases in OXT receptor mRNA 
and protein levels in prefrontal cortex, striatal, amygdala and hippocampal 
regions, and a reduction in OXT mRNA and peptide expression in hypothalamic 
nuclei. These data provide evidence that chronic alcohol exposure produces 
compensatory neuroadaptive changes in the endogenous OXT system in brain 
regions specifically involved in the addiction process (Hansson et al. 2018). 
 Preclinical evidence indicates that OXT administration influences a number of 
behavioral and physiological effects of alcohol (Lee and Weerts 2016). The early 
seminal body of research in this area focused on the effect of OXT on tolerance 
to the physiological effects of alcohol. Repeated systemic administration (ip.) of 
OXT prevented the development of tolerance to the hypothermic, hypnotic and 
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ataxic effects of alcohol (Jodogne et al. 1991). Oxytocin treatment was also 
found to modulate the severity of alcohol withdrawal symptoms (Szabo et al., 
1987). Additionally, central administration of OXT (icv.) was shown to block rapid 
tolerance to the effects of alcohol (Szabo et al. 1989). Central administration was 
found to be more efficacious than peripheral administration, pointing to a 
centrally mediated mechanism. In this regard, interactions with dopamine and 
serotonin neurotransmission were postulated to mediate this effect of OXT 
(Szabo et al. 1989). 
In more recent reports, systemic administration of OXT has been shown to 
reduce alcohol preference and intake in a variety of voluntary drinking models in 
rats (Bowen et al. 2011; McGregor and Bowen 2012) and mice (King et al. 2017; 
Peters et al. 2013). Specifically, McGregor and Bowen (2012) found that a single 
dose of OXT (1 mg/kg) produced a long-lasting reduction in preference for an 
alcohol-containing solution compared with a nonalcoholic sweet solution. 
Additionally, treatment with OXT for 2 weeks prior to the induction of a two-bottle 
free-choice paradigm resulted in lower alcohol preference in OXT-treated rats 
compared to controls. MacFadyen et al. (2016) reported that systemic 
administration of a lower dose range of OXT (0.1-0.5 mg/kg, ip.) reduced operant 
alcohol self-administration in rats. Peripheral OXT treatment in a higher dose 
range (1-10 mg/kg) reduced alcohol consumption in male and female prairie 
voles that had two-bottle choice free-access to 15% alcohol (Stevenson et al. 
2017a). In a continuous access paradigm, systemic OXT administration 
decreased alcohol intake in the first hours after treatment but had no significant 
 
 41 
effect on consumption over a 24-hour period (Stevenson et al. 2017a). Most 
recently, Tunstall et al. (2019) demonstrated that both systemic (ip.) and central 
(icv.) OXT administration blocked escalated alcohol drinking and the enhanced 
motivation for alcohol in alcohol-dependent but not nondependent rats. This 
effect was also replicated with IN administration of OXT (Tunstall et al. 2019).  
While this evidence implicates a role for OXT in AUDs, the mechanisms by 
which OXT reduces alcohol consumption is not fully understood.  In a recent study, 
direct (icv.) administration of OXT reduced alcohol consumption and alcohol-
induced dopamine efflux in the NAc (Peters et al. 2017). Additionally, OXTRs have 
been identified on neurons in the VTA projecting to the NAc (Peris et al. 2017). 
Thus, it is possible that OXT reduces alcohol self-administration by altering 
mesolimbic dopamine activity that ordinarily signals alcohol-related reward. 
However, few studies have examined the role of OXTRs in mediating the 
neuropeptide’s effect on the motivational actions of alcohol. Recent reports 
showed that viral-mediated overexpression of OXTRs in NAc reduced alcohol-
induced conditioned place preference and alcohol consumption in mice (Bahi 
2015; Bahi et al. 2016). Additionally, ICV, but not peripheral, administration of an 
OXTR agonist that does not cross the blood brain barrier (therefore, would not 
diffuse into the periphery) decreased alcohol drinking, suggesting that OXT 
reduced alcohol consumption through interaction with its own receptor via a central 
mechanism of action (Tunstall et al. 2019).  Although the OXTR appears to be 
involved in the rewarding effects of alcohol, it is important to note that Bowen and 
colleagues showed that attenuation of sedative and ataxic effects by central OXT 
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administration was mediated by GABAA receptors (Bowen et al. 2015). Thus, while 
additional studies are necessary to further investigate the conditions and 
mechanisms by which OXT reduces alcohol consumption, the growing body of 
literature investigating the effect of OXT on the neurobehavioral response to 
alcohol points to the OXT system as a promising target for the therapeutic 
intervention of alcohol use disorders. 
 
Oxytocin, Stress and Relapse  
 
Due to the strong link between stress, alcohol use and relapse, the ability 
of OXT to modulate stress processes has generated growing interest in its 
potential as a treatment for substance use disorders. Indeed, preclinical evidence 
suggests that OXT administration is effective in attenuating reinstatement of drug 
seeking to conditioned cues, drug- or stress- prime. In general, systemic injection 
of OXT has been shown to reduce drug-primed reinstatement in models 
investigating heroin (Georgiou et al. 2015), cocaine (Zhou et al. 2014) and 
methamphetamine (Carson et al. 2010a; Cox et al. 2017; Cox et al. 2013a) 
related behaviors. Additionally, OXT directly applied into the NAc blocked meth-
induced conditioned place preference (CPP; Baracz et al. 2012) and attenuated 
meth-primed reinstatement of meth-seeking behavior (Baracz et al. 2015; Baracz 
et al. 2016). In regard to cued reinstatement, systemic OXT decreases 
reinvigoration of drug-seeking behavior (lever responding) for cocaine (Bentzley 
et al. 2014; Leong et al. 2017) and methamphetamine (Bernheim et al. 2017) 
provoked by stimuli previously associated with drug reward. Similar results were 
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found when OXT was administered centrally. More specifically, icv. infusion of 
OXT reduced cue-induced reinstatement of cocaine-seeking behavior in both 
male (Morales-Rivera et al. 2014) and female rats (Leong et al. 2016). In 
congruence with the aforementioned regions, direct infusion of OXT into NAc 
(Weber et al. 2018) and the subthalamic nucleus (STN), a downstream projection 
of the accumbens (Leong et al. 2017), attenuated cocaine-seeking behavior.  
To our knowledge, only one published study has investigated the effects 
of OXT administration on alcohol relapse-like behavior in animal models. 
Following repeated cycles of chronic intermittent alcohol vapor exposure to 
induce dependence in rats, Hansson and colleagues (2017) injected (icv.) OXT in 
alcohol-dependent and non-dependent rats trained to orally self-administer 
alcohol using operant conditioning procedures. Central administration of OXT 
reduced cue-induced alcohol relapse-like behavior in alcohol-dependent rats, but 
not in non-dependent rats (Hansson et al. 2017).  
Additionally, OXT has also been shown to reduce stress-related relapse-
like behavior to other drugs of abuse. Systemic administration of OXT decreased 
methamphetamine-seeking behavior following predator odor exposure (Ferland 
et al. 2016) and yohimbine administration (Cox et al. 2013) in rats. In mice, 
centrally administered OXT (icv.) attenuated reinstatement of methamphetamine 
CPP induced by restraint stress (Qi et al. 2009; Han et al. 2014), and systemic 
administration of the OXT analog, carbetocin, reduced the effects of forced-swim 
stress on reinstatement of morphine-induced CPP (Zanos et al. 2014). While 
there are currently no studies that examine the effect of OXT on stress-induced 
 
 44 
reinstatement of alcohol-seeking behavior, exogenous OXT administration may 
help to attenuate the effects of stress associated with heavy drinking and drug 
use. In support of this hypothesis, Peters and colleagues demonstrated that OXT 
administration attenuated stress-induced increase in alcohol consumption in rats 
(Peters et al. 2013). 
Clinically, OXT administration has shown some efficacy in attenuating 
craving and withdrawal-related symptoms across multiple drugs of abuse. In the 
context of stress, a single dose of IN OXT was shown to reduce stress-induced 
craving and anxiety in cannabis-dependent individuals (McRae-Clark et al. 2013). 
However, Reed and colleagues demonstrated that IN OXT produced an increase 
in subjective stress compared to placebo in female cannabis users, whereas IN 
OXT produced a small (but non-significant) decrease in subjective stress in males 
(Reed et al. 2019). The authors found no differences in stress-related cannabis 
craving, though female cannabis users demonstrated a longer latency to self-
administer and used less cannabis overall compared to males (Reed et al. 2019). 
These data indicate differential effects of OXT in males and females, particularly 
in regard to stress-related behavior and highlight the importance of adequately 
assessing sex differences. In a study by Lee et al. (2014) a single dose of IN OXT 
reduced the desire to use drug in cocaine-dependent subjects, though OXT 
treatment had no effect on cue-induced cocaine craving (Lee et al. 2014).  In 
patients with a dual diagnosis of PTSD and AUD, IN OXT attenuated cortisol 
reactivity in response to a stress provocation (Flanagan et al. 2019).  Further, IN 
OXT treatment decreased alcohol withdrawal symptoms in treatment-seeking 
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patients compared to placebo and significantly reduced anxiety in dependent 
subjects following cessation of drinking (Pedersen 2017; Pedersen et al. 2013). 
Taken together, OXT treatment may be a useful therapeutic to reduce stress-
related physiological responses (e.g. anxiety, craving) relevant to drug and alcohol 




Alcoholism is a chronic, relapsing disorder that represents a substantial and 
disabling public health concern. Excessive alcohol consumption is linked to a 
number of diseases, including cancers, cardiovascular disease, liver cirrhosis, 
FAS and neuropsychiatric disorders (Rehm et al. 2009). The Center for Disease 
Control places excessive alcohol use/abuse as the third leading cause of 
preventable deaths in the U.S. (Mokdad et al. 2004). Economically, alcohol misuse 
is estimated to cost the U.S. roughly $249 billion per year. Despite the significant 
personal, social and economic burden AUDs present, there are few effective 
pharmacotherapies available to help curb alcohol addiction. The neuropeptide 
OXT has emerged as a promising novel therapeutic target in the treatment of a 
number of neuropsychiatric disorders, including alcohol addiction. Oxytocin may 
provide therapeutic value for the treatment of AUD through its anxiolytic, stress- 
and reward- related properties by acting directly through its own receptor and 
through interactions with other neurotransmitter systems within addiction circuitry. 
The present PhD dissertation aims to add to the knowledge about OXT’s 
interaction with alcohol consumption and expand upon the current findings to 
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investigate a role for OXT in stress-induced alcohol relapse-like behavior. Further, 
we examine potential mechanisms that underlie the ability of OXT to reduce 
alcohol consumption and attenuate reinstatement of alcohol-seeking behavior in 










As discussed in Chapter 1, a growing body of literature suggests that OXT 
plays a role in several neuropsychiatric disorders that involve deficits in social 
behaviors, including drug and alcohol addiction (Baskerville and Douglas, 2010; 
Lee and Weerts, 2016). For example, while alcohol use initially promotes pro-
social behaviors, continued excessive drinking can lead to long-term social 
deficits associated with alcohol dependence, a negative consequence that may 
be mediated, at least in part, by adaptations in the OXT system (McGregor and 
Bowen, 2012; Stauffer and Woolley, 2014; Young et al., 2014). In a recent 
clinical study, Pedersen and colleagues demonstrated that IN OXT treatment 
attenuated alcohol withdrawal symptoms in treatment-seeking human subjects 
compared to placebo (Pedersen et al. 2013). Further, a number of preclinical 
studies provide support for a role of OXT in modulating alcohol preference and 
consumption. In a recent study, OXT was shown to reduce operant responding 
for alcohol in Sprague-Dawley rats (MacFadyen et al. 2016). Acute OXT 
treatment also produced a significant and lasting decrease in preference for an 
alcohol-containing solution versus a non-alcoholic sucrose solution in alcohol-
preferring “P” rats  (McGregor and Bowen 2012). Additionally, Bowen and 
collegues demonstrated that chronic exposure to exogenous OXT in 
adolescence decreased alcohol consumption in adult rats (Bowen et al. 2011). 
Thus, administration of exogenous OXT has been shown to alter a number of 
alcohol effects, including its motivational effects. 
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Many of the OXT PVN projections in brain overlap with dopamine systems 
critically involved in processing motivationally relevant stimuli. An emerging 
literature suggests that OXT can alter dopaminergic neurotransmission within 
mesocorticolimbic dopamine systems, thereby altering motivational aspects of 
not only social and maternal behavior, but also alcohol/drug addiction 
(Baskerville and Douglas 2010; Burkett and Young 2012; Groppe et al. 2013; 
Love 2014). For example, direct (icv.) infusion of OXT blocked alcohol-induced 
increases in dopamine release in the NAc and reduced voluntary alcohol 
consumption in Wistar rats (Peters et al. 2016). Additionally, viral-mediated 
overexpression of OXTRs in the NAc reduced alcohol-induced CPP and alcohol 
consumption in C57BL/6J mice (Bahi 2015; Bahi et al. 2016). Taken together, 
accumulating evidence suggests that the OXT system may represent a promising 
target for the treatment of AUDs (Lee et al. 2016; Lee and Weerts 2016). 
However, few studies have examined the broad efficacy and specificity of 
systemically administered OXT in reducing voluntary alcoholl consumption, and 
whether oxytocin influences the motivational effects of alcohol. In the present 
study, we investigated the effects of systemic administration of OXT on alcohol 
self-administration in a binge-like drinking model, in a two-bottle choice paradigm 
and in a model involving operant conditioning procedures. Specificity of OXT 
effects in the operant studies was examined by conducting parallel studies with 
sucrose solutions. It was hypothesized that OXT would selectively decrease 
alcohol consumption in these models at doses that would not affect sucrose 
consumption under similar testing conditions.  
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Adult male C57BL/6J mice (25-30g) were obtained from Jackson 
Laboratories (Bar Harbor, ME). Mice arrived at 9-10 weeks of age and were 
acclimated to the experimental housing rooms for a minimum of 1 week prior to 
the start of experiments. Mice were individually housed under a 12 hr reversed 
light/dark cycle in an AAALAC accredited facility. All testing was conducted 
during the dark phase of the circadian cycle. Mice were provided free access to 
food and water, except at the start of operant oral self-administration training. All 
experimental protocols were approved by the Medical University of South 
Carolina Institutional Animal Care and Use Committee and consistent with 
guidelines of the NIH Guide for the Care and Use of Laboratory Animals.  
 
Binge-Like Ethanol Consumption 
 
The effect of OXT on binge-like ethanol consumption was examined in 
C57BL/6J mice (n= 40) using the drinking-in-the-dark (DID) paradigm (Rhodes et 
al. 2005). Mice were presented in the home-cage with a single 15-ml graduated 
bottle of 20% (v/v) ethanol 3 hr into the dark phase of the circadian light cycle. 
Mice were provided access to ethanol for 2 hr/day for 3 consecutive days. On the 
fourth day, access to ethanol was extended to 4 hr.  Vehicle injections were 
given 30 min prior to the 2-hr drinking sessions during the first three days to 
acclimate mice to handling and the injection procedure.  On Day-4, separate 
groups of mice were injected intraperitoneally (ip.) with OXT (0, 1, 3, or 10 
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mg/kg) 30 min prior to the 4 hr drinking session. These OXT doses and the route 
of administration were selected based on previous work in rodents (e.g. Bahi 
2015; Bowen et al. 2011; McGregor and Bowen 2012; Peters et al. 2013). 
Immediately following this test session, blood samples were collected to measure 
blood ethanol concentration (BEC) using an Analox Instrument analyzer 
(Lunenburg, MA). 
Since results from the previous study indicated that the 3 and 10 mg/kg 
doses of OXT were similarly efficacious in reducing ethanol consumption, a 
follow-up study was conducted to extend these findings to a lower dose range for 
OXT. Additionally, to assess the temporal distribution of ethanol consumption 
during the 4 hr session, a separate group of mice (n= 24) was tested in the DID 
model, with the ethanol bottles fitted with lickometers as previously described 
(Griffin et al. 2009).  Briefly, contacts (i.e., “licks”) with the ethanol tube 
completed a circuit grounded to the stainless steel grid floor inside of the home 
cage. The metal drinking spouts were covered with plastic shrink-wrap coating to 
limit extraneous contacts. The metal cage floor and tubes were connected 
through lickometer circuits (Med Associates, Inc., St. Albans, VT), and contacts 
were monitored and recorded by a computer outside of the testing room. Mice 
were acclimated to the lickometers in their home cage by providing drinking 
water (24 hr/day) in bottles connected to the lickometer for one week prior to DID 
testing. As in the previous experiment, vehicle injections were given to all mice 
30 min before the 2-hr drinking sessions and on the fourth day, separate groups 
 
 51 
of mice were injected (ip.) with OXT (0, 0.3, 1, or 3 mg/kg) 30 min prior to the 4-
hr test session.  
Finally, to investigate whether exogenous OXT administration was 
exerting its effects on alcohol consumption in the DID model via actions at the 
OXTR, a separate cohort of mice (n= 40) was pretreated with the selective brain 
penetrant, nonpeptide OXTR antagonist L-368,899 (10 mg/kg) (Borthwick 2010; 
Kuteykin-Teplyakov and Maldonado 2014; Olszewski et al. 2013) or vehicle 
(0.9% saline) 15 min prior to OXT (1 mg/kg) or vehicle (saline) administration 
(ip.), which was given 30 min before the start of the 4-hr test drinking session.  
 
Two-Bottle Choice Ethanol Drinking 
 
Mice (N= 12) were provided unlimited daily access to two drinking bottles 
in the home cage containing either 20% (v/v) ethanol or tap water. Since OXT 
has been reported to reduce general fluid intake in rats (Arletti et al. 1990), a 
separate group of mice (N= 9) was given two bottles containing water throughout 
the study to assess potential effects of OXT treatment on general water intake. 
The position of the bottles was alternated daily to avoid a side preference. Mice 
were weighed weekly and fluid intake was measured at 4 hr and 24 hr. After 
establishing stable daily alcohol and water intake over 3 weeks, half the mice in 
the alcohol vs. water and water vs. water groups were injected (ip.) with 1 mg/kg 
OXT while the remaining mice in each group received a saline injection. 
Following an additional 3 days when all mice were treated with saline, mice were 
tested again with the alternative drug (1 mg/kg OXT or saline). Data were 
collapsed across dose condition for analyses.  
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Locomotor Activity  
 
Following the DID study involving use of lickometer circuitry, mice were 
left undisturbed for 4 weeks and then tested for effects of OXT on locomotor 
activity. The mice (n= 24) were injected (ip.) with the same doses of OXT (0, 0.3, 
1, or 3 mg/kg) 30 min before the start of the test session.  Injections occurred 2.5 
hr into the dark phase of the circadian cycle to match the DID procedure.  
Locomotor activity in an open field arena was assessed using Med Associates 
(St. Albans, VT, USA) activity chambers (27 × 27 × 20 cm; ENV-510) situated in 
sound-attenuating cubicles with a ventilation fan. Animal movement was tracked 
through the use of 16 horizontal infrared photo beams, located on both the X and 
Y-axes for positional and rearing detection. Photo beam breaks were recorded 
and converted to distance traveled using activity-monitoring software (Activity 
Monitor 5.0; Med Associates).  
 
Operant Self-Administration  
 
Operant Conditioning Chambers 
 
Mice were tested in standard operant chambers configured with two 
retractable levers, a centrally located well for liquid reinforcers, house light, and a 
tone generator and stimulus light above the well. The chambers were situated in 
sound-attenuating cubicles with a ventilation fan (Med Associates, St. Albans, 
VT).  One lever was assigned as the “active” lever, with responses resulting in 
access to alcohol or sucrose reinforcement paired with a light and tone stimulus 
(80 dB).  Alcohol or sucrose reinforcement (20 ul) was delivered to the well by an 
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infusion pump (activated for 2 sec). Responses on the ‘inactive lever” were 
recorded but did not result in any stimulus consequences or reinforcement 
delivery. Stimulus events and responses were controlled and monitored using 
Med PC, Version IV software (Med Associates, Inc., St. Albans, VT).  At the end 
of each session, any residual fluid left in the well was collected with a pipette, 
measured, and subtracted from the total volume of reinforcer delivered. The 
corrected volume was used to calculate g/kg ethanol or ml/kg sucrose intake 
during the sessions.  
 
Ethanol and Sucrose Self-Administration Procedure  
 
Mice were trained to orally self-administer ethanol or sucrose using a post-
prandial consumption procedure to facilitate acquisition of the behavior.  One 
hour prior to the beginning of initial self-administration sessions, water bottles 
were removed from the cages and mice were given access to standard home 
cage chow for 15 min.  Water bottles were returned to the home cage following 
the conclusion of the behavioral session. During the post-prandial manipulation 
(2-3 weeks), weights were monitored, and food was provided after the behavioral 
session to maintain weight at 90-95% pre-training body weight.  Mice were 
trained to respond on a fixed-ratio (FR)-1 schedule for access to 12% 
unsweetened ethanol or 5% sucrose solution in 20 min sessions. Once mice 
acquired stable rates of responding, the response requirement was increased to 
FR2 and then FR4 over 1-3 weeks. When mice demonstrated stable responding 
on the FR4 schedule, they were returned to ad libitum food and water access for 
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the remainder of the study. Experiments were initiated after response rates had 
stabilized (<15% variability over 3 consecutive days). To assess the effects of 
oxytocin administration on operant self-administration of ethanol (n= 13) or 
sucrose (n= 18), mice were injected (ip.) with different doses of OXT (0, 0.1, 0.3, 
or 1 mg/kg) 30 min before self-administration sessions. Each mouse received all 
treatment conditions in a Latin-square design, counter-balanced to avoid an 
order of treatment bias. Baseline levels of responding were re-established 
without drug pre-treatment for a minimum of 3 days between treatments.  
 
Progressive Ratio Testing 
 
The effect of oxytocin on motivation to seek ethanol or sucrose reward 
was assessed in a subset of the animals trained to self-administer ethanol (n= 
10) or sucrose (n= 12) using a progressive ratio paradigm. To avoid any residual 
drug effects, mice were left undisturbed in the home cage for four consecutive 
weeks prior to re-establishing baseline lever responding.  After stable baseline 
(FR4) responding was re-established (<15% variability over 3 consecutive days), 
animals were tested on a progressive ratio (PR) schedule. Mice were injected 
(ip.) with either OXT (0.3 mg/kg) or vehicle 30 min prior to testing using a 
crossover design over two test sessions spaced 7 days apart.  The PR schedule 
followed an arithmetic series, with the response requirement to obtain ethanol or 
sucrose reinforcement increased by four (i.e., FR 4, 8, 12, 16, 20, etc.). 
Breakpoint was defined as the highest ratio value reached during the session. 
The session was terminated following any 5-min period of inactivity on the active 
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lever. Maximum session length was 3 hr, at which point the session was 
terminated.   
 
Drugs and administration 
 
Synthetic human OXT (CellSciences, Canton, MA) and the OXTR 
antagonist, L-368,899 hydrochloride (Tocris Bioscience, Minneapolis, MN) were 
dissolved in 0.9% saline, which served as the vehicle. Injections were 
administered intraperitoneally at a volume of 0.01 ml/g body weight in all 
experiments. Ethanol (95%) was obtained from AAPER (Shelbyville, KY) and 
diluted with tap water to the appropriate concentration. Sucrose was also diluted 
to the appropriate concentration with tap water (5% w/v). The ethanol and 
sucrose solutions were prepared daily and presented at room temperature.  
 
Statistical Analysis  
 
Primary dependent variables were ethanol intake (g/kg), BEC (mg/dl), 
sucrose intake (mL/kg), ethanol lick contacts, and distance traveled (cm) for the 
binge-drinking studies. Ethanol intake (mL; g/kg), water intake (mL), total fluid 
intake (mL), and ethanol preference ratio (24 hr) were analyzed in the 2-bottle 
choice ethanol drinking study. Dependent measures for the operant studies 
included lever responses and ethanol/sucrose intake, as well as break points on 
the PR schedule.  Data were analyzed by analysis of variance (ANOVA), with 
Dose as a between-subjects factor (DID model studies) or a within-subjects 
factor (2-bottle choice drinking and operant conditioning studies). The factor Time 
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served as a repeated measure in analyses of lick responses and locomotor 
activity. Breakpoint data from PR testing were analyzed by t-tests.  Further 
analyses were conducted using Newman-Keuls test, when appropriate. For all 
analyses, significance levels were set at p< 0.05, and data are presented as 




Effect of Oxytocin on Binge-Like Ethanol Consumption 
 
Oxytocin significantly reduced ethanol consumption and resultant blood 
ethanol concentrations (BEC) in a dose-related manner. ANOVA revealed a 
significant effect of Dose [F(3,36)= 12.31, p< 0.0001] on ethanol intake, and post 
hoc analysis indicated a significant decrease in consumption following 1 mg/kg, 3 
mg/kg, and 10 mg/kg OXT compared to vehicle (Figure 2.1a). Analysis of BEC 
data indicated a similar profile of results, with ANOVA indicating a significant 
effect of Dose [F(3,36)= 4.86, p< 0.01]. Further analysis indicated that 3 and 10 
mg/kg OXT doses significantly reduced BEC compared to the vehicle condition, 
with a trend for reduction at the 1 mg/kg dose (Figure 2.1b).  
In a follow-up study with a separate cohort of mice, a lower OXT dose 
range was examined on ethanol intake in the DID model. Additionally, lickometer 
circuitry was employed to examine the temporal pattern of ethanol intake in the 
study. As in the previous study, ANOVA revealed a significant effect of OXT 
Dose [F(3,19)= 35.18, p< 0.0001] on ethanol consumption during the 4-hr 
drinking session. Post hoc analysis revealed that 0.3, 1, and 3 mg/kg OXT doses 
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significantly decreased ethanol intake compared to the vehicle condition, and the 
two higher doses of OXT were more effective than the lowest (0.3 mg/kg) OXT 
dose in reducing ethanol intake (Figure 2.1c). Further, OXT administration 
decreased licking responses at the ethanol bottle in a dose-related manner 









Figure 2.1. Effect of oxytocin on binge-like ethanol drinking. Oxytocin 
reduced ethanol intake (g/kg) (a) and resulting blood ethanol concentrations 
(BEC) (b) in the DID model in a dose-related manner. (N= 10/group). Using a 
lower range of doses, OXT also reduced ethanol consumption (g/kg) (c) and 
decreased as well as delayed ethanol bottle lick contacts over the 4-hr drinking 
session (d) in the DID model in a dose-related manner. Values for ethanol intake 
are mean ± s.e.m. and mean lick responses are plotted as a function of 10-min 
intervals (N= 5-6/group). Values are mean ± s.e.m. (N= 10/group). Significantly 
differs from vehicle condition: * (p< 0.05); ** (p< 0.01); *** (p< 0.001). 
Significantly differs from 0.3 mg/kg OXT dose: ^ (p< 0.05). 




















































































intake over the entire 4-hr session with cumulative licks increasing steadily over 
time, mice treated with OXT exhibited significant delay in contact with the ethanol 
bottle, only beginning to drink 1 to 2 hours after bottles were available. This was 
supported by ANOVA of the lick data, which revealed significant main effects of 
OXT Dose [F(3,18)= 30.88, p< 0.0001] and Time [F(23,414)= 57.10, p< 0.0001], 
and a Dose x Time interaction [F(69,414)= 5.03, p< 0.0001]. Analysis of total 
cumulative lick responses indicated a significant effect of OXT Dose [F(3,18)= 
14.39, p< 0.001] and post hoc analyses indicated that all three OXT doses (0.3, 
1, and 3 mg/kg) significantly decreased ethanol lick contacts compared to vehicle 
over the entire 4-hr drinking session. Further, there was a trend for the highest 
OXT dose to reduce ethanol bottle contacts more than the two lower doses (p< 
0.07).  
Reversal of Oxytocin Effect on Ethanol Consumption by Oxytocin Receptor 
Antagonist 
 
To determine whether OXT reduced ethanol consumption via its receptor, 
separate groups of mice were treated with a selective OXT receptor antagonist, 
L368,889, before OXT or vehicle (saline) administration. As previously observed, 
OXT (1 mg/kg) significantly reduced ethanol consumption in the DID model. 
However, this effect was blocked in animals that were pretreated with the OXTR 
antagonist (Figure 2.2). These observations were supported by ANOVA, which 
revealed a significant main effect of OXT Dose [F(1,36)= 9.08, p< 0.005] and an 
OXT x Antagonist interaction [F(1,36)= 10.36, p< 0.003]. Post hoc analysis 
indicated that OXT alone significantly reduced ethanol intake and that 
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Figure 2.2. Oxytocin-induced reduction in binge-like ethanol consumption 
is blocked by pretreatment with an oxytocin receptor antagonist. Oxytocin 
(1 mg/kg) reduced ethanol intake in the DID model and this effect was reversed 
by pretreatment with the OXTR antagonist L368,889 (10 mg/kg). Values are 
mean ± s.e.m. (N= 10/group). Significantly differs from the vehicle-saline 


































ethanol intake was significantly greater in OXT-treated mice that received L-
368,889 (10 mg/kg) compared to mice that received saline pretreatment. The 
OXT receptor antagonist did not alter ethanol consumption when given alone.  
 
Effect of Oxytocin on Locomotor Activity 
 
The reduction in ethanol consumption by OXT in concert with the delayed 
temporal pattern of ethanol intake prompted additional examination of whether 
the OXT-induced decrease in ethanol intake is due to a general sedative effect of 
the neurohormone. Within 5 min following administration, OXT decreased 
locomotor activity in a dose-related manner. While this difference relative to the 
vehicle condition rapidly dissipated for the lower (0.3 and 1 mg/kg) OXT dose 
groups, reduced activity produced by the highest dose tested (3 mg/kg) persisted 
for a longer period of time during the test session (Figure 2.3). ANOVA of activity 
data (distance traveled in the open field) indicated significant main effects of 
Dose [F(3,19)= 9.87, p< 0.0001] and Time [F(11,209)= 12.76, p< 0.0001] as well 
as the Dose x Time interaction [F(33,209)= 3.90, p< 0.0001]. Overall, activity 
decreased across the testing session for all groups. Further, all OXT doses 
significantly decreased distance traveled compared to the vehicle group within 
the first 5 min of the test. However, while activity for mice treated with 0.3 and 1 
mg/kg OXT doses was similar to the vehicle group within 10 min, recovery to 
control (vehicle) levels required approximately 40-45 min for mice treated with 3 






Figure 2.3. Effects of oxytocin on locomotor activity. Oxytocin (0.3, 1, or 3 
mg/kg) or vehicle was injected (ip.) 30 minutes before locomotor activity was 
recorded in an open field during a 4-hr session. Shown are mean ± s.e.m. Values 
for distance traveled during first hour of locomotor activity measurement (N= 5-
6/group). Significantly differs from the vehicle condition: * (p< 0.05); + (p< 0.01); 




































Effect of Oxytocin on 2-Bottle Choice Ethanol Drinking 
 
 Oxytocin treatment reduced ethanol consumption without significantly 
altering total fluid intake under continuous access conditions (Table 1). At 4 hr 
following injection, OXT (1 mg/kg) significantly reduced ethanol intake (mL: 
[F(1,11)= 5.92, p< 0.05] and g/kg: [F(1,11)= 6.16, p< 0.05]), while not altering 
total fluid intake [F1,11)< 1.0]. Similarly, OXT (1 mg/kg) reduced ethanol intake 
over 24 hr (mL: [F(1,11)= 20.39, p< 0.001] and g/kg: [F(1,11)= 20.87, p< 0.001]). 
The decrease in ethanol consumption was accompanied by increased water 
intake [F(1,11)= 6.51, p< 0.05], resulting in no change in total fluid intake 
[F(1,11)< 1.0]. OXT treatment also significantly reduced ethanol preference 
[F(1,11)= 12.80, p< 0.01] (Table 1). In animals given access to only water, OXT 
did not alter intake at 4 hr [F(1,8)= 1.37, p> 0.1] or 24 hr [F(1,8)= 0.07, p> 0.1]. 
 
 
Effect of Oxytocin on Operant Ethanol Self-Administration  
 
After reaching the criteria for stable responding for ethanol, the effect of 
OXT on operant oral self-administration was assessed. For these studies, we 
omitted the higher doses (3 and 10 mg/kg) from the previous experiments and 
included a lower dose (0.1 mg/kg) of OXT. Preliminary analyses indicated no 
significant effect of dosing order on the main dependent variables: active lever 
responses and ethanol (g/kg) intake [F(5,46)< 1.6 for both variables]. Thus, data 






































in a dose-related fashion OXT reduced responding for ethanol on the active lever 
(Figure 2.4a) and the amount of ethanol (g/kg) self-administered (Figure 2.4b). 
These observations were supported by significant effects of OXT Dose for active 
lever responding [F(3,36)= 7.58 p< 0.001] and ethanol intake [F(3,36)= 8.41 p< 
0.001]. Post hoc analyses indicated that all doses of OXT significantly reduced 
ethanol responding and intake compared to the vehicle condition. Analysis of 
inactive lever responding indicated no significant effect of OXT Dose (Figure 
2.4a). 
 To investigate the effect of OXT on motivation to seek ethanol 
reinforcement, a subset of the same mice (n= 10) were challenged using a 
progressive ratio (PR) self-administration schedule. OXT decreased overall 
active lever responding during the PR sessions. Further, analysis of breakpoint 
data indicated that OXT (0.3 mg/kg) significantly reduced breakpoint ratio 
achieved for ethanol reward compared to vehicle [t(8)= 2.82, p< 0.03] (Figure 
2.4c).  
 
Effect of Oxytocin on Sucrose Self-Administration 
 
To investigate whether OXT administration influences self-administration 
of a natural reward, a separate cohort of mice was trained to respond for sucrose 
reinforcement. One mouse was excluded from the final analysis due to receiving 
incorrect doses in the Latin-square design.  Preliminary analyses indicated that 
dosing order did not have a significant effect on active lever responding or ml/kg 





Figure 2.4. Effects of oxytocin on oral operant ethanol self-administration 
and progressive ratio responding for ethanol. Oxytocin reduced active lever 
responding (a) and ethanol consumption (g/kg) (b) in a dose-related manner (N= 
13/group). Oxytocin (0.3 mg/kg) reduced breakpoint values (c) for progressive 
ratio responding. Values are mean ± s.e.m. (N=5/group). Significantly differs from 






































































Figure 2.5. Effects of oxytocin on operant sucrose self-administration and 
progressive ratio responding for sucrose. Oxytocin reduced active lever 
responding (a) and sucrose consumption (ml/kg) (b) at only the highest dose 
tested (1 mg/kg). (N= 18/group). Oxytocin (0.3 mg/kg) did not significantly alter 
breakpoint values for progressive ratio responding. Values are mean ± s.e.m. 



























































revealed a marginal OXT Dose effect on active lever responding [F(3,51)= 2.48, 
p< 0.07] (Figure 2.5a) and a significant effect on ml/kg intake [F(3,51)= 3.33, p< 
0.05] (Figure 2.5b). Post hoc analysis revealed that the highest dose of OXT (1 
mg/kg) significantly reduced ml/kg intake of sucrose compared to vehicle.  OXT 
treatment did not significantly alter inactive lever responding (Figure 2.5a).   
A subset of mice (n=12) from the sucrose self-administration experiment 
were then tested for responding under a PR schedule. OXT (0.3 mg/kg) did not 
significantly alter responding for sucrose during PR sessions and analysis of 
breakpoint data indicated no significant difference between OXT and vehicle 




 Results from the present study demonstrate that systemic administration 
of OXT reduces alcohol consumption in a binge-like drinking model, 2-bottle 
choice drinking paradigm, and in a model that employs operant self-
administration procedures (Table 2). Oxytocin decreased alcohol consumption in 
a dose-related manner, and the ability of OXT to reduce alcohol intake did not 
appear to be related to nonspecific (e.g., sedation, antidipsogenic) effects. 
Further, OXT reduced motivation to respond for ethanol at doses that did not 
alter responding for a natural reward (sucrose). These results are generally 
consistent with other reports indicating that systemic administration of OXT 
reduces ethanol intake in a variety of drinking models in rats (Bowen et al. 2011; 
MacFadyen et al. 2016; McGregor and Bowen 2012) and mice (Peters et al. 
2013). These data also complement a recent report showing that direct  
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icv. infusion of the neuropeptide reduced ethanol consumption in Wistar rats 
(Peters et al. 2016). Oxytocin reduced relatively high levels of ethanol intake 
along with resultant blood ethanol concentrations in the binge-like DID model. 
Use of lickometers provided an opportunity to analyze the effects of OXT on the 
temporal pattern of ethanol drinking during the final (fourth day) of the DID 
procedure. Results showed vehicle-treated mice initiated licking contacts at the 
ethanol bottle within the first 5-10 min of the drinking period and maintained a 
relatively steady pace of drinking throughout the entire 4-hr session. In contrast, 
OXT treatment delayed ethanol bottle contacts until 1-2 hours into the session. 
This profile suggests oxytocin reduced motivation to seek and consume ethanol 
under these testing conditions.  
Alternatively, the delay in initiating drinking produced by OXT could be due 
to a sedative effect of the neuropeptide. Oxytocin has been shown to reduce 
locomotor activity in rats (Klenerova et al. 2009). In the present study, OXT 
reduced locomotor actvity in an open field in a dose-related manner. However, 
this effect was transient, with activity returning to levels registered in vehicle-
treated mice within 10 min for mice treated with low doses of OXT (0.3 and 1 
mg/kg). In contrast, reduced activity produced by a high OXT dose (3 mg/kg) did 
not recover to control levels until at least 40-45 min into the test session. These 
results are congruent with other reports indicating that low-dose anxiolytic effects 
of OXT can be distinguishd from sedative effects produced by higher doses of 
the neuropeptide (Bahi et al., 2016; Klenerova et al., 2009). Interestingly, central 
(icv.) administration of OXT was shown to attenuate ethanol-induced sedative 
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effects in an open-field locomotor test (Bowen et al. 2015). Taken together, it 
does not seem likely that the reduction in alcohol drinking produced by low doses 
of OXT can be simply attributed to a nonspecific sedative effect of the 
neuropeptide. Additionally, while OXT has been reported to produce an 
antidipsogenic effect in rats (Arletti et al. 1990), in the present study OXT did not 
alter general fluid intake. In fact, reduced alcohol consumption was compensated 
by increased water intake. Further, in mice offered only water, OXT treatment did 
not alter total fluid intake. Thus, it is unlikely that reduced alcohol consumption in 
the various drinking models can be simply attributed to OXT decreasing general 
fluid intake.  
Using operant conditioning procedures, OXT was shown to reduce alcohol 
responding and intake in a dose-related fashion. Moreover, this effect was 
produced at doses that did not alter self-administration of a natural reward 
(sucrose). The highest OXT dose tested in these operant self-administration 
studies (1 mg/kg) reduced responding for both alcohol and sucrose. Other 
studies have shown OXT given either systemically or centrally (infused into the 
VTA) reduced sucrose intake in rats (Mullis et al. 2013; Zhou et al. 2015). While 
the present studies were conducted in only male mice, there is some evidence 
that females may be more sensitive than males to the supressant effects of OXT 
on sucrose consumption (Zhou et al. 2015). Nevertheless, it is noteworthy that in 
the present study low doses of OXT reduced alcohol responding and intake 
without altering sucrose self-administration. The fact that responding on an 
“inactive” lever in both alcohol and sucrose experiments was not significantly 
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altered by OXT also supports the notion that reduced alcohol self-administration 
is not related to a general sedative effect of the neuropeptide. 
Results from progressive ratio testing further support a selective effect of 
OXT in decreasing motivation to self-administer alcohol. Oxytocin (0.3 mg/kg) 
reduced breakpoint value for alcohol while not altering this measure for sucrose. 
Similarly, a recent study in rats showed 1 mg/kg OXT did not alter progressive 
ratio responding or breakpoint for sucrose pellets (Cox et al. 2013). While it is 
possible that higher doses of OXT may reduce motivation to respond for a 
natural reward, results from the present study demonstrate that at a low dose, 
OXT can selectively reduce responding for alcohol. Collectively, these results 
align with a growing body of literature demonstrating efficacy for OXT to reduce 
alcohol/drug seeking and consumption (Lee et al. 2016). 
The mechanism by which systemically administered OXT reduces alcohol 
consumption is not fully understood. Peripheral administration (ip. injection) of 
OXT was shown to produce a rapid rise in plasma and brain dialysate levels of 
OXT in mice (Neumann et al. 2013). While penetration of the neuropeptide 
through the blood-brain barrier is limited, passage of a small, yet physiologically 
relevant amount of exogenous OXT is thought to influence central OXT activity 
(Landgraf and Neumann 2004; Neumann and Landgraf 2012; Neumann et al. 
2013). There is evidence indicating that OXT can facilitate its own release in the 
hypothalamus (Moos et al. 1984; Rossoni et al. 2008; Theodosis 2002). This 
feed-forward loop may explain, at least in part, how acute and chronic 
systemically administered OXT can produce enduring functional and behavioral 
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effects. For example, Bowen and colleagues showed that repeated injections of 
OXT in adolescent rats resulted in upregulated oxytocin receptor mRNA 
expression in the hypothalamus in adult rats, which was accompanied by 
reduced alcohol consumption (Bowen et al. 2011). Nevertheless, whether 
reduced alcohol intake produced by systemic administration of OXT in the 
present studies can be attributed to direct effects of the exogenous neuropeptide 
in the brain or indirect effects on release of endogenous OXT in brain is unknown 
and will require further investigation.  
Oxytocin projections are known to influence mesolimbic dopamine activity 
in mediating the rewarding aspects of social behaviors (Young et al., 2014). The 
relatively high expression of OXTRs within structures such as the NAc suggests 
that modulation of mesolimbic dopamine pathways may underlie the ability of 
OXT to influence the rewarding effects of alcohol and other substances of abuse. 
In a recent study, direct (icv.) administration of OXT reduced ethanol 
consumption and ethanol-induced dopamine efflux in the NAc of Wistar rats 
(Peters et al. 2016). Thus, it is possible that OXT reduced ethanol self-
administration in the present study by blunting mesolimbic dopamine activity that 
ordinarily signals ethanol-related reward.  
 In the present study, the ablity of OXT to reduce binge-like drinking was 
blocked by pretreatment with an OXTR antagonist, suggesting that OXT reduced 
ethanol consumption via an interaction with its receptor. Few studies have 
examined the role of OXTRs in mediating the neuropeptide’s effects on 
motivational actions of alcohol. Recent studies involving viral-mediated 
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overexpression of OXTRs in the nucleus accumbens core (NAcc) have 
implicated a role for these receptors in ethanol drinking and conditioned reward 
(Bahi, 2015; Bahi et al. 2016). However, it is noteworthy that OXT was shown to 
block ethanol-induced ataxic and sedative/hypnotic effects via an apparent direct 
interaction with delta-subunit containing GABAA receptors (Bowen et al. 2015). 
Thus, there remains some abiguity as to the role of OXTRs in mediating the 
neuropeptide’s effects on physiological effects of ethanol and, in particular, 
ethanol-related reward and self-administration behavior. 
Differing by only two amino acids from the related nonapeptide arginine 
vasopressin (AVP), it is possible that OXT reduced the motivational effects of 
ethanol through actions at vasopressin receptors (Neumann and Landgraf, 
2012). The two hypophyseal neuropeptide systems generally produce opposing 
physiological actions. Interestingly, the arginine vasopressin 1b (V1b) receptor 
antagonist SR149415 was shown to reduce ethanol drinking in genetically high 
alcohol-preferring rats (Zhou et al. 2011) and dependent Wistar rats (Edwards et 
al. 2012). However, results from a study demonstrating that the synthetic OXTR 
agonist carbetocin, which exhibits low affinity for V1b (and V1a) receptors 
compared to OXTRs (Passoni et al. 2016), effectively reduced ethanol-induced 
conditioned reward supports a role for OXTRs (Bahi 2015). Further investigation 
is needed to determine the relative role of these related  neuropeptide receptors 
in mediating the ability of OXT to reduce ethanol reward and drinking. 
In summary, results from this study provide support and extend evidence 
demonstrating the ability of OXT to reduce the motivational effects of ethanol. 
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The present results indicate OXT is effective in reducing ethanol consumption in 
a model of binge-like drinking, an effect reversed by pretreatment with an OXTR 
antagonist. Oxytocin also decreased 2-bottle choice drinking in the home cage as 
well as ethanol responding and intake in an oral self-administration model 
involving operant conditioning procedures. Further, OXT reduced responding for 
ethanol under fixed- and progressive- ratio schedules at doses that did not alter 
responding for a natural reward (sucrose). Collectively, these and other recent 
reports provide support for the theraputic potential of this neuropeptide as a 
treatment for AUDs. A limited number of clinical studies have shown OXT to have 
some efficacy in decreasing craving for alcohol and other drugs of abuse (Lee et 
al. 2016).  For example, Pedersen and colleagues recently demonstrated that IN 
OXT attenuated alcohol withdrawal symptoms in treatment seeking human 
subjects compared to placebo (Pedersen et al. 2013). Thus, the OXT system 
may be a promising target for therapeutic intervention of AUDs, though additional 
studies are necessary to establish its clinical efficacy and further investigate the 





CHAPTER 3: Chemogenetic Activation of Hypothalamic 




As previously noted, a growing number of preclinical studies has shown 
that systemic administration of OXT attenuates alcohol consumption in a variety 
of models. However, the mechanisms by which exogenous OXT, especially OXT 
delivered in the periphery, reduces the motivational effects of alcohol is not fully 
understood. Historically, peripherally administered OXT was not thought to 
bypass the blood-brain-barrier in quantities sufficient to alter behavior (Opacka-
Juffry and Mohiyeddini 2012) but rather, impact behavior via a feed-forward 
mechanism stimulating release of endogenous OXT (Ludwig et al. 2002; Rossoni 
et al. 2008; Ermisch et al. 1985). Recent evidence has emerged to support 
increased central OXT levels following systemic administration (Bowen 2019; 
Tanaka et al. 2018; Bustion et al. 2016; Neumann et al. 2013; Freeman et al. 
2016; Dal Monte et al. 2014), though only a handful of these studies has 
addressed whether the observed increase in OXT was due to exogenous OXT 
crossing the BBB or peripherally stimulated release of central OXT (Smith et al. 
2019). Lee et al. (2018) recently demonstrated in nonhuman primates that d5-
denatured OXT (which can be distinguished from endogenous OXT) 
administered through IN and IV routes reached the CSF but did not activate a 
feed-forward mechanism to elevate OXT. Additionally, Smith and colleagues 
reported detectable concentrations of OXT in amygdala and hippocampus of 
OXT null mice following both IN and IP administration of the neuropeptide (Smith 
et al. 2019). These data validate that the source of measured OXT (by 
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microdialysis) originates solely from exogenous administration, as the knockout 
mice do not produce endogenous OXT.  Thus, while studies are largely 
consistent regarding elevated OXT in the CNS following peripheral 
administration, the mechanism by which systemic administration simulates 
prolonged activation of the central OXT system sufficient to activate OXTRs and 
alter behavior remains ambiguous. This void in the literature raises the question 
as to whether direct activation of endogenous OXT can produce a similar effect 
as exogenous OXT administration on behavior, especially in regard to reducing 
alcohol consumption. 
Although exogenous OXT may be capable of crossing the blood-brain-
barrier (Smith et al. 2019; Neumann et al. 2013), the behavioral effects of 
systemic OXT administration may also involve OXTR signaling in the periphery. 
Oxytocin receptors are found throughout the periphery where binding mediates 
the neuropeptide’s role in a number of behaviors including uterine contraction 
during parturition, milk-let down during lactation, feeding behavior and sexual 
reflexes in both males and females (Iwasaki et al. 2015; Gimpl and Farenholz 
2001).  Endogenous OXT is secreted from hypothalamic magnocellular neurons 
targeting both the periphery via axon terminals in the posterior pituitary and 
extrahypothalamic brain regions via axon collaterals (Knobloch et al. 2012). A 
number of receptor binding sites in the periphery are found in areas that could 
reasonably contribute to the behavioral effects of OXT on appetitive behavior and 
anxiety, including the gut, heart, vascular system and vagus nerve (Gimpl and 
Farenholz 2009).  However, studies investigating the relative contributions of 
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peripheral versus central OXT signaling have yielded mixed results. While there 
is evidence to suggest that peripheral OXT directly interacts with vagal afferents 
to decrease appetitive behavior in mice (Iwasaki et al. 2015), Tunstall et al. 
(2019) demonstrated that peripherally restricted OXTR antagonist, L-371,257, did 
not alter the effects of intranasal OXT in reducing alcohol consumption in 
dependent rats. Thus, the central versus peripheral contribution to OXT’s effect 
on alcohol consumption also remains an important question.  
Studies in this chapter will address these important questions. Specifically, 
we utilize pharmacological and chemogenetic approaches to selectively activate 
OXT-containing neurons within the hypothalamus (PVN) to examine the effect of 
endogenous OXT on anxiety-like behavior and alcohol consumption in both a 
binge-like-drinking model and in a model involving operant conditioning 
procedures. Additionally, through the use of BBB penetrant and peripherally 
restricted OXTR antagonists (L-368,899 and Atosiban, respectively), we test the 
hypothesis that activation of OXT+ neurons reduces motivation for alcohol via 
central, not peripheral, actions. Collectively, these results indicate that 
OXT/OXTR activity play a role in regulating anxiety-like behavior and alcohol 
consumption, and that this effect is mediated, at least in part, by central, rather 







MATERIALS AND METHODS 
 
 
Animals and housing 
 
Adult male Oxt-IRES-Cre (Oxt-Cre) mice at least 10 weeks old were used 
for all in vivo chemogenetic experiments. These transgeneic mice express Cre 
recombinase under the control of the OXT promotor. The breeding colony was 
established by back-crossing homozygote Oxt-Cre male mice with C57BL/6J 
female mice, both obtained from Jackson Labororaties (Bar Harbor, ME). All 
offspring were positive for the expression of Cre recombinase under the control 
of the OXT promoter as determined by standard polymerase chain reaction 
(PCR) genotyping protocols. 
Mice were individually housed under a 12-hour reverse light/dark cycle in 
an AAALAC-accredited facility. All testing was conducted during the dark phase 
of the circadian cycle. Mice were provided free access to food and water 
throughout the duration of the experiment. All experimental protocols were 
approved by the Medical University of South Carolina Institutional Animal Care 
and Use Committee and consistent with guidelines of the NIH Guide for the Care 
and Use of Laboratory Animals. 
 
Drinking in the dark (DID) procedure 
 
Ethanol consumption was assessed using a standard 4-day drinking in the 
dark (DID) protocol (Rhodes 2005), as previously described in Chapter 2. Briefly, 
mice were presented in the home cage with a single bottle of 20% (v/v) ethanol 
approximately 3 hours into the dark cycle for 2 hours on days 1-3 (baseline), and 
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for 4 hours on day 4 (test). On test day, intake was recorded at timepoints 0-2hr 
and 2-4hr. Vehicle injections were given 30 minutes prior to the 2-hr drinking 
session during the first 3 days to acclimate mice to handling and the injection 
procedure.  
 
Locomotor Activity and Open Field  
 
Following experiment 2, mice were left undisturbed for 4 weeks and then 
tested on the effect of activation of endogenous OXT on anxiety behavior and 
locomotor activity. Locomotor activity and anxiety behavior in an open field arena 
were assessed using Med Associates (St. Albans, VT, USA) activity chambers 
(27 × 27 × 20 cm; ENV-510) situated in sound-attenuating cubicles with a 
ventilation fan. Animal movement was tracked through the use of 16 horizontal 
infrared photo beams, located on both the X and Y-axes for positional and 
rearing detection. Mice were placed in the center of the box and allowed to 
explore the arena for 10 minutes. The box was uniformly light under bright light. 
Time spent in the periphery of the chamber was compared with time spent in the 
center (5x5 cm) to quantify anxiety-like behavior. For locomotor activity, 
photobeam breaks were recorded during the same session and converted to 





Mice were tested in standard operant chambers, as previously described 
in Chapter 2. Briefly, mice were trained to respond on a fixed-ratio (FR)-4 
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schedule for access to 12% ethanol solution (20ul delivered into well) in 20-
minute sessions. At the end of each session, any residual fluid left in the well was 
collected with a pipette, measured, and subtracted from the total volume of 
alcohol delivered. The correct volume was used to calculate g/kg alcohol intake 
during the daily sessions. Experimental tests were initiated after response rates 
and intake had stabilized (<15% variability over 3 consecutive days). Vehicle 
injections were given 30 minutes prior to all 20-minute drinking sessions to 
acclimate mice to handling and the injection procedure. 
 
Drugs and administration 
 
Clozapine-N-oxide (CNO; Tocris Bioscience, Minneapolis, MN), synthetic 
human OXT (CellSciences, Canton, MA), and the OXTR antagonists L-368,899 
hydrochloride (Tocris) and Atosiban (Tocris), were dissolved in 0.9% saline, 
which served as the vehicle. Injections were administered intraperitoneally (ip.) at 
a volume of 0.01ml/g body weight in all experiments. Ethanol (95%) was 
obtained from AAPER (Shelbyville, KY) and diluted with tap water to the 
appropriate concentration. The ethanol solution was prepared daily and 
presented at room temperature.  
 
Surgical procedures  
 
Male Oxt-Cre mice were anesthetized with isoflurane and received 
bilateral infusion of Cre-dependent virus obtained from Addgene (Cambridge, 
MA). To target hypothalamic OXT containing neurons, mice received bilateral 
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infusion of AAV8-hSyn-DIO-hM3Dq-mCherry (excitatory) or AAV8-hSyn-DIO-
mCherry (control virus) into the PVN using stereotaxic coordinates (AP: -0.78 
mm, ML: ± 0.2 mm, DVL -5.2 mm) (Wei et al. 2015; Franklin and Paxinos 2008; 
adjusted based on pilot data). Viral infusion was delivered over 5 minutes for a 
total volume of 0.25 µL followed by a 5 min wait for diffusion. The injector was 
slowly withdrawn at a rate of 250 microns every 15 seconds, and after fully 
removed, the process repeated on the opposite side. Experiments were 





Effect of Chemogenetic Activation of Hypothalamic Oxytocin-Containing Neurons 
on Alcohol Drinking in Binge-like Consumption Model  
 
 Previous evidence suggests that Gq-coupled Designer Receptors 
Exclusively Activated by Designer Drugs (DREADDs) cause selective activation 
of OXT-containing neurons (via administration of otherwise inert ligand CNO) 
when virus expression is restricted by the OXT promotor (Penagarikano et al. 
2015; Wei et al. 2015). Similarly, the use of OXT-IRES-Cre transgenic mice 
enables selective targeting of OXT neurons in the PVN via infusion of Cre-
dependent virus containing excitatory DREADD virus (Krashes et al. 2014). To 
examine the effect of chemogenetic activation of hypothalamic OXT-containing 
neurons on alcohol consumption, adult male Oxt-IRES-Cre mice were infused 
with a virus containing an excitatory DREADD (AAV8-hSyn-DIO-hM3Dq-
mCherry) (N=12) or control virus (AAV8-hSyn-DIO-mCherry) (N=11) targeting the 
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PVN. Subjects were left undisturbed for three weeks to allow for viral infection 
prior to the start of weekly DID cycles. At 30 minutes prior to the 4-hr test 
sessions during two consecutive weekly DID cycles, mice were injected with 
vehicle (saline) and CNO (3mg/kg). A within-subjects crossover design was 
used, with order of drug treatment (saline vs. CNO) counter-balanced across the 
two test sessions.  
To examine whether systemic OXT administration produced the expected 
effects on drinking in this transgenic mouse line (as previously demonstrated in 
C57BL/6J mice, see Chapter 1), a separate group of male Oxt-IRES-Cre mice 
(n=9) that did not receive viral infusions was injected with vehicle (saline) or OXT 
(1 mg/kg) 30 minutes prior to the 4-hr test sessions during two consecutive 
weekly DID cycles. Testing in this group was conducted in the same way as 
described above. Mice were run concurrently with Oxt-IRES-Cre mice harboring 
excitatory DREADD and control virus. 
Following the conclusion of DID cycles in Experiment 1, a subset of mice 
was left undisturbed for 4 weeks and then tested for effects of activation of 
endogenous OXT on anxiety behavior and locomotor activity. Mice (n= 20) were 
injected (ip.) with the same doses of CNO (0 or 3 mg/kg) 30 min before the start 
of the 10 minute test session.  Injections occurred 2.5 hr into the dark phase of 
the circadian cycle to match the DID procedure.  Data were collected for both 
locomotor activity and anxiety behavior in the open field arena within the same 




Effect of Pharmacological Antagonism of Oxytocin Receptors in Brain on the 
Ability of Endogenous Oxytocin to Reduce Alcohol Consumption 
 
To examine whether chemogenetic activation of OXT+ containing neurons 
was exerting its effects on alcohol consumption via actions at OXTRs, a separate 
cohort of Oxt-Cre mice that received infusion of an excitatory (Gq) DREADD 
(AAV8-hSyn-DIO-hM3Dq-mCherry, N=6) or control virus (AAV8-hSyn-DIO-
mCherry, N=6) was pretreated with the selective brain penetrant nonpeptide 
oxytocin receptor antagonist L,368,899 (10mgkg) (King et al. 2017) 15 minutes 
prior to CNO (3 mg/kg) or vehicle (saline) administration (ip.) which was given 30 
minutes before the start of the 4 hour test session during two consecutive weekly 
DID cycles. A within-subjects crossover design was used for oxytocin receptor 
antagonist dose with order of drug treatment (Saline or 10mg/kg L368,899) 
counter-balanced across the two test sessions. Activation of oxytocin containing 
neurons by systemic administration of CNO was treated as a between-subjects 
factor, such that animals that received CNO (or saline) in test 1 received the 
same drug treatment in est 2.   
 
 Effect of Pharmacological Antagonism of Peripheral Oxytocin Receptors on the 
Ability of Endogenous Oxytocin to Reduce Alcohol Consumption 
 
To investigate whether the reduction in alcohol drinking produced by 
targeted chemogenetic activation of OXT-containing neurons in PVN was related 
to signaling at peripheral OXTRs, a separate cohort of Oxt-Cre mice that 
received infusion of an excitatory (Gq) DREADD (AAV8-hSyn-DIO-hM3Dq-
mCherry, n=12) or control virus (AAV8-hSyn-DIO-mCherry, n=10) was pretreated 
with peripherally restricted OXTR antagonist Atosiban (ATO; 1 mg/kg or saline) 
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15 minutes prior to CNO (3 mg/kg) or vehicle (saline) administration (ip.), which 
was given 30 minutes before the state of the 4-hour test drinking session. Similar 
to Experiment 3, a within-subjects crossover design was used for OXTR 
antagonist dose with order of drug treatment (Saline or 1mg/kg ATO) counter-
balanced across the two test sessions, while activation of OXT-containing 
neurons by systemic administration of CNO (or saline) was treated as a between-
subjects factor.  
 
Effect of Chemogenetic Activation of Hypothalamic Oxytocin-Containing Neurons 
on Oral Operant Alcohol Self-Administration  
 
To assess the effects of chemogenetic-induced activation of hypothalamic 
OXT+ neurons on operant self-administration of alcohol, Oxt-Cre mice that 
received infusion of an excitatory (Gq) DREADD (AAV8-hSyn-DIO-hM3Dq-
mCherry, n=7) or control virus (AAV8-hSyn-DIO-mCherry, n=4) were injected 
(ip.) with CNO (3 mg/kg) or vehicle (saline) 30 minutes before self-administration 
session. Mice received both treatment conditions in a Latin square design, 
counterbalanced to avoid an order of treatment bias. Baseline levels of 
responding were re-established without drug pretreatment for a minimum of 
5 days between treatments. 
To examine whether systemic OXT administration produced similar effects 
on oral operant self-administration in this transgenic mouse line (as previously 
demonstrated in C57BL/6J mice, see Chapter 1), Oxt-IRES-Cre mice (n=8) that 
did not receive viral infusions were injected with vehicle (saline) or OXT (1 
mg/kg) 30 minutes prior to a 20-minute daily session. Testing in this group was 
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conducted in the same way as described above. Mice were run concurrently with 




At the conclusion of Experiments mice were transcardially perfused with 
ice-cold saline followed by 4% paraformaldehyde (PFA). After extraction, brains 
were post-fixed in 4% PFA solution overnight and then transferred to 20% 
sucrose in PBS for an additional 24hrs. Brains were frozen on dry ice and sliced 
on a cryostat at 50 µm. Slices were blocked 10% normal donkey serum (NDS) in 
PBS. Sections were incubated in primary antibody (Rat-Anti-mCherry 1:1000, 
Millipore #, Mouse Anti-Oxytocin 1:1000 Clone 4G11, Millipore #MAB5296) in 
PBS-TX with 2% NDS for 48hrs at 4 degrees C, followed by 2hr incubation at 
room temperature in secondary antibodies (Alexa Flour 555 at Donkey-Anti Rat, 
biotinylated donkey anti-mouse, Jackson Immuno). Finally, sections were 
incubated in Alex Flour 647-conjugated streptadivdin (1:250, Invitrogen) in PBS-
Tx for 30 minutes. Stained sections were mounted on Superfrost plus slides 
(Fischer, Pittsburgh, PA, USA) and cover slipped using Vectashield Mounting 
Medium (Vector Laboratories, Burlingame, CA, USA). Images were acquired 
using EVOS Cell Imaging Systems (Thermo Fisher Scientific) 
 
Statistical Analysis  
 
Alcohol intake (g/kg) at 2-hr and 4-hr time points during the Day 4 test 
sessions in Experiments 1 was analyzed by ANOVA, with Drug (saline vs. CNO) 
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and Time (2hr vs. 4hr) as a repeated measure. Data from mice that received 
infusions of excitatory DREADD virus or control virus were analyzed separately. 
Cumulative intake over the 4 hour test was analyzed as a separate ANOVA for 
each of the experimental groups. Total Distance and Time in Center data for 
Experiment 1 were analyzed by unpaired t-tests. In Experiment 3 and 4, the 
effect of OXTR antagonist pretreatment on alcohol intake during the Day-4 test 
sessions was analyzed separately in mice that receive infusions of excitatory 
DREADD virus or control virus by ANOVA, with Treatment (saline, CNO, saline + 
Antag, CNO+Antag) and Time as repeated factors. In Experiment 5 data were 
analyzed by ANOVA, with Drug (saline vs. CNO) and Time (Baseline versus 
Test) as a repeated measure. Statistical analyses were carried out using SPSS 
software package. Post-hoc comparisons were performed when appropriate 







Chemogenetic Activation of Hypothalamic Oxytocin-Containing Neurons 
Reduces Alcohol Drinking in Binge-like Consumption Model 
 
Data from one mouse infused with active virus was excluded from analysis 
after histological evaluation indicated misplaced viral expression. Mice that 
received intra-PVN infusion of excitatory DREADD virus and injected with CNO 
consumed significantly less alcohol compared to the same mice that were 
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injected with saline. This was supported by ANOVA, which revealed a significant 
main effect of Drug [F(1,20) = 9.816, p<0.01]. Further, alcohol consumption 
following CNO injection was similarly reduced at 0-2-hr and 2-4-hr time points, as 
Drug x Time interaction was not significant [F(1,20) = 2.324, p > 0.10], although a 
separate ANOVA revealed a significant main effect of Drug [F(1,20) = 8.50, p > 
0.001] for total intake consumed during the 4-hour session (Figure 3.1b). In 
contrast, CNO injection did not significantly alter alcohol intake in mice that 
harbored the control virus (Drug: [F(1,20) = 0.01, p>0.1] and Drug x Time 
[F(1,20) = 0.769, p > 0.1]) (Figure 3.1c).  
In a follow up study in a separate cohort of mice, we next examined 
whether systemic administration of oxytocin produced comparable effects in Oxt-
IRES-Cre mice that did not receive viral infusion.  Analysis of alcohol intake 
during the Day-4 test session indicated a significant main effect of Time[F(1,16) = 
11.23, p<0.01], with reduction in intake greater at the 0-2hr compared to 2-4hr 
measurement. ANOVA also revealed a significant main effect of Drug [F(1,16) = 
3.711, p<0.01], although Drug x Time interaction reached only trend level 
significance [F(1,16) = 4.04, p=0.06]. This indicates that systemic administration 
of oxytocin decreased alcohol consumption compared to mice that received 
saline, and this effect was similar at the 0-2-hr and 2-4-hr time points. 
Additionally, a separate ANOVA revealed a significant main effect of 
Drug[[F(1,16) = 7.437, p<0.05], indicating that total intake across the 4-hr test 
session was decreased in mice treated with OXT compared to those treated with 




Figure 3.1. Chemogenetic activation of hypothalamic oxytocin-containing neurons 
reduces alcohol consumption. (a) Sample image PVN in OXT-IRES-Cre mouse taken 
from coronal brain slice depicted mCherry-positive neurons in red (scale bar = 150 µM). 
Fluorescence expression was confirmed for all mice used in experiments for panels b-f. 
(b) chemogenetic activation of PVN OXT+ neurons reduced total alcohol consumption. 
Measurement at 0-2hr timepoint reached trend level significance (p=0.06) (c) Systemic 
CNO (3 mg/kg) administration had no effect on drinking in animals harboring control 
virus (d) systemic administration of OXT (1 mg/kg) decreased alcohol drinking in the first 
2 hours (0-2hr) of the test session, as well total ethanol intake over 4hrs (e) CNO-
induced activation of OXT+ neurons increase time in center in open field and (f) this 
effect does not appear to be due to changes in locomotor activity (distance traveled). 
Values are mean ± s.e.m (N=11-12/group) *p<0.05 versus VEH 




























































































Next, we examined whether acute chemogenetic activation of PVN-OXT 
neurons resulted in reduced anxiety-related behavior and/or locomotor activity. 
Mice that received intra-PVN infusion of excitatory DREADD virus and injected 
with CNO spent significantly more time in the center of the open field arena 
compared to mice treated with saline [t(9)= 2.33, p<0.05], suggesting a decrease 
in anxiety-like behavior. In mice harboring control virus, CNO injection did not 
alter time spent in center compared to mice injected with saline [t(7)= 0.02, 
p>0.05] (Fig. 3.1e). The anxiolytic effect observed following activation of 
oxytocin-containing neurons by CNO injection is not related to increased 
locomotor activity, as there was no significant difference in total distance 
travelled in the open field arena in mice with excitatory DREADD [t(9)= 1.09, 
p>0.05]  or control virus [t(7)= 0.42, p>0.05]  during the 10 minute test session 
(Fig. 3.1f) 
 
Pharmacological Antagonism of Oxytocin Receptors in Brain Reverses the Ability 
of Endogenous Oxytocin to Reduce Alcohol Consumption  
 
To determine whether chemogenetic-induced activation of PVN OXT-
containing neurons reduced ethanol consumption via action at the OXTR, mice 
with excitatory DREADD or control virus were treated with a selective blood brain 
barrier penetrant OXTR antagonist, L368,889, before CNO or vehicle (saline) 
administration. As previously observed, CNO (3 mg/kg) significantly reduced 
ethanol consumption in animals harboring excitatory DREADD virus (VEH versus 





Figure 3.1. Brain penetrant oxytocin receptor antagonist, L368,899, 
reverses the chemogenetic-induced reduction in drinking (a) In mice 
harboring excitatory DREADD, CNO-induced activation of OXT+ neurons 
decreased alcohol consumption at 0-2hr and total relative to vehicle and 
pretreatment with L368,899 (10 mg/kg) reversed this effect. (b) No effect was 
observed in animals harboring control virus. Values are mean ± s.e.m 


























































OXTR antagonist (CNO versus L368,899; Fig. 3.2a). These observations were 
supported by ANOVA, which revealed a significant main effect of Drug [F(3,20)= 
6.40, p< 0.01] and significant Drug x Time interaction [F(3,20)= 3.70, p< 0.05]. 
Post hoc (Newman-Keuls) analysis indicated that reduced drinking produced by 
activation of excitatory DREADD with CNO was completely reversed when mice 
were pretreated with OXTR antagonist L368,899 (10mg/kg), and the OXT 
receptor antagonist did not alter ethanol consumption when given alone (VEH 
versus L368,899). This effect was also shown in the total ethanol intake (g/kg) 
across the four hour test session (significant main effect of Drug [F(3,20)= 6.96, 
p< 0.01]. Similarly, the lack of a significant main effect of Drug [F(3,18)= 0.959, 
p> 0.05] in mice with control virus indicates neither injection of CNO or 
pretreatment with L368,899 had an effect on alcohol consumption during the test 
session (Fig. 3.2b) 
 
Pharmacological Antagonism of Peripheral Oxytocin Receptors Does Not 
Reverse the Ability of Endogenous Oxytocin to Reduce Alcohol Consumption  
 
Next, we examined the role of peripheral OXTR signaling in the observed 
decrease in alcohol drinking via chemogenetic inducted activation of PVN OXT-
containing neurons. Data from one mouse infused with active virus and two mice 
infused with control virus were excluded from the analyses after histological 
evaluation indicated misplaced viral expression. Mice with excitatory DREADD or 
control virus were treated with peripherally restricted (expected to not cross the 





Figure 3.2. Peripherally restricted oxytocin receptor antagonist, Atosiban, 
did not reverse chemogenetic-induced reduction in drinking (a) In mice 
harboring excitatory DREADD, CNO-induced activation of OXT+ neurons 
decreased alcohol consumption at 0-2hr and total relative to vehicle. 
Pretreatment with Atosiban (1 mg/kg; ATO) did not affect alcohol consumption in 
vehicle (ATO) or CNO (ATO+CNO) groups (b) No effect of CNO or ATO was 
observed in animals harboring control virus. Values are mean ± s.e.m 





























































mice harboring excitatory DREADD, CNO treatment significantly reduced 
drinking whether mice were pretreated with either vehicle or with the peripherally 
restricted OXTR antagonist Atosiban (Drug: [F(3,17)= 3.985, p< 0.05], Fig. 3.3a). 
Lack of significant Time x Drug interaction ([F(3,17)= 1.936, p> 0.1]), indicates 
that pretreatment with ATO had no effect no alcohol drinking at either timepoint. 
However, analysis of total ethanol intake (g/kg) for mice with Excitatory DREADD 
revealed that main effect of Drug F(3,17)= 3.023, p= 0.056]) reached only trend 
level significance. Further, ATO did not significantly alter drinking in mice 
harboring control virus (Drug: [F(3,12)= 0.249, p>0.1], For total Intake: Drug: 
[F(3,12)= 0.215, p>0.1] , Fig. 3.3b) 
 
Activation of Hypothalamic Oxytocin-Containing Neurons Reduces Oral Operant 
Alcohol Self-Administration 
 
After reaching the criteria for stable responding for EtOH, the effect of 
chemogenetic-induced activation of OXT+ neurons on operant oral self-
administration was assessed. Mice that received intra-PVN infusion of excitatory 
DREADD virus and injected with CNO demonstrated a decrease in responding 
for alcohol compared to animals injected with saline, as well as the average 
responding during the last 3 days of baseline (Fig. 3.4a). This was supported by 
ANOVA, which revealed a significant main effect of Drug [F(1,12) = 10.113, 
p<0.01] and significant Drug x Time interaction [F(1,20) = 2.324, p > 0.10].  
Analysis revealed similar results for ethanol intake ( Drug [F(1,12) = 10.113, 
p<0.01] and Drug x Time [F(1,12) = 7.99, p < 0.05]; Fig. 3.4b) In contrast, CNO 




Figure 3.3. Chemogenetic activation of PVN oxytocin- neurons on oral 
operant alcohol self-administration (a) chemogenetic activation of PVN OXT+ 
neurons reduced lever responding and (b) alcohol intake in mice harboring 
excitatory virus compared to vehicle and the average of the last 3 days of 
baseline responding prior to testing. In contrast, administration of CNO had no 
effect on (c) lever responses and (d) alcohol intake in mice that received infusion 
of control virus. For comparison, systemic OXT (1 mg/kg) also reduced (e) lever 
responding and (f) alcohol intake. Values are mean ± s.e.m (N= 7 /group Gq and 
N= 4/group CTL) *p<0.05 versus VEH, ^ p<0.05 versus 3-day average 
 









































































































3.4d) in mice that harbored the control virus (Responding: Drug: [F(1,6) = 0.04, 
p>0.1] and Drug x Time [F(1,6) = 0.204, p > 0.1], Intake: Drug: [F(1,6) = 0.043, 
p>0.1]  Drug x Time [F(1,6) = 0.218, p > 0.1]). 
In the same cohort of mice, we next examined whether systemic 
administration of oxytocin produced comparable effects on lever responding and 
alcohol intake. For this study, we used a single dose of OXT (1 mg/kg) previously 
shown to be effective in decreasing lever responding and ethanol intake (King et 
al., 2017, see Chapter 2). As expected, lever responding was reduced during the 
test session compared to baseline AVG (significant main effect of Time[F(1,20) = 
12.804, p<0.01]). ANOVA also revealed a significant main effect of Drug [F(1,20) 
= 8.377, p>0.01] and Drug x Time interaction [F(1,20) = 9.437, p<0.01], reflecting 
significantly reduced lever responding for alcohol in mice treated with OXT (1 
mg/kg) compared to vehicle (Base versus CNO, VEH versus CNO, all post hocs 
p <0.05; Fig. 3.4e). Similar results were obtained for alcohol intake (Time[F(1,20) 
= 34.774, p<0.001], Drug[F(1,20) = 18.167, p<0.001], and Drug x Time [F(1,20) = 





A growing body of evidence has established a role for the OXT system in 
various aspects of alcohol and drug addiction. However, much of this work has 
centered around exogenous peripheral administration (i.e., intraperitoneal, 
intravenous, intranasal) of the neuropeptide or synthetic analog, carbetocin. The 
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precise mechanism by which peripherally applied OXT crosses the blood-brain 
barrier and facilitates release within the brain remains unclear, prompting the 
question as to whether activation of endogenous OXT can produce a similar 
effect as exogenous OXT administration. Here we report that direct activation of 
OXT-containing neurons in the PVN via targeted expression of excitatory 
DREADD (and systemic injection of CNO) decreases total alcohol consumption 
in a binge-like model. Activation of OXT-containing neurons decreased anxiety 
behavior in the open field test and this effect was not due to changes in 
locomotor activity. Further, using pharmacological and chemogenetic 
approaches, we demonstrate that the effects of activation of PVN OXT-
containing neurons on alcohol consumption can be reversed with a blood-brain-
barrier penetrant OXTR antagonist, while peripheral administration of an OXTR 
antagonist that does not cross the blood-brain-barrier did not reverse this effect. 
Finally, chemogenetic-induced activation of OXT+ neurons reduced lever 
responding and ethanol intake in a model that employs operant self-
administration procedures. Together, these data suggest a central mechanism 
for OXT’s effect on alcohol drinking and anxiety-like behavior and implicate 
OXTR neurotransmission as a potential mechanism of action.   
 In the present study, activation of PVN OXT+ neurons decreased alcohol 
consumption and anxiety-like behavior. These findings are consistent with 
previous reports that OXT decreases alcohol drinking (Tunstall et al. 2019; 
Hansson et al. 2018; Stevenson et al. 2017; King et al. 2017; Peters et al. 2017; 
Bowen et al. 2011; McGregor & Bowen 2012) and anxiety-like behavior (Lee et 
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al. 2017; Li et al. 2016; Bredewoid and Veenema 2018) in rodents. While data 
from Experiment 1 demonstrates a reduction in total intake in mice that 
experienced CNO-induced activation of OXT+ containing neurons, the decrease 
in alcohol consumption measured at the different time points (0-2hr and 2-4hr) 
was not significantly different compared to mice treated with vehicle. Regardless, 
these data corroborate the previous finding (Chapter 2) that systemic OXT 
treatment decreased binge-like ethanol consumption over the four hour test 
period. The current data included investigation of the systemically administered 
OXT on drinking, as previous experiments in our lab using the DID model did not 
involve measurements of intake at different time points.  
Systemic administration of OXT demonstrated a more robust reduction in 
alcohol drinking in the first two hours (0-2hr; reached significance) in comparison 
to acute chemogenetic activation of PVN-OXT neurons. This effect may be 
related to the fact that activation of DREADD receptors in OXT+ neurons is 
driving the endogenous OXT system and therefore is restricted by physiological 
limits (such as availability of OXT, rate of neuropeptide synthesis. etc).  
Administration of exogenous OXT, however, may push the system beyond 
physiological relevant doses and reveal a more exaggerated effect on behavior.  
In congruence with previous data (see Chapter 2), the ability of activation 
of PVN OXT+ containing neurons to reduce alcohol consumption was reversed 
by pretreatment with a brain penetrant OXTR antagonist, suggesting that OXT 
neurotransmission reduced alcohol consumption via an interaction with its 
receptor.  Oxytocin receptors have been identified in a number of reward- and 
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anxiety-associated brain regions that are integral to motivational effects of 
alcohol, including PFC, striatal, and limbic regions (Grinevich et al. 2016). 
Further, changes in OXTR expression in a number of these regions (e.g., 
prelimbic cortex, NAc core and shell, CeA) have been demonstrated as a direct 
result of alcohol experience (Hansson et al. 2018). Oxytocin may directly impact 
reward signaling by altering mesolimbic dopamine activity via OXTR located on 
VTA neurons projecting to the NAc (Peris, et al. 2017; Peters et al. 2016). 
Moreover, recent reports showed that viral-mediated overexpression of OXTRs in 
NAc reduced alcohol-induced CPP and alcohol consumption in mice (Bahi 2015; 
Bahi et al. 2016).  
Using a chemogenetic approach, results from the present work also 
provide evidence to support the hypothesis that OXT’s effect of reducing alcohol 
drinking is likely centrally mediated. However, OXT-containing neurons in the 
PVN secrete OXT into the bloodstream via axon terminals in the posterior 
pituitary as well as target extrahypothalamic brain regions via axon collaterals 
(Knobloch et al. 2012). Therefore, chemogenetic-induced activation of these 
neurons could potentially lead to secretion of OXT into the periphery and produce 
effects through signaling at peripheral OXTRs. The present study provides 
evidence that peripheral receptors did not a make a major contribution to the 
effect of activating OXT+ neurons in the PVN on alcohol consumption. More 
specifically, pretreatment with nonbrain penetrant OXTR antagonist, Atosiban, 
had no effect on activation of OXT+ neurons in the PVN on alcohol consumption. 
Whereas pretreatment of brain penetrant OXTR antagonist, L368,899, reversed 
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this effect. These results are consistent with a recent report by Tunstall et al. 
demonstrating icv. administration of a large molecule OXTR agonist, PF-
06655075, that does not cross the BBB, significantly reduced alcohol drinking in 
dependent rats. However, the same compound administered systemically (not 
expected to enter the CNS) did not have an effect. The authors also showed that 
application of nonbrain penetrant OXTR antagonist L-371,257 did not reverse the 
ability of intranasal OXT to reduce alcohol drinking in dependent rats (Tunstall et 
al. 2019). Taken together, these data suggest that OXTR signaling in the brain 
reduces alcohol consumption independent of OXTR binding in the periphery.  
While the mechanism by which OXT reduces alcohol consumption 
remains unknown, one possible explanation is through interaction with 
GABAergic neurotransmission. Oxytocin has been reported to interact with 
GABAergic signaling to modulate limbic reward, fear and anxiety circuits (Dolen 
et al. 2013; Yoshida et al.  2009; Knobloch et al. 2012; Viviani et al. 2010; Sabihi 
et al. 2017) and may block the acute effects of alcohol (Bowen et al. 2015). 
Specifically, in the CeA, OXT has been shown decreased GABAergic signaling in 
both dependent and nondependent rats (Tunstall et al. 2019).  However, there is 
evidence to support both OXTR independent (via direct interaction with δ 
subunit-containing GABAA receptors; Bowen et al. 2015), and OXTR dependent 
(Sabihi et al. 2017) mechanisms to regulate behavior.  Interestingly, some 
OXTR-expressing cells contain GABA (Yoshida et al. 2009) and OXTRs have 
been shown to be located on GABAergic interneurons in the CeA (Huber et al. 
2005), as well as mPFC (Nakajima et al. 2014) that may attenuate activity of 
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downstream limbic regions, including the amygdala (Berretta et al. 2005, Gabbott 
et al. 2005). Thus, the effects of OXT neurotransmission on GABAergic signaling, 
particularly in the CeA, may contribute to the acute reinforcing effects of alcohol, 
as well as the negative affective state associated with chronic alcohol use.  
However, since the OXTR antagonist L368,899 was systemically administered, 
we cannot impy that OXTR activity in any brain region independently mitigates 
the effects of targeted chemogenetic-induced activation of OXT+ neurons. 
Further studies involving local OXTR blockade will be required to more directly 
address this issue. 
One important limitation of the present work is that the studies were 
conducted exclusively in male Oxt-IRES-Cre mice. In the present investigation 
female Oxt-IRES-Cre mice were run concurrently with males (See Appendix). 
However, systemic injection of CNO reduced alcohol consumption in female mice 
harboring control virus (with no active DREADD receptor) across several studies, 
suggesting that CNO had off-target effects. Thus, data from mice infused with 
excitatory DREADD virus are challenging to interpret. This is unfortunate 
especially considering sex-specific OXTR distribution (Dumias and Veemena 
2016). Although very few studies have examined the potential sex-related 
differences in OXT modulation of alcohol intake, there is some evidence that 
female mice may be more sensitive to the behavioral effects of OXT (Kohtz et al. 
2018). Thus, this is an issue that will require further investigation.   
 Another issue regards the specificity of the peripherally restricted OXTR 
antagonist, Atosiban. Atosiban is an OXT analogue (competitive antagonist) that 
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also acts as an antagonist of the vasopressin receptor V1a (Vrachnis et al. 
2011). This raises some concern, as a role for vasopressin (AVP) has been 
implicated in the transition to dependence (Zhou & Kreek, 2018) and AVP 
receptor antagonism has been shown to decrease alcohol consumption in 
humans and rodents (Zhou et al. 2018; Edwards et al. 2012; Katz et al. 2016; 
Ryan et al. 2017).  However, these effects appear to be mediated largely by the 
vassopressin V1b receptor (Zhou et al. 2018; Edwards et al. 2012). Regardless, 
an association between V1a receptor subtype and alcohol drinking has also been 
established. Both heterozygous and homozygous mouse knockout of the V1a 
receptor increased alcohol consumption (Sanbe et al. 2008, Caldwell et al. 
2006), and a modest association was found between a V1a receptor SNP and 
maximum drinks per day in humans (Maher et al. 2011). However, a recent study 
investigating the role of AVP in alcohol-associated anxiety, showed that V1b, but 
not V1a, antagonism was effective in reducing alcohol-related behaviors 
(Dannenhoffer et al. 2018). Further, in peripheral tissue, the V1a receptor is 
expressed in a variety of vascular walls in arteries, arterioles and veins and 
regulates vascular contraction, glucocorticoid release from the adrenal gland and 
renin production in the kidney (Morel et al. 1992; Vrachnis et al. 2011). While 
unlikely, these physiological functions may contribute to the observed reduction 
in alcohol consumption. Nonetheless, the results of the present study are in 
congruence a recent report that showed a more selective non-BBB penetrant 
OXTR antagonist, L-371,257, did not reverse the effects of OXT administration 
on alcohol consumption (Tunstall et al. 2019). Thus, while other OXTR 
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antagonists, such as esGly–NH2,d(CH2)5[Tyr(Me)2,Thr4]OVT,  5, desGly–
NH2,d(CH2)5[D-Tyr2,Thr4]OVT, and L-371,257 offer clear advantages for in vivo 
studies requiring the discrimination of OXT versus V1a receptors in rodents 
(Manning et al. 2008), the current examination provides some evidence that 
peripheral OXTR do not contribute to the effect of chemogenetic induced 
activation of OXT+ containing neurons on alcohol consumption. 
In sum, results from the present study provide new evidence indicating a 
role for OXT/OXTR system activity and, in particular, central activity of this 
neuropeptide system in the regulation of motivated alcohol drinking. These 
findings implicate the OXT system as a potential therapeutic target in treatment 


















CHAPTER 4: Oxytocin Attenuates Stress-Induced Reinstatement 




The compulsive nature of alcohol seeking and use, along with high rates 
of relapse present a major challenge in the treatment of alcohol addiction. Stress 
is a common trigger for relapse, yet mechanisms by which stress provokes 
relapse and promotes excessive levels of alcohol consumption are not fully 
understood. Thus, understanding brain mechanisms underlying relapse and the 
influence of stress on drinking has emerged as a central issue in addiction 
research. 
Understandably, the ability of OXT to modulate both stress and 
motivational processes has generated growing interest in its potential as a 
treatment for substance use disorders. For example, in a recent clinical study, IN 
OXT was shown to alleviate alcohol withdrawal symptoms in treatment-seeking 
subjects (Pedersen et al. 2013). Additional support comes from a growing 
number of studies showing that systemic administration of OXT reduces alcohol 
consumption in rodents (Bowen et al. 2011; MacFadyen et al. 2016; McGregor 
and Bowen 2012). Further, direct brain (icv.) infusion of OXT, or manipulation of 
OXTR expression in brain reduced alcohol reward and consumption (Bahi 2015; 
Bahi et al. 2016; Peters et al. 2017). Recent work in our laboratory demonstrated 
that systemic administration of OXT reduced binge-like alcohol drinking and oral 
self-administration of alcohol using operant conditioning procedures in male 
C57BL/6J mice in a dose-related manner (King et al. 2017; See Chapter 2). 
Importantly, OXT reduced alcohol consumption at doses that did not significantly 
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alter sucrose intake. Taken together, accumulating evidence suggests that the 
OXT system may represent a promising target for the treatment of alcohol use 
disorders.  
While evidence supports a role for OXT in regulating alcohol consumption, 
few studies have examined the effects of OXT on alcohol relapse-like behavior. 
The present study aimed to examine the ability of systemic OXT to attenuate 
stress-induced reinstatment of alcohol-seeking behavior in male and female 
mice. Two different stress procedures were employed: brief exposure to a 
predator odor and acute challenge with the pharmacological stressor yohimbine. 
Given that OXT is know to function as an anti-stress neuropeptide (Landgraf and 
Neumann 2004; Windle et al. 2004), it was predicted that systemic OXT 
administration would attenuate stress-induced reinstatement of alcohol-seeking 
behavior in a dose-related manner in male and female mice. Further, since there 
is some evidence to suggest that gonadal hormones can influence the functional 
activity of OXT (Ivell and Walther 1999), it was predicted that females would 
exhibit a greater response to OXT treatment compared to males.  
 
MATERIALS AND METHODS 
 
Animals and Housing 
Adult male and female C57BL/6J mice (25 to 30 g) were obtained from 
Jackson Laboratories (Bar Harbor, ME) at 9 to 10 weeks of age and were 
acclimated to the experimental housing rooms for a minimum of 1 week prior to 
the start of experiments. Male and female mice were group housed (4 per cage) 
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in the same colony room, but with males and females on separate racks. The 
animals were maintained under a 12-hour reversed light/dark cycle in an 
AAALAC-accredited facility. All testing was conducted during the dark phase of 
the circadian cycle. Mice were provided free access to food and water, except at 
the start of operant oral self-administration training. All experimental protocols 
were approved by the Medical University of South Carolina Institutional Animal 
Care and Use Committee and consistent with guidelines of the NIH Guide for the 
Care and Use of Laboratory Animals. 
 
Operant Conditioning Chambers 
Mice were tested in standard operant conditioning chambers configured 
with 2 retractable levers, a centrally located well for liquid reinforcers, house light, 
a tone generator, and a stimulus light above the well. The chambers were 
situated in sound-attenuating cubicles with a ventilation fan (Med Associates; 
Fairfax, VT). One lever was assigned as the “active” lever, with scheduled 
responses activating an infusion pump that delivered alcohol (12% v/v ethanol) 
reinforcement (20 µl) into the well along with activating a light and a tone stimulus 
(80 dB). Responses on the “inactive lever” were recorded but did not result in any 
stimulus consequences or reinforcement delivery. The position of the “active” 
lever (left vs. right of well) was counterbalanced across subjects. Stimulus events 
and responses were controlled and monitored using Med PC, Version IV 
software (Med Associates). At the end of each session, any residual fluid left in 
the well was collected with a pipette, measured, and subtracted from the total 
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volume of alcohol delivered. The corrected volume was used to calculate g/kg 
alcohol intake during the 20-min daily sessions. Male and female mice were 
tested in separate chambers throughout the experiments (8 chambers/sex).  
 
Operant Alcohol Self-Administration 
Mice were trained to self-administer alcohol using standard operant 
conditioning procedures, as previously described (King et al. 2017). Briefly, mice 
were first trained to respond for alcohol reinforcement under a fixed ratio-1 (FR1) 
schedule. Response requirements were gradually increased until mice achieved 
stable lever responding under a FR4 schedule of reinforcement (<15% variability 
across 3 consecutive daily sessions). Once stable baseline alcohol 
responding/intake was established, mice entered into the extinction phase of the 
study. During daily extinction sessions, responding on the “active” lever no longer 
had stimulus consequences and alcohol reinforcement was no longer delivered. 
After 14 days of extinction (when responding has reached <15% of baseline 
responding), all mice were tested for stress-induced reinstatement of alcohol 
responding.  
 
Study 1: Predator Odor-Induced Reinstatement Testing 
Mice were transferred to a chamber and exposed to a predator odor 
(2,3,5-Trimethyl-3-thiazoline; TMT) for 15 min. This stressor, a synthetically 
derived component of fox feces, was selected because of its ethological 
relevance and validity (Janitzky et al. 2015), as well as the fact that we have 
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successfully used TMT to produce robust relapse-like behavior in our preliminary 
studies. TMT (0.03 mL; 1% v/v; Ferland et al. 2016) was placed on a gauze pad 
in a weigh boat in the chamber such that mice could not manipulate it. After the 
15-min exposure period, mice were immediately placed into self-administration 
chambers to examine alcohol-seeking behavior under extinction conditions. At 30 
min prior to the reinstatement test session (15 min prior to TMT exposure), 
separate groups of mice were injected (ip.) with vehicle (saline) or OXT (0.1, 0.5, 
1 mg/kg) (N= 8-10/group).  
 
Study 2: Yohimbine-Induced Reinstatement Testing 
Mice were injected with yohimbine (0.3, 0.625 mg/kg; ip.) 60 min prior to 
the reinstatement test session. At 30 min post-yohimbine injection, mice are 
injected (ip.) with vehicle (saline) or OXT (1 mg/kg).  Reinstatement testing was 
conducted under extinction conditions 30 min after OXT injection. Results from a 
series of pilot studies indicated that the 60 min pretreatment time for yohimbine 
administration was optimal for triggering reinstatement responding (unpublished 
data). In this case, OXT was administered after yohimbine treatment to keep the 
pretreatment time for the neuropeptide consistent with that used in the TMT 
study (Study 1). Each mouse received both yohimbine doses in a 
counterbalanced order with one week of extinction responding between tests. 






Synthetic human OXT (CellSciences, Canton, MA) and yohimbine (Tocris 
Bioscience, Minneapolis, MN), were dissolved in 0.9% saline, which served as 
the vehicle. Injections were administered intraperitoneally in a volume of 
0.01 ml/g body weight in all experiments. Alcohol (95% ethanol) was obtained 
from AAPER (Shelbyville, KY) and diluted with tap water to the appropriate 
concentration. The alcohol solution was prepared daily and presented at room 
temperature. 
 
Statistical Analysis  
The primary dependent variable analyzed was lever responses during 
different phases of the studies. Lever responses were averaged over the last 
three daily sessions of baseline alcohol self-administration and the last 3 days of 
extinction testing prior to reinstatement testing. Number of reinforcers earned and 
amount of alcohol intake (g/kg) averaged over the last three self-administration 
sessions were also analyzed. For Study 1, lever responses, reinforcers earned, 
and alcohol intake in male and female mice were analyzed by t-tests. Responses 
during reinstatement testing were analyzed by ANOVA, with Sex and Dose as 
between-subject factors. For Study 2, since male and female mice were not 
tested simultaneously, reinstatement responding for males and females was 
separately analyzed by ANOVA, with OXT Dose as a between-subject factor and 
yohimbine Treatment as a repeated measure. Initial analyses also included order 
of yohimbine dose as a factor but since this variable did not significantly interact 
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with the other variables, data were presented and analyzed as collapsed over 
this factor. Post-hoc analyses (Newman-Keuls) were conducted when 




Oxytocin Effects on TMT-Induced Reinstatement of Alcohol-Seeking in Male and 
Female Mice 
 
All animals demonstrated stable and preferential responding on the active 
lever. Males and females did not significantly differ in responding on the active 
lever [t(66)= 0.08, p> 0.1] and inactive lever [t(66)= 0.95, p> 0.1] (Figure 4.1a), 
and there was no sex-related difference in the number of alcohol reinforcers 
earned [t(66)= 0.25, p> 0.1] (Figure 4.1b). However, average alcohol intake was 
significantly higher in females compared to males [t(66)= 2.87, p< 0.01] due to 
differences in body weight (Figure 4.1c).  
During reinstatement testing, TMT exposure significantly increased 
alcohol-seeking behavior, and OXT treatment significantly reduced this stress-
induced relapse-like responding in both male and female mice in a dose-related 
manner (Figure 4.1d). ANOVA revealed a significant main effect of Dose 
[F(3,63)= 8.39, p< 0.001], indicating that OXT was effective in reducing alcohol 
responding in both males and females. While it appears that females may have 
been more sensitive to the effects of OXT, this was not supported by the 




Figure 4.1. Effects of oxytocin on TMT-induced reinstatement of alcohol-
seeking behavior. Lever responding, alcohol reinforcers and alcohol Intake 
during self-administration. (a) Males and females did not significantly differ in 
responding on the active lever, and there was no sex-related difference in the 
number of (b) alcohol reinforcers. (c) Average alcohol intake was significantly 
higher in females compared to males. Systemic OXT attenuates TMT-induced 
reinstatement of alcohol seeking behavior in a dose-related manner in male (left) 
and female (right) mice. Values are mean ± s.e.m. (N= 10/group). Significantly 
differs compared to males: ** (p< 0.01) Significantly differs from vehicle condition: 
























































































Separate analysis of data from males revealed a significant effect of Dose 
[F(3,35)= 5.22, p< 0.01] and post-hoc comparisons indicated that the highest 
OXT dose tested (1 mg/kg) reduced responding compared to vehicle (p< 0.05). 
In females, a main effect of Dose [F(3,34)= 4.54, p< 0.01] and post-hoc analysis 
indicated that both 0.5 and 1 mg/kg doses of OXT significantly reduced alcohol 
seeking behavior compared to vehicle (ps< 0.05).  
 
Oxytocin Effects on Yohimbine-Induced Reinstatement of Alcohol Seeking in 
Male Mice 
 
Active and inactive lever responses, number of alcohol reinforcers earned, 
and alcohol intake over the last 3 days of oral alcohol self-administration in males 
are shown in Figure 4.2a, 4.2b, and 4.2c, respectively.  Yohimbine treatment 
increased alcohol responding during reinstatement testing and this effect was 
blocked by pretreatment with OXT (1 mg/kg) (Figure 4.2d). Increased 
reinstatement responding following injection of yohimbine did not significantly 
differ as a function of dose of the drug. ANOVA revealed a significant main effect 
of OXT Dose [F(1,17)= 22.15, p< 0.001], but the yohimbine Treatment x OXT 
Dose interaction was not significant. This indicates that systemic administration 
of OXT (1 mg/kg) reduced alcohol seeking behavior provoked by both yohimbine 







Figure 4.2. Effects of oxytocin on yohimbine-induced reinstatement in male 
mice. Active and inactive lever responses (a), number of alcohol reinforcers 
earned (b), and alcohol intake (c) over the last 3 days of oral alcohol self-
administration. Yohimbine treatment increased alcohol responding during 
reinstatement testing and this effect was blocked by pretreatment with OXT (1 
mg/kg) (d). Values are mean ± s.e.m. (N= 7-10/group) Significantly differs from 
average last 3 days of extinction (ext): ** (p< 0.01). Significantly differs from 

































































Figure 4.3. Effets of oxytocin on yohimbine-induced reinstastement in 
female mice. Active and inactive lever responses (a), number of alcohol 
reinforcers earned (b), and alcohol intake (c) over the last 3 days of oral alcohol 
self-administration. Similar to males, yohimbine treatment increased alcohol 
responding during reinstatement testing and this effect was attenuated by 
pretreatment with OXT (1 mg/kg) (d). Values are mean ± s.e.m. (N= 7-10/group) 
Significantly differs from average last 3 days of extinction (ext): ** (p< 0.01). 


































































Oxytocin Effects on Yohimbine-Induced Reinstatement of Alcohol Seeking in 
Female Mice  
 
Active and inactive lever responses, number of alcohol reinforcers earned, 
and alcohol intake over the last 3 days of oral alcohol self-administration in 
females are shown in Figure 4.3a, 4.3b, and 4.3c, respectively.  As in males, 
yohimbine treatment increased alcohol responding during reinstatement testing 
and this effect was blocked by pretreatment with OXT (1 mg/kg) (Figure 4.3d). 
ANOVA indicated that both doses of yohimbine produced a similar increase in 
alcohol responding [F(1,26)= 1.62, p> 0.1], and OXT blocked this increase in 
responding [F(1,26)= 23.52, p< 0.001]. The lack of a significant yohimbine  
Treatment x OXT Dose interaction indicates that OXT was effective in reducing 




Results from the present study demonstrate that systemic administration 
of OXT reduces stress-induced reinstatement of alcohol-seeking behavior. In 
Study 1, OXT attenuated predator odor (TMT)-induced reinstatement in a dose-
related manner in both male and female mice.  In Study 2, OXT attenuated 
increased alcohol-seeking following administration of the pharmacological 
stressor yohimbine in both sexes. Although OXT has been shown to effectively 
reduce cue- and drug-primed reinstatement to alcohol and other drugs of abuse 
(Baracz et al. 2015; Baracz et al. 2016; Cox et al. 2017; Ferland et al. 2016; 
Hansson et al. 2018; Kohtz et al. 2018; Weber et al. 2018), to our knowledge, 
 
 116 
this is the first report to demonstrate that OXT attenuates stress-induced alcohol 
relapse-like behavior in mice.  
Our finding that OXT reduces stress-induced alcohol reinstatement 
responding is consistent with other studies that have shown OXT decreases 
stress-related relapse-like behavior to other drugs of abuse. Systemic 
administration of OXT decreased methamphetamine-seeking behavior following 
predator odor exposure (Ferland et al. 2016) and yohimbine administration (Cox 
et al. 2013) in rats. In mice, centrally administered OXT (icv.) attenuated 
reinstatement of methamphetamine conditioned place preference (CPP) induced 
by restraint stress (Qi et al. 2009), and systemic administration of the oxytocin 
analog, carbetocin, reduced the effects of forced-swim stress on reinstatement of 
morphine-induced CPP (Zanos et al. 2014). Collectively, results from the present 
study and related reports in the literature indicate that OXT treatment is effective 
in attenuating relapse-like behavior provoked by various stress procedures.  
The present study demonstrated OXT was effective in reducing the ability 
of two different stress procedures (predator odor (TMT) exposure and systemic 
administration of the alpha-2 noradrenergic antagonist yohimbine) to reinstate 
alcohol-seeking behavior. While both stressors produced a significant increase in 
alcohol-seeking behavior, the use of TMT and yohimbine as tools to induce 
stress and fear responses are controversial (Blanchard et al. 2003; Chen et al. 
2015; Endres and Fendt 2007; Fendt and Endres 2008; Mantsch et al. 2016; 
McGregor et al. 2002). In rodents, TMT exposure reliably produces an elevation 
in plasma CORT levels (Morrow et al. 2000) and elicits a number of autonomic 
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and behavioral changes that are indicative of fear and anxiety (Endres et al. 
2005; Fendt et al. 2005). However, it has been suggested that TMT is not a fear-
inducing stimulus but rather a generalized noxious odor (Fendt et al. 2005; 
McGregor et al. 2002). Studies investigating the neural basis of TMT effects on 
rodents demonstrate activation of the HPA-axis (Day et al. 2004; Myers and 
Rinaman 2005) and increases in c-fos expression in brain regions shown to be 
important in fear processing and stress-related responses, such as the 
amygdala, BNST, LS, and hypothalamus (Day et al. 2004; Janitzky et al. 2015). 
Thus, there is ample neural, physiological, and behavioral evidence indicating 
that TMT exposure produces a stress-like state that may trigger alcohol-seeking 
behavior in the operant conditioning reinstatement model.  
The use of yohimbine as a stressor in this relapse model also has been 
called into question (Chen et al. 2015). It is suggested that yohimbine may not be 
exerting its effects on alcohol/drug seeking behavior by producing an aversive 
(stress) state but, rather, merely potentiating cue-related responding. Further, 
yohimbine was not found to induce conditioned place aversion, suggesting a lack 
of stress-like effects (Chen et al. 2015). However, evidence from several studies 
indicate that yohimbine engages critical components of stress circuitry that are 
known to mediate stress responses, including reinstatement of alcohol/drug 
seeking behavior (Buffalari and See 2011; Le et al. 2013; Shaham et al. 2003; 
Shalev et al. 2010). Further, human studies indicate that yohimbine induces both 
physiological and psychological stress-like responses (Greenwald et al. 2013) 
and alcohol craving (Umhau et al. 2011). Taken together, there is sufficient 
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evidence indicating that both stress procedures employed in the present study 
produced an aversive state, and OXT was effective in attenuating their ability to 
provoke alcohol relapse-like behavior in male and female mice.  
While results from the present study demonstrated that OXT is effective in 
attenuating stress-induced alcohol relapse-like behavior in both male and female 
mice, it is difficult to conclude whether a sex-related difference in sensitivity to 
this effect exists. Results from Study 1 suggest that females may exhibit greater 
sensitivity to OXT than males (shift to the left in the dose-effect function). 
Unfortunately, only a single dose was used in Study 2 and this dose (1 mg/kg 
OXT) was equally effective in reducing stress-induced reinstatement of alcohol 
seeking in both females and males. Other studies have provided evidence for 
sex-related differences in sensitivity to OXT. For example, lower doses of OXT 
were more effective in reducing cue-induced reinstatement of cocaine (Kohtz et 
al. 2018) and sucrose (Zhou et al. 2015) responding in female rats compared to 
their male counterparts.  Further, sexually dimorphic expression of OXTRs in the 
brain has been reported in several strains of rats and mice (Dumais et al. 2016; 
Dumais et al. 2013; Dumais and Veenema 2016), although no such sex 
differences were found in a study with C57BL/6J mice (Hammock and Levitt 
2013). Oxytocin expression and signaling in the brain has been shown to be 
modulated by gonadal hormones (Dumais and Veenema 2016; Ivell and Walther 
1999; Patchev et al. 1993). Fluctuations in estrogen and progesterone levels 
across the estrous cycle may influence sensitivity to OXT in females (Dumais et 
al. 2013; Dumais and Veenema 2016). Although we did not assess estrus status 
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in our studies, other reports have indicated that the effects of OXT on relapse-like 
behavior are not dependent on phase of estrus at the time of testing (Cox et al. 
2013; Leong et al. 2017; Leong et al. 2016). Thus, possible sex-related 
differences in sensitivity to OXT as well as the role of sex hormones influencing 
effects of OXT on alcohol relapse-like behavior remain to be determined.  
The mechanism by which OXT decreased stress-induced re-invigoration 
of alcohol responding is not well understood. Previous work in our laboratory 
demonstrated that OXT doses less than 3 mg/kg reduced alcohol self-
administration in C57BL/6J mice without altering general locomotor activity (see 
Chapter 2; King et al. 2017). Thus, it is unlikely that OXT reduced alcohol relapse 
responding provoked by TMT or yohimbine exposure due to a nonspecific 
sedative effect.  
Oxytocin is known to exert anti-stress and anxiolytic effects (Jurek et al. 
2015; Peters et al. 2014; Slattery and Neumann 2010). Oxytocin interacts with 
CRF neurons and the peptide has been shown to dampen stress-induced HPA-
axis activation (elevated CORT levels), as well as reduce stress-related 
behavioral responses in animal models of anxiety and depression (Neumann et 
al. 2000; Windle et al. 2004). Further, high levels of OXT and OXTR mRNA 
expression are localized in forebrain regions such as the extended amygdala, 
where OXT signaling can play a significant role in the regulation of anxiety, 
stress, and reward-related behaviors (Dabrowska et al. 2011; Gimpl and 




Another potential mechanism by which OXT decreases reinstatement of 
alcohol-seeking behavior may be through direct influence on reward signaling. 
Oxytocin receptors have been identified in a number of brain regions known to 
significantly contribute to drug-related reward and relapse-like behavior. This 
includes the NAcc (Tan et al., 2017; Dolen et al., 2013), VTA (Peris et al., 2017) 
and mPFC (Li et al, 2016; Nakajima et al., 2014). Intra-NAcc infusion of OXT has 
been shown to attenuate drug primed- (Baracz et al. 2015; Baracz et al. 2016) 
and cue- (Bernheim et al. 2017) induced reinstatement of methampethamine 
seeking. Additionally, Leong et al. (2017) demonstrated that elevated Fos 
expression in the mPFC, NAcc, and subthalamic nucleus (STN) in response to 
cocaine associated cues was normalized by a systemic injection of OXT in rats. 
Interestingly, direct infusion of OXT into the NAcc and STN reduced whereas 
intra-PFC OXT increased cue-induced reinstatement of cocaine-seeking 
behavior (Weber et al. 2018; Leong et al. 2018). A few studies have examined 
the influence of OXT on alcohol-related reward effects. For example, acute icv. 
infusion of OXT reduced alcohol consumption and elevated dopamine release in 
the NAc in rats (Peters et al., 2017). Viral-mediated overexpression of OXTRs in 
the NAc was shown to reduce alcohol drinking and alcohol-induced CPP (Bahi 
2015; Bahi et al. 2016).  Hansson et al. (2018) demonstrated increases in OXTR 
mRNA and protein levels in PFC, striatal, amygdala, and hippocampal regions in 
alcohol dependent rats after 3 weeks of abstinence, implicating similar brain 
regions as the aforementioned studies. Thus, there is evidence to suggest that 
the effects of OXT within brain reward circuitry may not only contribute to its 
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ability to reduce alcohol self-administration, but also reduce alcohol relapse-like 
behavior. Unfortunately, there are no studies investigating the effects of site-
specific administration of OXT on reinstatement of alcohol-seeking behavior 
using operant conditioning procedures. Future studies are needed to investigate 
specific brain regional changes that mediate the ability of OXT to blunt alcohol 
relapse-like behavior.  
Systemic administration of OXT raises the issue of blood-brain barrier 
penetrance (Lee et al. 2018). A number of studies have recapitulated effects of 
systemic OXT administration with direct (icv. or site-specific) intracranial 
infusions across a number of behavioral tasks (Cox et al. 2017; Lee et al. 2018; 
Love 2014; Ring et al. 2006; Slattery and Neumann 2010; Windle et al. 1997). 
Additionally, peripheral administration of OXT has been shown to induce Fos 
expression in OXT neurons in the PVN (Carson et al. 2010; Leong et al. 2017), 
suggesting that peripheral administration may induce endogenous central 
release. However, Lee et al. (2018) demonstrated that while OXT administered 
through IN and IV routes of administration increased OXT levels in cerebral 
spinal fluid, it did not activate a feed forward mechanism to elevate endogenous 
OXT. Thus, the mechanism by which exogenous OXT delivered in the periphery 
activates OXT signaling in the brain remains unclear. Further studies are needed 
to address this issue, as it is relevant to the potential for OXT to serve as a 
therapeutic for alcohol/drug addiction. 
In conclusion, our findings reveal that systemic OXT administration 
attenuates stress-induced reinstatement of alcohol seeking in male and female 
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mice. Exogenous OXT decreased alcohol-seeking behavior in a dose-related 
manner in response to acute challenge with a predator odor. The reduction in 
reinstatement responding was similar between males and females, though 
females showed a decrease in responding at lower doses of OXT compared to 
males. Additionally, OXT administration produced a similar decrease in alcohol 
relapse-like behavior triggered by the pharmacological stressor yohimbine in both 
sexes. Taken together, these results indicate that OXT may be potential 














CHAPTER 5. The Role of Oxytocin Receptor Signaling in Stress-
Induced Relapse Behavior  
 
The endogenous OXT system appears to be sensitive to both stressors 
and long-term exposure to alcohol and thus, may develop compensatory 
neuroadaptive changes in brain regions specifically involved in the addiction 
process, including relapse (Lee & Weerts 2016). Work from our laboratory (see 
Chapter 4; King and Becker 2019) demonstrated OXT reduces stress-induced 
reinstatement of alcohol seeking in male and female mice. These data add to a 
growing body of literature that has shown that both systemically and centrally 
administered OXT decreases stress-related relapse-like behavior (Ferland et al. 
2016; Cox et al. 2013; Qi et al. 2009; Zanos et al. 2014). However, the 
mechanism by which OXT reduces relapse-like behavior remains unknown. 
While there is some evidence to suggest that OXT attenuates the reinvigoration 
of drug seeking via effects at its own receptor (Han et al. 2014; Baracz et al. 
2013, Qi et al. 2009), other studies have shown that co-administration of OXT 
and a selective OXTR antagonist was unable to reverse the modulating effect of 
OXT on relapse-like behavior (Baracz et al. 2015; Baracz et al. 2016; Everett et 
al. 2018; Dong et al. 2017).  
Additionally, we have previously demonstrated (see Chapter 3) that the 
effects of OXT on alcohol drinking do not involve peripheral OXTR signaling. 
However, induced central and peripheral OXT release have been shown to be 
coupled, especially in a situation of stress (Neuman, 2007; Wotjak et al. 1998). In 
humans, higher levels of peripheral OXT secretion have been associated with 
faster vagal recovery following acute stress (Engert et al. 2016), suggesting the 
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involvement of peripheral mediated actions. As our model of stress-induced 
relapse-like behavior involves exposure to predator odor (TMT), the specific 
contribution of central versus peripheral OXTR signaling on the neuropeptide’s 
attenuating effect on stress-induced reinstatement of alcohol seeking should also 
be evaluated.   
The OXT system is likely to interfere with the negative consequences of 
withdrawal and protracted abstinence, such increased stress and negative 
affectivity which contribute to susceptibility to stress-induced relapse (Bowen and 
Neumann 2017; Koob and Volkow 2016; Koob et al. 2014). Hypothalamic OXT 
projection fibers have been found in number of stress-related brain regions, 
including those integral to the motivational effects of alcohol such as central 
nucleus of the amygdala (CeA) (Knobloch et al. 2012; Bale et al. 2001). The CeA 
receives input from a number of cortical, limbic and midbrain regions that release 
several stress-related neuropeptides, including CRF, NPY, DYN, AVP and OXT 
(Koob et al. 2014; Koob and Volkow 2016). Oxytocin receptors are present on 
discrete populations of neurons in the CeA, thereby enabling OXT to contribute 
to regulation of anxiety, stress and reward behaviors (Knobloch et al. 2012; 
Huber et al. 2005) Indeed, OXT neurotransmission has been shown to play an 
important role stress, fear and anxiety responses through actions in the CeA 
(Bale et al. 2001; Knobloch et al. 2012; Ebner et al. 2005; Neumann et al. 2007) 
and the PVN (Neumann et al. 2000; Bale et al 2001; van den Burg et al. 2015) 
via inhibition of stress-induced CRF synthesis (Jurek et al. 2015). Additionally, 
oxytocinergic circuits from the hypothalamus have been shown to modulate 
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GABA signaling in the CeA (Huber et al. 2005; Viviani et al. 2011; Knobloch et al. 
2012). This is especially compelling considering that the CeA plays a key role in 
the aversive symptoms associated with alcohol withdrawal (Koob et al. 2014; 
Koob 2015). Interestingly, a reduction in OXT-induced modulation of GABAergic 
transmission has been implicated in depression- and anxiety-related behaviors 
(Han et al. 2018) as well the acute effects of alcohol (Tunstall et al. 2018). 
However, it is not known whether OXT, via OXTR signaling, acts in the CeA to 
regulate stress-induced relapse-like behavior.  
Studies in this chapter will examine the role of OXTR signaling in the 
ability of OXT to modulate alcohol relapse-like behavior in male and female mice. 
First, we examine the contributions of central versus peripheral OXTR signaling 
on attenuation of stress-induced reinstatement of alcohol-seeking behavior. 
Second, we investigate the role of OXTR signaling in the amygdala via co-
administration of systemic OXT and intra-CeA infusion of a selective OXTR 
antagonist.    
 
MATERIALS AND METHODS 
 
Animals and Housing 
Adult male and female C57BL/6J mice (25 to 30 g) were obtained from 
Jackson Laboratories (Bar Harbor, ME) at 9 to 10 weeks of age and were 
acclimated to the experimental housing rooms for a minimum of 1 week prior to 
the start of experiments. Male and female mice were group housed (4 per cage) 
in the same colony room, but with males and females on separate racks. The 
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animals were maintained under a 12-hour reversed light/dark cycle in an 
AAALAC-accredited facility. All testing was conducted during the dark phase of 
the circadian cycle. Mice were provided free access to food and water, except at 
the start of operant oral self-administration training. All experimental protocols 
were approved by the Medical University of South Carolina Institutional Animal 
Care and Use Committee and consistent with guidelines of the NIH Guide for the 
Care and Use of Laboratory Animals. 
 
Drugs and administration 
Synthetic human OXT (CellSciences, Canton, MA) and the OXTR 
antagonists L-368,899 hydrochloride (Tocris) and Atosiban (Tocris) were 
dissolved in 0.9% saline. Systemic administration of OXT (1 or 0.5 mg/kg), L-
368,899 (5, 10 or 20 mg/kg) and Atosiban (1 or 10 mg/kg), was delivered via 
intraperitoneal (ip.) injection at a volume of 0.01 ml/g body weight for all 
experiments. Doses were based on previous experiments (see chapters 2-4). For 
direct brain infusion, L-368,899 hydrochloride (Tocris) was dissolved in PBS and 
bilaterally microinjected (0.5µl over 2 mins) into the central nucleus of the 
amygdala (CeA) to achieve a dose of either 1 or 2 ug/side. Injectors were left in 
place for an additional 2 minutes to ensure drug diffusion before removal.  
 
Surgical procedures  
 C57BL/6J mice were anesthetized with isoflurane and implanted with dual guide 
cannulae (Plastics One) aimed at the central nucleus of the amygdala (AP -1.2 
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mm, ML: ± 3.0 mm, DV: – 3.9 mm). When inserted, microinjector tips extended 
0.5mm beyond the guide. Mice received surgery after establishing stable alcohol 
lever responding and intake in operant conditioning chambers, about 2-3 weeks 
into baseline (coordinates adjusted for age). Mice were allowed one week for 
recovery before returning to daily sessions.  
 
Operant Alcohol Self-Administration 
Mice were tested in standard operant conditioning chambers, as 
previously described in Chapter 2, 3 & 4. Briefly, mice were first trained to 
respond for alcohol reinforcement under a fixed ratio-1 (FR1) schedule. 
Response requirements were gradually increased until mice achieved stable 
lever responding under a FR4 schedule of reinforcement (<15% variability across 
3 consecutive daily sessions). Once stable baseline alcohol responding/intake 
was established, mice entered into the extinction phase of the study. During daily 
extinction sessions, responding on the “active” lever no longer had stimulus 
consequences and alcohol reinforcement was no longer delivered. After 14 days 
of extinction (when responding has reached <15% of baseline responding), all 
mice were tested for stress-induced reinstatement of alcohol seeking behavior 






Experiment 1. Effect of pharmacological antagonism of oxytocin receptors 
on oxytocin-induced attenuation of stress provoked relapse-like behavior 
Mice were transferred to an enclosed chamber and exposed to predator 
odor (2,3,5-trimethyl-3-thiazoline (TMT)) for 15 minutes, as previously described 
in Chapter 4. TMT (0.03 ml; 1% v/v in saline) was placed on a gauze pad in a 
weight boat in the chamber such that mice could not manipulate it. After the 15 
minutes exposure period, mice were immediately place into self-administration 
chambers to examine alcohol-seeking behavior under extinction conditions. At 30 
minutes prior to the reinstatement test (15 minutes prior to TMT exposure), mice 
were injected blood-brain barrier penetrant OXTR antagonist, L-368,899 (0 or 
10mg/kg; i.p.), 45 mins prior to the reinstatement test session. At 30 min post 
OXTR antagonist injection, mice were injected (ip.) with vehicle (saline) or OXT 
(0.5 or 1 mg/kg). Each mouse received both doses of the OXTR antagonist in a 
counterbalanced order with 1 week of extinction responding between tests.  
 
Experiment 2. Effect of central versus peripheral oxytocin receptor 
signaling on stress-induced relapse-like behavior 
 Since the results from the previous study indicated that 10 mg/kg dose of 
OXTR antagonist, L-368,899, was not effective in reversing the effects of either 
dose of OXT on stress-induced reinstatement in female mice, a follow up study 
(Experiment 2a) was conducted to examine wider range of L368,899 doses 
against a lower dose of OXT (0.5 mg/kg).  
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To examine potential sex differences in peripheral OXTR signaling we 
also investigated the effects of peripherally-restricted OXTR antagonist, Atosiban 
(Experiment 2b). At 45 minutes prior to the reinstatement test (30 minutes prior 
to TMT exposure), mice were injected blood-brain barrier penetrant OXTR 
antagonist L-368,899 (0, 5, 10, 20 mg/kg; i.p.) or peripherally restricted OXTR 
antagonist Atosiban (0, 1, 10 mg/kg; i.p.). At 15 min post OXTR antagonist 
injection, mice were injected (i.p.) with vehicle (saline) or OXT (0.5 mg/kg). Tests 
with L-368,899 (N=12 male/12 female) and Atosiban (N=12 male/12 female) 
were conducted in separate groups of mice. Each mouse received all OXTR 
antagonist (L-368,889 or Atosiban) doses in a counterbalanced order with 1 
week of extinction responding between tests. 
 
Experiment 3. Effect oxytocin receptor blockade in the central amygdala on 
stress-induced relapse-like behavior 
Following recovery from stereotaxic surgery (one week), mice returned to 
daily oral operant self-administration sessions to re-establish stable baseline 
responding for alcohol and intake levels over 2-3 weeks. Mice then entered into 
the extinction phase of the study for 14 days. At 30 minutes prior to daily 
extinction sessions mice received a saline injection and were handled to 
acclimate them to the microinjection procedure. 
On day 15, mice were tested for stress-induced reinstatement of alcohol 
responding following the 15-minute stress (TMT exposure) procedure described 
in Experiment 1. At 45 minutes prior to the reinstatement test session (30 
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minutes prior to TMT exposure), mice received bilateral infusion of OXTR 
antagonist L-368,899 or vehicle (PBS). Different doses of L-368,899, low;1 
ug/side (N=14 male/8 female) or high; 2 ug/side (N= 23 male/ 20 female) were 
tested in two separate cohorts. Following microinjection procedure (~15 minutes 
prior to TMT exposure), mice injected (ip.) with vehicle (saline) or OXT (0.5 
mg/kg). At the conclusion of Experiment 2, the mice were euthanized, and brains 
were histologically examined for injector placement. 
 
Statistical Analysis  
The primary dependent variable analyzed was lever responses during 
different phases of the studies. Lever responses were averaged over the last 
three daily sessions of baseline alcohol self-administration and the last 3 days of 
extinction testing prior to reinstatement testing. Number of reinforcers earned and 
amount of alcohol intake (g/kg) averaged over the last three self-administration 
sessions were also analyzed. For Experiment 1 & 2, lever responses, reinforcers 
earned, and alcohol intake in male and female mice were analyzed by t-tests. For 
Experiment 1, responses during reinstatement testing were analyzed by ANOVA, 
with Sex (M,F) and Group (VEH, ANTAG) as a between-subject factors and OXT 
Dose (0, 0.5, 1) and Time (Ext, Reinstate) as repeated measures. Analysis of 
lever responding in Experiment 2 was also by ANOVA in which Sex (M,F) and 
Group (VEH, OXT) served as a between-subject factors and Dose(2a: 0, 5, 10, 
20 L368,899 or 2b: 0, 1, 10 Atosiban) and Time (Ext, Reinstate)  were repeated 
measures. Initial analyses for all studies in Experiment 1 and 2 also included 
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Order as a factor but since this variable did not significantly interact with the other 
variables, data were presented and analyzed as collapsed over this factor. For 
analysis of locomotor activity, distance traveled (cm) served as the dependent 
variable and the factor Time served as a repeated measure. The design for 
studies in Experiment 2 was 2 Sex (M,F) x 2 IP (VEH, OXT) x Micro (VEH, 
ANTAG) x 2 Time (Ext, Reinstate). Analysis with ANOVA was preformed using 
Sex, IP and Order as between-subject factors and Micro and Time as within-
subject variables. Post-hoc analyses (Newman-Keuls) were conducted when 
appropriate. For all analyses, significance levels were set a p < 0.05, and all data 




Baseline data including active lever and inactive lever responses, number 
of alcohol reinforcers earned, and alcohol intake over the last 3 days of oral 
alcohol self-administration in males and females can be seen in Table 3. All 
animals demonstrated stable and preferential responding on the active lever. 
Males and females did not significantly differ in responding on the active lever 
and there was no sex-related difference in the number of alcohol reinforcers 
earned. However, average alcohol intake was significantly higher in females 





Effects of Pharmacological Antagonism of Oxytocin Receptors on Stress-Induced 
Relapse-like Behavior in Male and Female Mice 
 
During reinstatement testing, TMT exposure significantly increased alcohol-
seeking behavior and OXT treatment significantly reduced this stress-induced 
relapse-like responding in both males and female mice in a dose related manner 
(Figure 5.1). Pretreatment with OXTR antagonist L368,899 reversed the effects 
of 1 mg/kg OXT on stress-induced reinstatement in male mice, whereas 
administration of the OXTR antagonist had no effect on reinstatement responding 
in females. These results were supported by the overall ANOVA, with Sex (M,F) 
and Group (VEH, ANTAG) as a between-subject factors and Dose (0, 0.5, 1 
OXT) and Time (Ext, Reinstate) as repeated measures indicated a significant 
main effect of Sex [(F(1,100) = 34.76, p< 0.0001], Dose [(F(2,100) = 26.17, p< 
0.0001], Group [(F(1,100) = 6.09, p< 0.05] and Time [(F(1,100) = 191.15, p< 
0.0001], as well as significant interactions between Time, Sex and Group 
[(F(1,100) = 14.06, p< 0.0001], Time, Sex and Dose [(F(2,100) = 10.83, p< 
0.0001],  and Time, Group and Dose [(F(2,100) = 4.54, p< 0.05]. However, the 
interaction between all test variables (Sex x Group x Dose x Time) did not reach 
statistical significance [(F(2,100) = 1.90, p >0.1].  
Separate ANOVA including Group (VEH, ANTAG), Dose (0, 0.5, 1) and 
Time (Ext, Reinstate) were also conducted for males and females independently.  
Analysis of lever responding during reinstatement test for males indicated a 
significant main effect of Group [(F(1,52) = 14.89, p< 0.0001], Dose [(F(2,52) = 





















Active Lever Responses Inactive Lever Responses Reinforcers Ethanol Intake (g/kg)
Experiment 1
     Male 67.1 (3.96) 17.4 (3.45) 16.7 (0.89) 0.85 (0.05)
     Female 75.32(4.52) 12.8 (1.40) 18.1 (1.03)  1.51 (0.09)*
Experiment 2
     Male 80.8 (3.76) 15.1 (1.31) 20.2 (0.88) 1.17 (0.06)
     Female 72.6 (4.05) 10.6 (3.52) 18.3 (0.94)   1.49 (0.06)*
Experiment 3
     Male 77.9 (5.50) 10.4 (1.94) 19.1 (1.23) 0.83 (0.08)
     Female 67.5 (5.52) 9.10 (1.16) 16.9 (1.31) 0.92 (0.06)




Time x Group x Dose interaction [(F(2,52) = 4.38, p< 0.05] (Figure 5.1a). Post 
hoc analysis based on these effects indicated that 1mg/kg OXT significantly 
attenuated stress-induced reinstatement compared to both VEH and 0.5 mg/kg 
OXT treated animals, whereas 0.5 mg/kg OXT was not sufficient to attenuate 
stress-induced reinstatement of alcohol-seeking behavior.  Pretreatment with 
OXTR antagonist reversed the effects of 1mg/kg OXT on stress-induced 
reinstatement but had no effect on lever responding during reinstatement test 
when co-administered with VEH or 0.5mg/kg OXT.  
For female mice, ANOVA revealed a significant main effect of Dose [(F(2,48) = 
42.47, p< 0.001] and Time [(F(1,48) = 51.92, p< 0.001] and Dose x Time 
interaction [(F(2,48) = 60.98, p< 0.001] (Figure 5.1b). These results indicate that 
OXT administration similarly reduced stress-induced relapse-like behavior at both 
the 0.5mg/kg and 1 mg/kg dose compared to vehicle and this effect was seen 
regardless of pretreatment with VEH or OXTR antagonist.  
 
Sex differences in the Reversal of the Oxytocin Effect on Stress-Induced 
Reinstatement by Central, not Peripheral, Oxytocin Receptor Antagonist  
 
ANOVA with Sex (M,F) and Group (VEH, OXT) as a between-subject 
factors and Dose (0, 5, 10, 20 OXTR antagonist) and Time (Ext, Reinstate) as 
repeated measures indicated a significant main effect of Sex [(F(1,80) = 55.80, 
p< 0.0001], Group[(F(1,80) = 60.73, p< 0.0001], Dose [(F(3,80) = 3.28, p< 0.05] 
and Time [(F(1,80) = 254.06, p< 0.0001], as well as significant interactions 





Figure 5.1. Effects of pharmacological antagonism of oxytocin receptor on 
oxytocin-induced attenuation of stress provoked relapse-like behavior in 
male and female mice. Systemic OXT attenuates stress-induced reinstatement 
of alcohol seeking behavior in a dose-related manner. Pretreatment with OXTR 
antagonist, L368,899 (10 mg/kg), reverses the effect of OXT on relapse-like 
behavior in (a) male mice but has no effect on level responding in (b) females. 
Values are mean ± s.e.m (N=10/group) *p<0.001 VEH versus OXT, #p<0.001 






























































Dose [(F(3,80) = 11.14, p< 0.001]. However, the interaction between all test 
variables (Sex x Group x Dose x Time) did not reach statistical significance 
[(F(3,80) = 0.803, p >0.1]. These results demonstrate that TMT significantly 
increased significantly alcohol-seeking behavior during reinstatement test 
compared to extinction in both male (Figure 5.2a) and female (Figure 5.2b) 
mice. Reinstatement responding was significantly attenuated by OXT treatment, 
though the magnitude of this effect was dependent on sex.  Further, ability of the 
selective OXTR antagonist, L368,899, to reverse the effect of OXT on stress-
induced relapse-like behavior was dose-dependent. 
Separate ANOVA including Group (VEH, OXT), Dose (0, 5, 10, 20) and 
Time (Ext, Reinstate) were conducted for males and females independently.  For 
males, analysis by ANOVA of lever responding during reinstatement indicated a 
significant main effect of Group [(F(1,52) = 14.89, p< 0.0001], Dose [(F(2,52) = 
4.40, p< 0.05] and Time [(F(1,52) = 245.75, p< 0.001], as well as significant Time 
x Group x Dose interaction [(F(2,52) = 4.38, p< 0.05] (Figure 5.2a). Post hoc 
analysis based on these effects indicated TMT exposure provoked stress-
induced relapse-like behavior in vehicle groups pretreated with 0, 5,10 20 mg/kg 
dose of L368,899. This effect was significantly attenuated by 0.5 mg/kg OXT in 
animals pretreated with 0 and 5 mg/kg L368,899, but not 10mg/kg or 20 mg/kg 
L368,899. Additionally, VEH treated animals that received the highest dose of 
L368,899 (20 mg/kg) demonstrated a significant reduction stress-induced 





Figure 5.2. Effect of brain penetrant oxytocin receptor antagonist, L368,899, 
on stress-induced reinstatement of alcohol-seeking behavior. Administration 
of brain penetrant OXTR antagonist reversed the effect of OXT on stress-induced 
reinstatement of alcohol-seeking behavior in male, but not female, mice. 
Systemic OXT attenuated stress-induced reinstatement of alcohol-seeking 
behavior and this effect was reversed by pretreatment with OXTR antagonist 
L368,899 (10 mg/kg) in (a) male, but not (b) female mice. Additionally, higher 
range doses of L368,899 administered alone (20 mg/kg in males, 10 and 20 
mg/kg in females) reduced lever responding compared to VEH-VEH treated 
groups. Values are mean ± s.e.m (N=6/group) *p<0.001 OXT versus VEH, 
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that high doses of L368,899 may have behavioral effects independent of OXT 
treatment. 
For female mice, ANOVA revealed a significant main effect of Group 
[(F(1,40) = 63.31, p< 0.001] and Time [(F(1,40) = 31.98, p< 0.001] and Time x 
Group[(F(1,40) = 49.66, p< 0.001], Group x Dose and [(F(3,40) = 5.05, p< 0.001] 
and Group x Dose x Time [(F(3,40) = 4.48, p< 0.001] interactions (Figure 5.2b) . 
Post hoc analysis revealed that TMT provoked relapse-like behavior in VEH 
groups pretreated with 0, 5 and 10 mg/kg L368,899. Oxytocin treatment 
attenuated stress-induced reinstatement of alcohol-seeking behavior in all groups 
regardless of L368,899 dose. Additionally, pretreatment with 10 mg/kg and 20 
mg/kg L368,899 reduced alcohol-seeking behavior compared to VEH groups that 
received saline (VEH-VEH). 
 
Peripherally Restricted Oxytocin Receptor Antagonist Does Not Block the Effect 
of Oxytocin on Stress-Induced Reinstatement of Alcohol Seeking  
 
TMT provoked relapse like behavior in male and female mice (Figure 5.3) 
compared to extinction responding and systemic OXT administration attenuated 
this behavior similarly across all three doses of peripherally restricted OXTR 
antagonist, Atosiban (ATO). Pretreatment with ATO did not affect the ability of 
OXT to attenuate relapse-like behavior in male or female mice. These 
observations were supported by ANOVA with Sex (M,F) and Group (VEH, OXT) 
as a between-subject factors and Dose (0, 1, 10 OXTR-A) and Time (Ext, 





Figure 5.3.  Effect of peripherally restricted oxytocin receptor antagonist, 
Atosiban, on stress-induced reinstatement of alcohol-seeking behavior. 
Peripherally restricted OXTR antagonist, Atosiban, does not block the effect of 
OXT on stress-induced reinstatement of alcohol-seeking behavior in male and 
female mice. The ability of OXT to attenuate stress-induced alcohol relapse-like 
behavior was not reversed by administration of peripherally restricted OXTR 
antagonist in male (a) or female (b) mice. Values are mean ± s.e.m (N=6/group) 
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Group[(F(1,60) = 101.18, p< 0.001], Dose [(F(2,60) = 5.09 , p< 0.001] and Time 
[(F(1,60) = 115.31, p< 0.001], as well as significant interactions between Time x 
Dose [(F(2,60) = 3.80, p< 0.05] and Time x Group [(F(1,60) = 90.92, p< 0.001]. 
Separate ANOVA including Group (VEH, OXT), Dose (0, 1, 10 ATO) and Time 
(Ext, Reinstate) were conducted for reinstatement test for males (Figure 5.3a) 
and females (Figure 5.3b) independently. However, the Time x Dose x Group 
interaction did not achieve statistical significance in either sex. 
 
Effect of Oxytocin Receptor Blockade in the Central Amygdala on Stress-Induced 
Alcohol Relapse-Like Behavior  
 
Initial analyses indicated that order of drug treatment did not significantly 
influence treatment (L368,899 vs. PBS) effects, as indicated by nonsignificant 
Order x Drug and Order x Drug x Time interaction. Thus, data were collapsed 
over this variable (Order) for further analysis. Analysis by ANOVA was preformed 
using Sex (M,F), IP (VEH, OXT) and as between-subject factors and Micro (VEH, 
ANTAG) and Time (Ext, Reinstate) as within-subject variables. Analysis revealed 
a significant main effect of IP [(F(1,14) = 4.56, p< 0.05] and Time [(F(1,14) = 
11.47, p< 0.001], as well as a significant IP x Time interaction [(F(1,14) = 11.47, 
p< 0.001]. These results indicate TMT produced a significant increase in lever 
responding in VEH treated animals and OXT administration attenuated this 
effect. Further intra-CeA infusion of OXTR antagonist, L368, 899, (1 ug/side) had 
no effect on the ability of systemically administered OXT to attenuate stress-
induced reinstatement of alcohol-seeking behavior, and this (lack of) effect was 





Figure 5.4. Effect of oxytocin receptor blockade in the central amygdala on 
stress-induced alcohol relapse-like behavior. Direct infusion of OXTR 
antagonist, L368,899, (1 µg/ul) in the CeA does not block the effect of 
systemically administered OXT on stress-induced alcohol relapse-like behavior in 
(a) male or (b) female mice (N= 7/group M, 4/group F). However, intra-CeA 
infusion of a higher dose of L368,899 (2µg/ul) reversed the effect of systemic 
OXT treatment (0.5 mg/kg) on stress-induced reinstatement of alcohol-seeking in 
(c) male, but not (d) female, mice (N= 11-12/group M, 9-11/group F).  Values are 

















































































In a follow up study in a separate cohort of mice we examined whether a 
higher dose (2ug/side) of L368,899 directly applied to the CeA could reverse the 
effects of systemically administered OXT on stress-induced reinstatement of 
alcohol seeking. ANOVA revealed a significant main effect of Sex [(F(1,35) = 
8.98, p< 0.01] and IP [(F(1,35) = 6.63, p< 0.05], as well as Sex x Time [(F(1,35) = 
7.98, p< 0.01] and IP x Time [(F(1,35) = 10.61, p< 0.01] interactions. However, 
Sex x IP x Time interaction was nonsignificant.  
Separate ANOVA including IP (VEH, OXT) and Micro (VEH, ANTAG) 
during reinstatement test were conducted for males and females independently.  
For males, ANOVA revealed a significant main effect of Micro [(F(1,21) = 5.24, 
p< 0.05]. The IP x Micro interaction did not reach statistical significance.  These 
results indicate that intra-CeA infusion of L368,899 (2ug/side) reversed the 
effects of OXT on stress-induced reinstatement in male mice.  
For female mice, OXT attenuated reinvigoration of lever responding to 
stress relative to vehicle condition regardless of infusion (L368,899 or PBS) and 
intra-CeA infusion of L368,899 (2ug/side) alone was sufficient to significantly 
reduce lever responding compared to the VEH-VEH treatment group. These 
results were supported by ANOVA which revealed a significant main effect of IP 
[(F(1,18) = 13.76, p< 0.001] and significant IP x Micro interaction [(F(1,18) = 5.34, 








In agreement with previous studies, systemically administered OXT 
reduced reinstatement of alcohol-seeking behavior provoked by stress exposure 
in male and female mice. However, the mechanism by which OXT reduces 
stress-induced relapse-like behavior remains unknown. To characterize OXT 
neurotransmission in this behavior, we examined the effect of two different OXTR 
antagonists across a range of doses applied systemically and infused directly 
into CeA. In males, systemic and intra-CeA administration of brain penetrant 
OXTR antagonist, L-368,899, blocked the ability of systemic OXT to reduce 
stress-induced relapse-like behavior, though this effect appears to be dose-
dependent. Somewhat surprisingly, pretreatment with OXTR-A L,368,899 
systemically or directly infused into CeA failed to prevent the action of oxytocin in 
female mice. Additionally, high doses of L368,899 alone appear to reduce lever 
responding in both male and female mice compared to vehicle-vehicle treated 
groups. Pretreatment with a peripherally restricted OXTR antagonist (Atosiban, 
ip.) did not reverse the effect of systemic OXT on stress-induced reinstatement in 
either sex. Taken together, results from this study suggest that the effect of OXT 
on alcohol relapse-like behavior is centrally, not peripherally, mediated and may 
be independent of actions at the OXTR, especially in females. 
Sex differences observed in the response to OXT are in congruence with 
results from the previous studies (See Chapter 4) that show trend level 
significance in sex-related differences in the behavioral response to OXT 
treatment. In the current study, female mice exhibit greater sensitivity to both 
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OXT (Experiment 1) and OXTR antagonist (Experiment 2a) than males. Sexually 
dimorphic expression of OXTRs has been described in a number of brain regions 
across multiple rodent species (Dumais et al. 2016; Dumais et al 2013; Dumais 
and Veenema 2016), in which males consistently demonstrate higher OXTR 
expression than females (Dumais and Veenema 2016). Currently, no such sex 
differences have been identified in C57BL/6J mice (Hammock and Levitt 2013), 
though this may be an artifact due to lack of comprehensive analysis (Dumais 
and Veenema 2016).  It is also important to note that OXT may not exclusively 
bind to OXTRs (Manning et al. 2012), and therefore, sexually dimorphic 
expression in related systems, such as vasopressin, could possibly mask or 
contribute to sex differences in the sensitivity to OXT (Dumais and Veenema 
2016). Further, the greater sensitivity to the effect of an OXTR antagonist on 
alcohol-relapse like behavior in females may be reflective of differences in 
endogenous brain OXT levels. Sex differences in OXT-immunoreactive neurons 
have been identified in which OXT is typically higher in females compared to 
males (Dumais and Veenema 2016). However, it is unclear whether sex 
differences in brain OXT-immunoreactivity reflect differences in OXT release. 
Thus, future studies are necessary to specifically link sexually dimorphic OXTR 
expression and peptide levels to the OXT-modulation of relapse-like behavior.  
The central mechanism by which OXT administration modulates 
reinstatement of alcohol-seeking behavior remains relatively unknown. The 
results from the current study corroborate previous reports (see chapter 3) that 
demonstrate that systemic administration of a brain penetrant OXTR antagonist 
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blocks the inhibitory effect of OXT on alcohol-related behaviors. However, there 
are very few studies investigating the role of OXTRs on relapse-like behavior and 
evidence for an OXTR-mediated mechanism are mixed, especially in regard to 
site-specific infusion. In a series of studies by Baracz and colleagues, direct 
infusion of an OXTR antagonist into NAcc or STh did not specifically block the 
OXT-induced attenuation of methamphetamine-primed relapse behavior (Baracz 
et al. 2015, Baracz et al. 2016). Interestingly, Everett et al. (2018) demonstrated 
that prior systemic and intra-NAcc administration of a V1aR, but not OXTR, 
antagonist attenuated the inhibitory effects of OXT on methamphetamine -primed 
reinstatement (Everett et al. 2018) . In contrast, the same group demonstrated 
that OXT dose-dependently modulated acute dopamine reward in STh through 
actions at the OXTR (Baracz and Cornish 2013). Unfortunately, the above 
studies regarding the effects of OXTR neurotransmission on drug- and alcohol-
seeking behaviors only involve males and therefore provide no insight to sex 
differences in OXTR-mediated regulation of alcohol relapse-like behavior. Future 
studies are necessary to provide insight into the receptor specificity of OXT’s 
effect in reducing stress-induced reinstatement of alcohol-seeking behavior in 
both males and females. 
Discrepancies in OXTR function may be related to changes in the OXT 
receptor system in response to drug or alcohol exposure. Indeed, it has 
previously been shown that the OXT system is dysregulated following chronic 
alcohol exposure (Stevenson et al. 2017; Silva et al. 2002, Hansson et al. 2018). 
Specifically, in alcohol-dependent rats, Hansson et al. (2018) demonstrated an 
 
 146 
upregulation of OXTR mRNA and OXTR protein levels in PFC, striatal, amygdala 
and hippocampal regions after 3 weeks of abstinence in contrast to a 
downregulation of the same systems during intoxication. These data suggest that 
OXTRs undergo dynamic neuroadaptations following the cessation of alcohol 
exposure, with may alter their function and contribute to withdrawal and relapse-
like behavior. Additionally, it is also important to note that in addition to the known 
OXTR, the existence of another uncharacterized OXTR subtype has been 
proposed (Chan et al. 2003; Adan et al. 1995), which may also help to explain 
the inconsistent effect of the OXTR antagonists on OXT modulation of 
reinstatement behavior. Regardless, compensatory changes in OXTR expression 
following alcohol exposure may explain why OXT has little effect through its own 
receptor to modulate stress-induced reinstatement in females and may suggest 
that exogenously administered OXT might interaction with other 
neurotransmitters or neuropeptides in specific brain regions to modulation 
behaviors associated with alcohol abuse.  
Numerous studies have implicated a key role for the CeA in the transition 
to alcohol dependence (Koob 2009; Koob and Volkow 2010). Results from the 
present the study demonstrate that in males, intra-CeA infusion of a selective 
OXTR antagonist blocked the attenuating effects of systemically administered 
OXT on alcohol-relapse behavior. One potential mechanism by which this is 
occurring is through interaction with GABAergic neurotransmission. Excessive 
drinking appears to dysregulate numerous neuropeptide systems that converge 
on GABAergic circuitry in the CeA, producing the negative emotional symptoms 
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observed in alcohol abstinence (Roberto et al. 2004). Evidence suggests that 
GABA transmission in the amygdala is regulated by OXT (Huber et al. 2005). An 
infusion of OXT into the CeA has been shown to increase GABA activity in this 
region (Huber et al. 2005) and decreases in OXTR expression have been 
demonstrated to modulate presynaptic GABA release (Ripamonti et al. 2017). 
Additionally, local application of OXT to the lateral CeA activates a subpopulation 
of GABAergic interneurons that inhibit neurons in the medial CeA, the main 
output of the CeA to the brainstem (Huber et al. 2005), thereby attenuating 
behavioral fear responses (Viviani et al. 2011). In the context of alcohol 
exposure, Tunstall et al. (2019) demonstrated that OXT decreased GABA 
signaling in the CeA in both dependent and nondependent rats. However, OXT 
neurotransmission may affect GABAergic signaling in the CeA through different 
mechanisms in male and females. A recent study by Campbell-Smith and 
colleagues demonstrated that administration an OXTR antagonist into the CeA 
reversed OXT-induced suppression of fear responses in male rats (Campbell-
Smith et al. 2015). Further, another study showed that OXT rescued stress-
induced depression and anxiety-related behaviors by acting on OXTR in the CeA 
to enhance GABAergic transmission in male mice (Han et al. 2018). However, in 
females, administration of GABAA, but not OXTR, antagonist in the CeA, blocked 
OXT- mediated increases in social preference and anxiety-like behavior (Dong et 
al. 2017). Therefore, the different effects of pharmacological antagonism of 
OXTRs on stress-induced reinstatement observed in male and female mice may 
relate to the fact that systemically administered OXT either does not act on 
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OXTRs in the CeA, or that the effect of OXT on the CeA is offset by its activity in 
other brain regions, e.g., BNST, PFC, NAc. Future studies are necessary to 
alternative interaction with other neurotransmitter systems, as well as determine 
specific brain regional contributions that mediate the ability of OXT to attenuate 
relapse-like behavior.  
A limitation of the current study, as discussed in Chapter 3, is the use of 
the OXTR antagonist Atosiban. The specificity of Atosiban raises some concern 
due to actions at both the OXTR and vasopressin V1a receptor. Vasopressin V1a 
receptor signaling has been implicated in anxiety- and stress- behaviors (Wsol et 
al. 2014; Gray et al. 2012; Hernandez et al. 2016). Oxytocin has been shown to 
activate the V1a receptor, not its own, to modulate some prosocial and 
autonomic effect in males that were previously attributed solely to the OXT 
system (Bowen and McGregor 2014; Sala et al. 2011; Hicks et al. 2014; Wsol et 
al. 2014). Interestingly, systemic administration of a V1a receptor antagonist, 
SR49059, has been shown to block OXT-induced reduction in relapse to 
methamphetamine-seeking behavior (Everett et al. 2018). Additionally, there is 
some evidence to suggest that Atosiban may also act as a biased agonist 
(Galandrin and Bouvier 2006) that favors Gi coupled signaling pathways over Gq 
(Busnelli 2012; Vrachnis et al. 2011; Devost et al. 2008). Thus, a more 
comprehensive spectrum of signaling pathways must be taken into consideration 
when interpreting the present results. Data from the current study demonstrated 
that blockade of peripheral OXTR and possibly V1aR, via OXTR antagonist 
Atosiban, did not alter the ability systemically administered OXT to reduce 
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alcohol relapse-like behavior. These results provide compelling evidence to 
support a centrally-mediated mechanism of action, though it is unclear whether 
these effects are due to action at OXTR or V1aR. Future studies investigating the 
specific contribution of OXTR and V1aR signaling mechanisms on alcohol-
relapse like behavior are necessary. 
In conclusion, results from the present study provide new evidence 
indicating a role for OXT/OXTR activity in the regulation of stress-induced 
reinstatement of alcohol-seeking behavior. Our findings reveal potential sex 
differences in OXTR signaling within the CeA to modulate stress-induced 
reinstatement of alcohol-seeking behavior. The ability of OXT to attenuate 
alcohol-relapse behavior is mediated by central, not peripheral, OXTR signaling 
in male mice. Additionally, the present study is the first to demonstrate that 
OXTR signaling in the CeA mediates, at least in part, the ability of systemically 
administered OXT to attenuation stress-induced reinstatement of alcohol-seeking 
behavior in male mice. However, in female mice systemic or direct CeA infusion 
of OXTR antagonist L368,899 was ineffective in blocking the effects of OXT on 
stress-induced reinstatement of alcohol-seeking behavior. Taken together, these 
results indicate the OXT/OXTR system as a potential therapeutic target for 
mitigating relapse initiated by stress in both males and females. Future studies 
are necessary to provide greater insight into potential sex difference in the 





CHAPTER 6: Conclusions and Future Directions 
 Oxytocin and Alcohol Consumption 
 
The current PhD dissertation has demonstrated that systemic 
administration of OXT reduces alcohol consumption in a variety of drinking 
models. Across a broad dose range systemic OXT reduced alcohol intake in a 
binge-like model, 2-bottle choice drinking paradigm and a model that employs 
operant self-administration procedures. Oxytocin decreased ethanol consumption 
in a dose-related manner and the ability of OXT to reduce ethanol intake did not 
appear to be related to nonspecific (e.g., sedation, antidipsogenic) effects. 
Further, oxytocin reduced motivation to respond for alcohol at doses that did not 
alter responding for a natural reward (sucrose). We also report that direct 
activation of OXT+ neurons in the PVN via targeted expression of excitatory 
DREADD (and systemic injection of CNO) decreased alcohol consumption in the 
DID model, as well as lever responding and intake in oral operant self-
administion, mimicking the effects of exogenous OXT. Using the same approach, 
we also demonstrate that activation of PVN OXT+ neurons decreased anxiety-
like behavior in an open field and this effect was not due to changes in locomotor 
activity. Finally, the effect of OXT on alcohol consumption appears to be 
mediated, at least in part, by action at the OXTR. This observation was 
supported by the reversal of OXT’s effect on alcohol consumption by selective 
brain penetrant OXTR antagonist, L368,899. Additionally, using pharmacological 
and chemogenetic approaches, we demonstrate that the effect of CNO-induced 
activation of PVN OXT+ neurons on alcohol consumption can be reversed with 
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the (blood-brain-barrier penetrant) OXTR antagonist L368,899, whereas 
peripheral administration of an OXTR antagonist that does not cross the blood-
brain-barrier (Atosiban) did not reverse this effect. Together, these data suggest 
that the behavioral effects of OXT on alcohol drinking and anxiety-like behavior 
are centrally mediated and implicate OXTR neurotransmission as a potential 
mechanism of action.   
One important limitation of the present work is that these studies were 
conducted exclusively in males. Although very few studies have examined the 
potential sex-related differences in the ability of OXT to modulate alcohol intake, 
there is some evidence that female mice may be more sensitive to the behavioral 
effects of OXT (King et al. 2018, Zhou et al. 2015, Kohtz et al. 2018). Thus, it 
would be beneficial to examine a broad range of OXT doses in female mice.  
 In the chemogenetic studies, female Oxt-IRES-Cre mice were run 
concurrently with males, however, systemic injection of CNO reduced alcohol 
consumption in female mice harboring control virus (with no active DREADD 
receptor) across several studies. These results suggest that CNO produced off-
target effects, making the data from female mice infused with excitatory 
DREADD virus challenging to interpret. There are a number of considerations 
that may help to explain off-target effects of this chemogenetic technique. First, 
the ligand CNO used to activate DREADD receptors has been shown to be back-
converted into clozapine (Gomez et al. 2017; Jendryka et al. 2019), an atypical 
antipsychotic. Clozapine has been shown to suppress alcohol drinking in rodents 
in a dose range (2-4 mg/kg; Green et al. 2004; Ingman and Korpi 2006) similar to 
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the dose of CNO (3 mg/kg) used in the current investigation. However, we also 
used DREADD agonist Compound 21, which is thought to be more selective, and 
observed similar off-target effects in control mice.  Data from our lab 
(unpublished) demonstrated that the off-target effects of both DREADD agonists 
(CNO and Compound 21) on alcohol consumption are not present in mice that 
have not received stereotaxic surgery targeting the PVN. Thus, it is possible that 
damage from surgery and/or viral infusion produced a larger inflammatory 
response in females, compromising the integrity of the blood-brain-barrier. Future 
studies utilizing IHC procedures to stain for inflammatory markers could help to 
resolve this question. Finally, the issue may be related to the transgenic Oxt-
IRES-Cre mouse itself rather than the DREADD virus or DREADD agonist. It is 
possible that Cre recombinase was incorporated into target cells during 
development in a sex-specific manner, such that the recombinase enzyme is 
constitutively active in female mice. Therefore, studies investigating the pattern 
of activation (by measurement of c-fos expression) of OXT neurons may help to 
elucidate differences in male and female Oxt-IRES-Cre mice.  
Another limitation of chemogenetic approach is that male Oxt-IRES-Cre 
mice are larger and gain weight more quickly compared to C57BL/6J mice. This 
represents a significant issue as the main output in many alcohol-related studies 
is ethanol intake (g/kg is a body weight dependent measure). Although the mice 
were backcrossed with C57BL/6J mice, Oxt-Cre males also drink less on a mL 
basis compared to C57BL/6J mice, regardless of size.  One factor that may 
contribute to this observation is viral surgery targeting the hypothalamus (PVN) 
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may damage areas involved in the homeostatic regulation of energy balance, 
satiety, food and fluid intake.  
Given these limitations this transgenic mouse model still provides an 
excellent opportunity to investigate pathway specific OXT-modulation of behavior 
in males. Studies to further elucidate the specific mechanisms involved in OXT-
modulation of alcohol consumption could selectively activate OXT PVN neurons 
projecting to discrete brain regions via direct infusion of CNO into the brain 
region of interest (versus global activation of OXT+ containing neurons by 
systemic injection of CNO). This approach may also help limit off-target effects. 
Another way to selectively target PVN projection fibers to discrete brain regions 
(i.e., BNST, CeA, PFC) would be through the use of a Cre-dependent 
retrogradely transported AAV containing excitatory, inhibitory or control virus. In 
this strategy, virus is taken up by presynaptic terminals at the site of infusion and 
retrogradely transported to cell bodies expressing Cre-recombinase in the 
hypothalamus. Finally, use of site-specific administration of OXTR antagonists in 
conjunction with activation of PVN OXT+ containing neurons may provide 
information about OXTR signaling.  
 
 
Oxytocin and Stress-Induced Reinstatement of Alcohol-Seeking Behavior 
 
 In agreement with both preclinical and clinical literature, the data 
presented in this dissertation demonstrate the efficacy of OXT administration in 
attenuating relapse-like behavior. Oxytocin attenuated predator odor (TMT)- and 
yohimbine-induced reinstatement in a dose-related manner in both male and 
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female mice.  In male mice, systemic and intra-CeA administration of brain 
penetrant OXTR antagonist, L-368,899, blocked the ability of OXT to reduce 
stress-induced relapse-like behavior and this this effect appears to be dose-
dependent. Additionally, pretreatment with a peripherally restricted OXTR 
antagonist, Atosiban, did not reverse the effect of OXT on stress-induced 
reinstatement in either sex. Taken together, results from this study suggest that 
the effect of OXT on alcohol relapse-like behavior is centrally, not peripherally, 
mediated and may be independent of actions at the OXTR, especially in females. 
Although males and females may be similar on a behavioral level, they 
often use different mechanisms to respond to challenges (i.e. stress) and social 
and emotional cues (Bangasser and Valentino 2014; Palanza and Parmigiani 
2017) Data obtained in males are often irrelevant for inferring the efficacy of 
pharmacological treatments in females. In this vein, results presented in this 
dissertation illustrate the importance of studying both sexes. Regarding the effect 
of OXT on stress-related alcohol relapse-like behavior, future studies should 
explore the possibility that OXT is interacting with other neurotransmitter systems 
and receptors other than its own. There is evidence to suggest that OXT interacts 
with multiple receptors including GABAA (Bowen al. 2015; Dong et al. 2017), 
vasopressin V1aR (Everett et al. 2018), dopamine D2R (de la Mora et al. 2016; 
Fuxe et al. 2012) and mGlurR2/3 (Bernheim et al. 2017) to regulate stress- and 
reward- related behaviors, including reinstatement of drug-seeking behavior. 
Thus, site specific co-administration of OXT and antagonists targeting the 
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aforementioned receptors will provide insight into OXTR signaling in both males 




A growing body of literature suggests that OXT plays a significant role in 
alcohol (and other drug) addiction, as well as in stress-related neuropsychiatric 
disorders that are often co-occurring in AUD. The current dissertation presented 
strong evidence to suggest that OXT (exogenous administration or driving the 
endogenous system) reduces alcohol self-administration and reinstatement 
behavior. However, a number of questions remain unanswered about the 
mechanism and circuitry underlying the ability of OXT to produce these effects. 
Taken together, the OXT system may be a promising target for therapeutic 
intervention of AUDs, though additional studies are necessary to establish its 
clinical efficacy and further investigate the mechanisms and conditions by which 
the OXT system regulates stress- and reward- related behaviors differently in 
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Figure 1. Chemogenetic activation of hypothalamic oxytocin-containing 
neurons decreased alcohol consumption in female mice. (a) chemogenetic 
activation of PVN OXT+ neurons reduced alcohol consumption in the first two 
hours of the test session (0-2hr) and total alcohol consumption (b) Systemic 
CNO (3 mg/kg) administration decreased drinking at all time points relative to 
vehicle in animals harboring control virus (c) systemic administration of OXT (1 
mg/kg) decreased alcohol intake at all timepoints relative to vehicle. Values are 































































































Figure 2. Effect of chemogenetic activation of hypothalamic oxytocin-
containing neurons on oral operant alcohol self-administration in female 
mice (a) chemogenetic activation of PVN OXT+ neurons reduced lever 
responding and (b) alcohol intake in mice harboring excitatory virus compared to 
vehicle and the average of the last 3 days of baseline responding prior to testing. 
Administration of CNO had no significant effect on (c) lever responses and (d) 
alcohol intake in mice that received infusion of control virus. Systemic OXT (1 
mg/kg) also reduced (e) lever responding and (f) alcohol intake. Values are mean 
± s.e.m (N= 8 /group Gq and N= 6/group CTL) *p<0.05 versus VEH, ^p<0.05 
versus 3 day average 
 
 




































































































Figure 3. Effect of chemogenetic activation of hypothalamic oxytocin-
containing neurons on stress-induced alcohol relapse-like behavior in 
female mice (a) Active and inactive lever responding during the baseline oral 
operant alcohol self-administration. Animals harboring excitatory (Gq) DREADD 
exhibited higher responding on the active lever than animals that received control 
virus but there was no difference in (b) ethanol intake between groups. For 
reinstatement, animals were exposed to predator odor (TMT) for 15 minutes and 
then tested for alcohol-seeking behavior under extinction conditions (c) mice with 
excitatory DREADD virus that received a vehicle injection demonstrated an 
increase in lever responding (alcohol-seeking behavior) compared to the average 
of the last 3 days of extinction. Activation of PVN OXT+ neurons via 
administration of CNO (3 mg/kg) significantly reduced stress-induced relapse-like 
behavior relative to vehicle. Similarly, in mice that received control virus (d) TMT 
exposure reinvigorated alcohol-seeking behavior in both VEH and CNO treated 
animals. However, animals treated with CNO exhibited a significant decrease in 
stress-induced relapse-like behavior compared to VEH. Values are mean ± s.e.m 
(N= 10 /group Gq and N= 8/group CTL) *p<0.05 versus Ext, ^p<0.05 VEH 
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